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DISSERTATION ABSTRACT 
 
Jonathan E. Elliott 
 
Doctor of Philosophy 
 
Department of Human Physiology 
 
September 2014 
 
Title:  Insight into the Physiologic Impact of Right-to-Left Intrapulmonary and 
Intracardiac Shunt in Healthy Humans 
 
 
 Large diameter intrapulmonary arteriovenous anastomoses (IPAVA) have been 
known to exist in humans for >60 years, and the prevalence of patent foramen ovale 
(PFO) is ~35-40% in the general population. However, respiratory physiologists have 
largely ignored the presence of a PFO and only recently begun to appreciate IPAVA. 
Reasons some remain critical of IPAVA to be physiologically relevant is due to the 
relatively undefined role for blood flow through IPAVA to contribute to pulmonary gas 
exchange efficiency and the unknown and mechanism(s) regulating blood flow through 
IPAVA. 
 In Chapter IV the role for blood flow through IPAVA to contribute to pulmonary 
gas exchange efficiency (A-aDO2) was investigated using an experimental paradigm 
minimizing contributions from alveolar ventilation-to-perfusion inequality and diffusion 
limitation to the A-aDO2. The increase in blood flow through IPAVA corresponded to an 
increase in the A-aDO2 and an increase in total venous admixture of ~2% of the cardiac 
output. Bronchial shunt was estimated to be ~1%, which suggests blood flow through 
IPAVA and Thebesian blood flow constitute the remaining ~1% of the cardiac output 
during intravenous infusion of epinephrine. We originally proposed to quantify blood 
 v 
flow through IPAVA during the conditions in Chapter IV using radiolabeled 
macroaggregated albumin; however, ongoing studies demonstrated the need to validate 
this technique when breathing hyperoxia. 
 In Chapter V the effect of sildenafil, nifedipine, and acetazolamide on blood flow 
through IPAVA during exercise breathing room air and 100% O2 was investigated, and 
no effect was observed. These pharmacologic interventions act through mechanisms with 
the potential to prevent or reduce the hyperoxia-mediated reduction in blood flow through 
IPAVA. Nifedipine and acetazolamide may prevent or limit pulmonary vascular smooth 
muscle contraction, while sildenafil may augment relaxation of pulmonary vascular 
smooth muscle. 
 Lastly, in Chapter VI it was demonstrated that after acclimatization to hypobaric 
hypoxia in healthy humans, blood flow through IPAVA was reduced, and subjects with a 
PFO have impaired pulmonary gas exchange efficiency and a reduced degree of 
ventilatory acclimatization. 
 This dissertation includes previously unpublished co-authored material. 
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CHAPTER I 
INTRODUCTION 
 The primary function of the lung is to facilitate movement of oxygen into the 
body and remove carbon dioxide out of the body, a critical process that is collectively 
referred to as pulmonary gas exchange. A second, less appreciated, function of the lung is 
to filter the incoming venous blood and prevent thrombi from reaching the arterial 
circulation and manifesting as emboli. Obligatory to efficiently performing both of these 
tasks is directing blood flow through the pulmonary capillary network. However, large 
diameter (15-750 µm) intrapulmonary arteriovenous anastomoses (IPAVA), which have 
been known to exist in healthy human lungs for over 60 years, offer a vascular conduit 
for blood flow to bypass the pulmonary capillary network (171, 188, 225, 228, 262). 
Thus, by acting as a collateral pathway, blood flow through these pathways could 
theoretically compromise both functions of the lung; impairing pulmonary gas exchange 
efficiency as a right-to-left shunt as well as providing thrombi a pathway to circumvent 
the pulmonary capillary filter. 
 Despite the anatomic data demonstrating the existence of IPAVA, respiratory 
physiology and medicine have only recently begun to appreciate these vessels and their 
potential clinical impact. One reason some remain critical of IPAVA to be 
physiologically or pathophysiologically relevant, is due to the relatively undefined role 
that blood flow through IPAVA has in contributing to pulmonary gas exchange efficiency 
and some types of stroke (2). Secondarily, the mechanisms regulating blood flow through 
IPAVA remain unclear. Currently little is known other than conditions that increase 
blood flow through IPAVA (i.e., during exercise, in acute normobaric hypoxia, and 
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during the intravenous infusion of catecholamines), and conditions that decrease blood 
flow through IPAVA (i.e., with alveolar hyperoxia). Accordingly, the overarching 
purpose of this dissertation is to establish the role that blood flow through IPAVA has on 
pulmonary gas exchange efficiency and to begin to investigate the potential mechanistic 
regulation of these vessels; thereby helping to define the physiologic relevance of IPAVA 
in healthy humans. 
 In addition to blood flow through IPAVA, the presence of a functionally patent 
foramen ovale (PFO) also provides a ‘collateral pathway’, albeit one that is much more 
direct, which impairs both the filtering ability of the lung and pulmonary gas exchange 
efficiency. As a requisite right-to-left shunt in the fetal cardiopulmonary circulation, the 
foramen ovale is patent in 100% of healthy humans in utero. After birth, the reversal of 
pressure gradients between the right and left atria result in the septum primum covering, 
and therefore functionally closing, the foramen ovale within the septum secundum (71, 
82, 118). Over time, fusion of the septum primum/secundum occurs in the majority of 
infants (i.e., permanent anatomical closure of the foramen ovale) preventing blood flow 
through the foramen ovale. However, recent work using transthoracic saline contrast 
echocardiography (TTSCE) has revealed ~35-40% of adult humans continue to have a 
PFO (55, 156, 266). Although right-to-left blood flow through a PFO would be expected 
to be intermittent and variable in volume (64), recent work by Lovering et al. has shown 
that subjects with a PFO can have significantly worse pulmonary gas exchange efficiency 
at rest breathing either room air or in acute normobaric hypoxia (12% O2) (145). Thus, 
not only is the prevalence of PFO in the general population more common than 
previously reported (~25-35%) from prior autopsy studies (82), these subjects possess an 
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additional source of right-to-left shunt resulting in a measureable decrement in 
pulmonary gas exchange efficiency determined via arterial blood gas analysis, compared 
to subjects without a PFO. Remarkably, past work that has set the foundation for our 
current understanding of pulmonary gas exchange efficiency has presumably been carried 
out in subjects with and without a PFO. Included in this prior work, is work that was 
designed to understand human acclimatization to high-altitude. Accordingly, it remains 
unknown how our current understanding of pulmonary gas exchange, either at sea level 
or high-altitude, may differ when taking into consideration the presence of a PFO. 
 The first objective addressed in Chapter IV, was to demonstrate that blood flow 
through IPAVA participated relevantly in pulmonary gas exchange and contributes to the 
efficiency of this process in healthy humans. We had originally proposed to quantify 
blood flow through IPAVA during the conditions in Chapter IV using radiolabeled 
macroaggregated albumin; however, ongoing studies demonstrated the need to validate 
this technique when breathing hyperoxia. The second objective, addressed in Chapter V, 
was to investigate the impact of several pharmacologic interventions targeting blood flow 
through IPAVA during exercise breathing 100% O2 and provide potential insight into the 
mechanistic regulation of these vessels. The third objective, addressed in Chapter VI was 
two fold; A) to characterize human acclimatization to high-altitude (i.e., after 
acclimatization to 5260m) in healthy humans with and without a PFO, with pulmonary 
gas exchange as a key element, and B) to explore the long-term regulation of blood flow 
through IPAVA after acclimatization after acclimatization to high-altitude. 
 4 
HISTORICAL PERSPECTIVE 
 The historical perspective provided herein is based largely off of two 
comprehensive historical reviews, provided by Dr. Andrew Lumb (149) and Dr. John 
West (254). Respiratory physiology has a unique and particularly colorful history in the 
context of pulmonary gas exchange that is also, as alluded to earlier, intimately linked to 
high-altitude physiology. Atmospheric pressure provides the driving pressure that 
ultimately determines the inspired PO2, which in part regulates alveolar PO2 (PAO2) and 
consequently arterial PO2 (PaO2); hence, pulmonary gas exchange. Establishing that 
barometric pressure provides this driving pressure and that it decreases with increasing 
altitude represented a key advance in respiratory physiology. Evangelista Torricelli is 
credited with inventing the mercury barometer in 1644, remarking, that, “We live 
submerged at the bottom of an ocean of the element air, which by unquestioned 
experiments is known to have weight…” Although speculated by Torricelli, experimental 
evidence that barometric pressure falls with increasing altitude was provided by Blaise 
Pascal in 1648, however it would be another 200 years before the significance of this 
finding was realized. 
 Progress in respiratory physiology slowed during the mid 1700’s until the 
profound scientific breakthrough of the characterization of respiratory gases. However, 
leading up to this point there had been several similar, yet unique hypotheses describing 
air. As far back as 570 BC early Greek philosophers, including Hippocrates and 
Anaximenes recognized that air, or ‘pneuma’ as it was referred to at the time, was 
essential to life. Erasistratus believed that air was taken up by the lung and converted into 
a ‘vital-spirit’ within the heart. Interestingly, this vital spirit was also thought to be 
 5 
further converted into ‘animal spirit’ in the brain that was transmitted via the nervous 
system to muscles. Much of this early speculation was investigated by Claudius Galen in 
the 2nd and 3rd century. He too shared Erasistratus’s belief that pneuma was instilled in 
the blood within the lung and was converted to vital spirit in the heart; however, Galen 
also proposed that some blood passed through invisible pores within the interventricular 
septum of the heart, an idea that would persist for another 1400 years. Challenging 
Galen’s theory of invisible interventricular pores was first done by the prolific Arabic 
scientist, Ibn Al Nafis in the 13th century (258), later by Servetus in the 16th century 
(who’s work was deemed heretical by the Catholic church, and with it he was burned at 
the stake), and shortly thereafter again by Realdus Colombo. In the 17th century several 
Oxford physiologists, namely Robert Boyle, Robert Hooke, Richard Lower and John 
Mayow, made major contributions to respiratory physiology. Together they 
demonstrated, by pumping air out of a closed container, that flames were extinguished 
and animals perished, confirming the presence of a vital component present in air. 
Mayow later described the vital component of air as ‘nitro-aerial spirit’ in 1674. 
Although air was still recognized as “vital”, the theory of phlogiston was put forth by 
George Ernst Stah. Phlogiston was thought to be released during the process of 
combustion and therefore was not sustainable for life. In contrast, ‘dephlogisticated air’ 
was sustainable for life and was identified as such by Joseph Priestly in the late 18th 
century. His work involved burning mercuric oxide and noting that candles burned with 
“a remarkably vigorous flame” in this ‘pure air’ and that mice could respire and live 
much longer than in ‘common air’. Of course, mercuric oxide has the chemical 
composition HgO, which releases oxygen on combustion, although Priestly was unaware 
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of this at the time. Shortly thereafter, Carl Scheel also inadvertently produced oxygen in 
his experiments and drew similar conclusions as Priestly, although rather than 
dephlogisticated air, Scheel refered to it as ‘fire air’. Finally, it was Antoine-Laurent 
Lavoisier, a French scientist who in 1777 discovered that ‘eminently respirable air’ was 
not a pneuma, a vital spirit, a nitro-aerial spirit, dephlogisticated air, pure air, or fire air, 
but was actually a chemical element, namely oxygen. In fact Lavoisier actually described 
all three respiratory gases (although carbon dioxide was discovered earlier by Joseph 
Black) described in a passage of his work: “Eminently respirable air (oxygen) that enters 
the lung, leaves it in the form of chalky aeriform acids (carbon dioxide) in almost equal 
volume…Respiration acts only on the portion that is eminently respirable…the excess, 
that is its mephitic portion (nitrogen), is a purely passive medium which enters and 
leaves the lung…without change or alteration. The respirable portion of air has the 
property to combine with blood and its combination results in its red color.” 
 Around this same time with the advent of man-carrying balloons either by hot air 
or helium, the ill effects of high-altitude and the ‘effects of (low) air pressure’ were being 
explored. These balloonists were enticed with the desire to ascend higher and higher, 
reaching altitudes in excess of 10,000m although, not surprisingly, they would often 
return partially paralyzed, unconscious, or even dead. Less extreme and rapid of high-
altitude ascents have taken the form of mountaineering with many accounts in the 19th 
century on the deleterious effects of high-altitude and the imminent development of 
mountain sickness, physical weakness, and of course breathlessness. However, it was the 
French environmental physiologist Paul Bert who effectively married the two fields of 
respiratory physiology and high-altitude physiology. Not surprisingly, Bert is also known 
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as the father of modern high-altitude physiology, with his landmark contribution La 
Pression Barométric published in 1878 (17). It was Bert who elucidated the deleterious 
effects of high-altitude (low pressure) being attributable to reduced PO2. In fact, prior to a 
tragic balloonist ascent, Bert sent caution by way of a letter to the balloonist team when 
he learned they had planned for too little supplemental oxygen. Unfortunately, the letter 
arrived too late. 
 By this time it was clear oxygen was not only necessary for life but it was 
metabolically ‘consumed’. John Dalton published his law of partial pressures in the early 
19th century (43), and later that century additional traction was gained describing the 
presence of oxygen and carbon dioxide in the blood. Much of this work was spearheaded 
by German chemists; Gustav Magnus demonstrated that oxygen and carbon dioxide was 
present in arterial and venous blood but oxygen was most abundant in arterial blood, 
while Lothar Meyer demonstrated that oxygen was not only dissolved in blood by way of 
its non-linear extraction profile. Hemoglobin was soon identified as the compound in 
blood that gave it is characteristic red color, and Hüfner characterized the affinity for 
hemoglobin with oxygen showing that 1.34 ml of oxygen can bind to 1 g of hemoglobin. 
Hüfner used crystallized hemoglobin and showed that the relationship between the 
prevailing PO2 and hemoglobin saturation was a rectangular hyperbola. Credit to the first 
description that the so called ‘oxygen-hemoglobin dissociation curve’ was sigmoidal and 
not rectangular, is to the Danish physiologist, Christian Bohr, due to his experimental 
approach resembling that of Hüfners except rather than using crystallized hemoglobin, 
Bohr used whole human blood (21). 
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 In the 20th century expeditions to high-altitude were becoming increasingly 
popular (257), not only from personal intrigue but for medical and physiological research, 
often centering on respiratory physiology as the measurement of the partial pressure of 
oxygen in arterial blood had become possible. One of the first expeditions was led by 
Nathan Zuntz with Joseph Barcroft and C. Gordon Douglas in 1906. Data collected on 
this expedition indicated that in one subject exercising, his V̇O2 was 1.52 L/min, while 
his PAO2 was 57 mm Hg. Bohr had recently described a numerical procedure to calculate 
the change in PO2 throughout the time course along the pulmonary capillary, and using 
these data from Zuntz he calculated PaO2 to exceed PAO2. Based on his fundamental 
algorithm now known as the ‘Bohr Integration’, and these data from Zuntz, Bohr’s 
interpretation was that the lungs may actively secrete oxygen (23). John Haldane, was a 
prominent respiratory physiologist who rigorously investigated the oxygen secretion 
theory using his own methodological approach. This involved taking three small blood 
samples from the subject, 1) under the experimental conditions, 2) after breathing a small 
percentage of carbon monoxide, and 3) one that was saturated with carbon monoxide 
using coal-gas. To the 2nd blood sample, a standard solution of carmine was added in 0.5-
1.0 ml increments until the ‘pink hue’ matched the 1st vial, the volume was recorded and 
the addition of carmine continued until the hue matched the 3rd vial, and again the volume 
was recorded. Then, the ratio of the volume of carmine required to match the hue of the 
2nd vial to the 1st vial compared the total volume (carmine + blood sample), was divided 
by the ratio of the final volume of carmine necessary for the hue to match the 3rd vial 
compared to the final total volume of blood/carmine (83, 84). Clearly there was a very 
subjective component to this method, and that is qualitatively comparing the pink hues in 
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each vial. Furthermore, a correction factor had to be employed because when the 
carmine-blood samples were exposed to daylight, the color was diminished or very 
difficult to distinguish compared to analyzing the sample in a dark setting. Through these 
experiments the average PaO2 was determined by Haldane to be ~200 mm Hg, notably 
higher than even the inspired PO2 at sea level (~150 mm Hg), and therefore Haldane 
became a strong supporter of Bohr’s oxygen secretion theory. 
 Together Bohr and Haldane championed the oxygen secretion theory until a 
Danish couple, August and Marie Krogh investigated the matter further, as described in 
the historical account offered by Albert Gjedde (74). August Krogh was a pupil a Bohr’s, 
and by way of inventing a microtonometer, determined that PaO2 measured in a rabbit 
was always lower than PAO2 (121). The publication of this initial report was intentionally 
delayed by Krogh in an attempt to resolve the controversy privately first, however, for 
uncertain reasons Bohr was unwavering. Subsequently, the Kroghs published six 
additional papers, all in series, that centered around dismantling the oxygen secretion 
theory. The second paper in this installment ruled out the possibility that oxygen may be 
being converted to carbon dioxide, and thus impacting the PO2 measurement (123). The 
third paper investigated the possibility that the vagus nerve was capable of actually 
secreting gas, which Krogh disproved using turtles showing that severing the vagus nerve 
reduced gas exchange by way of increases in flow rather than inhibiting oxygen secretion 
(124). The fourth paper (125) showed that oxygen tensions cannot be accurately 
calculated using the carbon monoxide approach of Haldane and Douglas (52, 84). The 
fifth paper in this series demonstrated that the solubility of oxygen was much greater than 
that measured by Bohr (126). The sixth paper provided evidence that Bohr’s previous 
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calculations of diffusion coefficients with the help from Haldane were erroneously low 
and based on arbitrary assumptions (122). Finally the seventh paper in this series 
summarized the main findings from the prior six publications (127). Collectively these 
manuscripts refuted the oxygen secretion theory and instead paved the way for the 
‘passive diffusion’ theory and, although Bohr was perhaps more relenting to his prior 
hypothesis, he passed away at his desk in 1911, while Haldane was steadfastly committed 
until his death in 1936. 
 The following year, 1911, after publication of the 7 part series from the Kroghs, 
an important high-altitude expedition took place on the summit of Pikes Peak in Colorado 
at 4300m. The expedition was led by Haldane and published by Douglas (51), which 
reports many influential observations, including the hyperventilation following ascent, 
periodic breathing during sleep, and polycythemia accompanying acclimatization. 
Interestingly the oxygen secretion hypothesis was revisited during this expedition, not 
surprisingly considering whom the leader of the expedition was. It was reported that 
Douglas achieved a V̇O2 during exercise of 2.195 L/min and had an PAO2 of ~60 mm 
Hg, and an PaO2 that was again measured erroneously to be above PAO2. The authors 
then used Krogh’s own calculations of the diffusion capacity of the lung, determined to 
be ~38 ml/min/mm Hg, to determine that the gradient between alveolar PO2 and that in 
the mixed venous blood would need to be 58 mm Hg if the diffusion theory were true. Of 
course this meant the Pv̅O2 was only 2 mm Hg, and unlikely to be physiologically 
possible. Approximately 2 years later Marie Krogh refuted these calculations by 
determining that the diffusing capacity of the lung increased with exercise by as much as 
20-40% (128). Thus, the diffusing capacity of the lung in Douglas was likely greater than 
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~38 ml/min/mm Hg, which allowed for a more reasonable PO2 gradient and cardiac 
output (Q̇T), that was likely possible by way of passive diffusion and therefore without 
oxygen secretion. 
 Concluding the historical context surrounding the feud between the Kroghs 
pushing the diffusion theory and Bohr and Haldane pushing the oxygen secretion theory, 
are data obtained in 1923 by another classical high-altitude expedition to Cerro de Pasco, 
Peru by Joseph Barcroft (7). Barcroft noted that the measured PaO2 was always lower 
than the calculated value for PAO2. Although Haldane would not let go the oxygen 
secretion theory, it is fitting that the final report providing evidence against this pervasive 
theory in the history of respiratory physiology came from a high-altitude expedition. The 
next major advancement in respiratory physiology pertaining to pulmonary gas exchange 
surrounded the matching between alveolar ventilation and pulmonary blood flow. Much 
of this work stemmed from World War II and was initially founded by Wallace Fenn, 
Hermann Rahn, and Arthur Otis (259). Compared to the historical context surrounding 
diffusion, that of alveolar ventilation-to-perfusion matching is quite dull. However it is no 
less important, and will be expanded upon in Chapter II. Intermingled in this era is 
another substantial body of work, that pertaining to arteriovenous connections existing in 
multiple vascular beds, including the lungs. This work would later become the foundation 
for that which we now know represents intrapulmonary arteriovenous anastomoses 
(IPAVA). Again, the historical context of work surrounding the description of IPAVA is 
not exactly colorful, but fundamental to this dissertation and will also be expanded upon 
in Chapter II. 
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 Collectively, this historical perspective is intended to provide an initial starting 
point describing the turbulent and exciting history of respiratory physiology. Particularly 
the fascinating origins of how we have come to understand the importance of the air we 
breathe and the remarkable link between respiratory physiology and high-altitude 
physiology. Lastly, the controversy surrounding the oxygen secretion vs. diffusion 
theories was expanded upon to illustrate that, as is common in science, theories are only 
theories until proven wrong. Secondarily, methodological limitations such as those 
experienced by Haldane in measuring PaO2 represented the crux of some of these issues. 
As will be described, some potential interesting parallels may be drawn from this 
historical review and the current state of our working knowledge of pulmonary gas 
exchange. 
 
BACKGROUND AND SIGNIFICANCE 
Pulmonary Gas Exchange Efficiency 
 Although the lung serves multiple important functions, a major role is to 
exchange gases between the atmosphere and blood. Pulmonary gas exchange is a 
deceptively complex process, that is dependent upon many factors, including the 
diffusion capacity of the blood-gas barrier (Dm), pulmonary capillary blood volume (Vc), 
pulmonary blood flow, the gradient between alveolar (PAO2) and mixed venous PO2 
(Pv̅O2) the non-linear O2 dissociation curve that is also impacted by body temperature, 
acid-base status, and PCO2, the rate at which O2 combines with hemoglobin that is also 
non-linear and is a function of the prevailing O2 saturation (θ), and the fact that O2 is also 
transported dissolved in the plasma. The efficiency of this process is ultimately defined 
 13 
by the difference between PAO2 and arterial PO2 (PaO2), termed the alveolar-to-arterial 
PO2 difference (A-aDO2). An A-aDO2 of 0 mm Hg reflects perfect pulmonary gas 
exchange, while impairments in this process manifest as an A-aDO2 >0 mm Hg. Three 
factors can theoretically contribute to impairments in pulmonary gas exchange efficiency; 
alveolar ventilation-to-perfusion (V̇A/Q̇) inequality, incomplete equilibration between 
end-capillary PO2 (Pc’O2) and PAO2 (diffusion limitation), and right-to-left shunt. The 
normal mammalian lung at rest is remarkably efficient at exchanging gases between the 
alveolar air and capillary blood, because all of these factors are not problematic at rest. 
However, during conditions that challenge the lungs ability to exchange gases (i.e., 
during exercise or breathing hypoxic gas mixtures), the efficiency of this process 
decreases. Thus, the matching between alveolar ventilation (V̇A) and pulmonary blood 
flow may deteriorate, pulmonary capillary transit time may decrease and be insufficient 
for complete O2 equilibration, and the contribution of right-to-left shunt may increase due 
to the reduction in Pv̅O2. 
 Over the last century, considerable work has been done to investigate the relative 
contribution that each of the three aforementioned factors has in explaining the measured 
A-aDO2 at rest and during exercise at sea level and high-altitude. Although technically 
very challenging, several techniques have been developed to partition the contribution of 
these factors apart and much of our current understanding of pulmonary gas exchange 
efficiency has come from this work. The multiple inert gas elimination technique 
(MIGET) was developed to quantify V̇A/Q̇ inequality based on the retention and 
excretion of 6 inert gases of varying solubility (236). In theory, the MIGET can also 
quantify the contribution of intrapulmonary right-to-left shunt due to the fact that blood 
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flow through an intrapulmonary right-to-left shunt represents a V̇A/Q̇ ratio of 0. Thus, any 
portion of the A-aDO2 not explained by V̇A/Q̇ inequality and intrapulmonary right-to-left 
shunt determined using the MIGET is attributed to the effects of diffusion limitation and 
postpulmonary right-to-left shunt via the bronchial and Thebesian circulations (229). 
With a quantification of V̇A/Q̇ inequality and intrapulmonary shunt using the MIGET, 
partitioning the remainder of the A-aDO2 between diffusion limitation and 
postpulmonary shunt can be done using the 100% O2 technique (196). The 100% O2 
technique is based on the principle that with the removal of alveolar N2, as occurs when 
breathing a fraction of inspired O2 (FIO2) = 1.0, the PAO2 in all lung units must increase 
to that of the inspired PO2 less alveolar PCO2 (PACO2). There is then little discrepancy in 
PAO2 between lung units, regardless of their respective VA/Q ratios, and how poorly 
ventilated they may be. Furthermore, when breathing a FIO2 = 1.0, Pv̅O2 is only 
marginally increased (to ~50 mm Hg) compared to breathing room air at sea level and 
therefore, not only is the driving gradient between PAO2 and Pv̅O2 maximally increased, 
but the slope of the O2 dissociation curve between those points reduced. It follows then 
that when breathing a FIO2 = 1.0 V̇A/Q̇ inequality and diffusion limitation are eliminated 
as potential contributing factors to the A-aDO2, leaving only right-to-left shunt. In 
combination, the MIGET and 100% O2 technique then theoretically allow for the 
quantification and separation between V̇A/Q̇ inequality (from the MIGET), all sources of 
right-to-left shunt (from the 100% O2 technique), and diffusion limitation (from the 
remainder of the A-aDO2 not explained by V̇A/Q̇ inequality and right-to-left shunt). 
Furthermore, by subtracting intrapulmonary right-to-left shunt (from the MIGET) from 
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all sources of right-to-left shunt (from the 100% O2 technique), the contribution of 
postpulmonary right-to-left shunt can be obtained. 
 Of course, the above partitioning assumes these gas exchange dependent 
techniques are accurately measuring each factor; specifically, the contribution of right-to-
left shunt from the MIGET and 100% O2 technique. Non-capillary gas exchange has been 
documented in humans (108, 109, 209) and cats (40) and therefore may result in an 
underestimation of intrapulmonary right-to-left shunt using the MIGET. Breathing a FIO2 
= 1.0 during exercise has been shown to prevent or reduce blood flow through IPAVA 
detected using saline contrast echocardiography (54, 144), and therefore right-to-left 
shunt measured during exercise breathing a FIO2 = 1.0 would not include contributions 
from blood flow through IPAVA. Interestingly, the classical understanding of pulmonary 
gas exchange efficiency described by data obtained using the MIGET and 100% O2 
technique emphasizes the relative importance of V̇A/Q̇ inequality and diffusion limitation 
while suggesting a minimal contribution of right-to-left shunt from all sources. 
 The idea that blood flow through IPAVA contributes relevantly to pulmonary gas 
exchange efficiency as a source of right-to-left shunt (24, 143, 216) is not supported by 
prior work using the MIGET or 100% O2 technique. Pooling data from several studies 
using the MIGET (101, 112, 175, 185, 195), intrapulmonary shunt averages 0.2 ± 0.7% 
of the Q̇T during exercise (V̇O2 = 3.7 ± 0.7 L/min) breathing room air at sea level. Work 
by Vogiatzis et al. (233) reports right-to-left shunt measured during exercise in subjects 
breathing a FIO2 = 1.0 to average 0.5 ± 0.5% of the Q̇T. In contrast to these data obtained 
using the MIGET and 100% O2 technique, data obtained using solid microspheres and 
radiolabeled macroaggregates of albumin (MAA) reports appreciably higher values of 
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intrapulmonary right-to-left shunt. Intravenously injected 25 and 50 µm microspheres in 
exercising dogs confirms that blood flow through IPAVA does occur during exercise and 
was calculated to be 1.4% (range 0.2 to 3.1 %) of the Q̇T (215). Studies in healthy 
humans using Technetium 99m-labelled MAA (99mTc-MAA) and gamma camera 
imaging measured blood flow through IPAVA to be 1.3% (range −0.3 to 2.7%) of the Q̇T 
during maximal exercise (141). These studies used MAA with a mean diameter of 20–40 
µm and 90% of MAA between 10 and 90 µm in size. Work prior to this used 99mTc 
albumin microspheres with a size range of 7-25 um in diameter and an increase in shunt 
of 2.4% of the Q̇T was reported in 5 normal subjects during exercise, with a range of -2.4 
to 5.9% (261). 
 Accordingly, there appears to be a discrepancy between intrapulmonary shunt 
measured using the MIGET and right-to-left shunt measured using the 100% O2 
technique compared to blood flow through IPAVA determined using large diameter 
99mTc-MAA and solid microspheres. As previously mentioned this discrepancy is not 
without precedence (72, 245). All prior work investigating the potential contribution of 
blood flow through IPAVA to pulmonary gas exchange efficiency has been done in 
humans during conditions where the relative contribution of V̇A/Q̇ inequality and 
diffusion limitation cannot be rigorously excluded. For this reason, blood flow through 
IPAVA has only been correlated with impairments in pulmonary gas exchange efficiency 
(24, 143, 216). 
Regulation of Blood Flow Through IPAVA: Hyperoxia 
 In addition to the physiological relevance of blood flow through IPAVA being 
unclear with respect to pulmonary gas exchange efficiency, the mechanistic regulation of 
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blood flow through IPAVA remains unclear as well. Conditions known to increase blood 
flow through IPAVA (exercise, breathing hypoxic gas mixtures, and the intravenous (i.v.) 
infusion of catecholamines) are all associated with increases in Q̇T and pulmonary arterial 
systolic pressure (PASP). One attractive hypothesis to regulating blood flow through 
IPAVA is that it responds passively to this increase in Q̇T and PASP (133, 216). 
However, during exercise breathing a FIO2 = 1.0 blood flow through IPAVA is prevented 
or significantly reduced despite Q̇T only decreasing by ~10% for a given V̇O2 and no 
change in PASP (80). How then can we explain the hyperoxia-mediated reduction in 
blood flow through IPAVA? One possible explanation is that a distinctly different 
mechanism underlying the hyperoxia-mediated reduction in blood flow through IPAVA 
exists, which is presumably an active, but selective, vasoconstriction of pulmonary 
vascular smooth muscle. Indeed, breathing a FIO2 = 0.40 has been shown to cause 
significant redistributions in pulmonary blood flow within as short as 10 min as 
demonstrated in sheep using 15 µm microspheres (162). Similarly, the absolute V̇A/Q̇ 
ratio is increased in anesthetized pigs ventilated with a FIO2 = 0.50 measured using 15 
µm microspheres (93). 
 Thus, these data demonstrate that hyperoxia is capable of acutely and dynamically 
altering the pulmonary vasculature. Although vascular smooth muscle tone is affected by 
a multitude of vasoactive substances, a common theme is the necessity to increase or 
decrease intracellular calcium levels in order to elicit a vasoconstrictor or vasodilator 
response, respectively. Considering the possibility that IPAVA are lined with vascular 
smooth muscle raises the potential to pharmacologically target these vessels during 
exercise breathing a FIO2 = 1.0. Pharmacologically reversing the hyperoxia-mediated 
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reduction in blood flow through IPAVA during exercise breathing a FIO2 = 1.0 would 
suggest a potential mechanistic regulatory pathway controlling blood flow through 
IPAVA. Alternatively, if IPAVA are unresponsive to these pharmacologic interventions, 
it can be determined that the pathways involved may not be obligatory to regulating 
blood flow through IPAVA during exercise in hyperoxic conditions. This work represents 
the first pharmacological investigation into this area. 
Pulmonary Gas Exchange Efficiency After Acclimatization to Hypobaric Hypoxia in 
Subjects With and Without a Patent Foramen Ovale 
 It is well established that pulmonary gas exchange progressively worsens in a 
workload dependent manner during exercise at sea level (48). This impairment in 
pulmonary gas exchange efficiency during exercise is exacerbated in acute hypoxia, such 
that for any given V̇O2, the alveolar-to-arterial PO2 difference (A-aDO2) is greater 
compared to exercise in normoxia (235). Following acclimatization to hypobaric hypoxia, 
pulmonary gas exchange efficiency is thought to improve compared to acute hypoxia (88, 
203). Seminal work from Dempsey et al. (47) reported a trend for an increased A-aDO2 
during treadmill walking after 4 days at 3100m compared to sea level, and a partial 
normalization during the same exercise protocol following 21 days at 3100 m compared 
to that obtained after 4 days. Bebout et al. (13) subsequently demonstrated that, compared 
to acute normobaric hypoxia, acclimatization to 3800m for 2 weeks resulted in an ~3 mm 
Hg reduction in the A-aDO2 during submaximal cycle ergometer exercise. Calbet et al. 
(28) subsequently reported that, compared to acute normobaric hypoxia, acclimatization 
to 5260m for 9-10 weeks resulted in an ~9 mm Hg reduction in the A-aDO2 during 
submaximal cycle ergometer exercise. Collectively, these data suggest that pulmonary 
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gas exchange efficiency in non-acclimatized individuals improves with acclimatization to 
high-altitude compared to acute hypoxia. 
 The initial impairment in pulmonary gas exchange efficiency in acute hypoxia is 
likely explained by an increase in diffusion limitation secondary to the reduction in 
PAO2, and increase in Q̇T (i.e., decreased pulmonary capillary transit time) for a given 
V̇O2 compared to exercise breathing room air at sea level (183, 184, 229). After 
acclimatization, the improvement in pulmonary gas exchange efficiency is also thought to 
result from a comparatively lessened degree of diffusion limitation; secondary to, not 
only an increase in PAO2 and decreased Q̇T for a given V̇O2 compared to exercise in 
acute hypoxia (28, 29, 31) but also to, potential improvements in pulmonary diffusing 
capacity (3). Additional rationale for the emphasis on initial impairments and subsequent 
improvements in diffusion limitation explaining the initial impairment and subsequent 
improvement in pulmonary gas exchange efficiency during exercise at high-altitude is 
that the contributions of V̇A/Q̇ inequality and right-to-left shunt to the A-aDO2 decrease 
as the level of hypoxia increases (255, 256). 
 However, the prior work describing this paradigm is: 1) based off of data 
collected using functional gas exchange dependent methods, (i.e., the MIGET and 100% 
O2 technique) that may not include the contribution of blood flow through IPAVA to the 
A-aDO2; and, 2) has presumably been carried out in subjects with and without a PFO. 
Yet, individuals with a PFO have an additional source of right-to-left shunt, via the 
foramen ovale, compared to individuals without a PFO. Lovering et al. (145) has 
demonstrated that pulmonary gas exchange efficiency at rest (but not during exercise) in 
subjects with a PFO is significantly worse when breathing room air at sea level and in 
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acute normobaric hypoxia (FIO2 = 0.12) compared to subjects without a PFO. As 
mentioned earlier, the contributions of V̇A/Q̇ inequality and right-to-left shunt to the A-
aDO2 decrease as the level of hypoxia increases; however, a hallmark of acclimatization 
to high-altitude is an increase in PaO2. Therefore, for the same reason that the effect of a 
given volume of right-to-left shunt to the A-aDO2 is less in acute hypoxia (due to the 
difference between Pv̅O2 and PaO2 decreasing), the effect of this same volume of right-
to-left shunt to the A-aDO2 is greater after acclimatization (due to the difference between 
Pv̅O2 and PaO2 increasing). Of course, the increase in PaO2 after acclimatization to high-
altitude is only secondary to an increase in alveolar ventilation. Meaning for the same 
volume of pulmonary blood flow, there will be an overall increase in the V̇A/Q̇ ratio that 
should correspond to a reduction in the extent of heterogeneity in PO2 between alveoli 
(31, 63, 204).  
 In summary, the improvement in pulmonary gas exchange efficiency after 
acclimatization is likely driven by a lessened degree of diffusion limitation, however the 
contribution of right-to-left shunt to the A-aDO2 is also increased; and individuals with a 
PFO have an additional source of right-to-left shunt. Furthermore the prevalence of PFO 
in the general population is ~35-40% (55, 156, 266). Accordingly, it remains possible 
that after acclimatization to high-altitude, pulmonary gas exchange efficiency may only 
be improved in individuals without a PFO. Similarly, other physiologic adaptations 
accompanying acclimatization to high-altitude also have never been investigated in 
subjects with and without a PFO, specifically blood flow through IPAVA and ventilatory 
acclimatization. 
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STATEMENT OF PROBLEM 
 Pulmonary gas exchange is a complex process that can be impaired by several 
factors (i.e., V̇A/Q̇ inequality, diffusion limitation and right-to-left shunt). Partitioning the 
relative contribution from each factor from the measured A-aDO2 has technical 
challenges, but in order to draw conclusions on one contributor (i.e., right-to-left shunt) 
the others must be eliminated (i.e., V̇A/Q̇ inequality and diffusion limitation). To date, the 
contribution of blood flow through IPAVA on pulmonary gas exchange efficiency has 
not been evaluated in an experimental setting that eliminates contributions from V̇A/Q̇ 
inequality and diffusion limitation. Therefore, whether or not blood flow through IPAVA 
contributes to pulmonary gas exchange efficiency remains controversial. Secondarily, the 
mechanisms regulating blood flow through IPAVA remain speculative, particularly those 
mediating the hyperoxia-mediated reduction in blood flow through IPAVA during 
exercise. Lastly, although blood flow though IPAVA has been demonstrated to increase 
in acute normobaric hypoxia, the long-term regulation of blood flow through IPAVA 
during chronic hypoxia at rest and during exercise has not been investigated. Moreover, 
prior work characterizing human acclimatization to high-altitude has been carried out in 
subject populations with and without PFO. 
 
PURPOSE AND HYPOTHESES 
 The primary purpose of this dissertation is three fold; 1) to investigate the 
contribution of blood flow through IPAVA on pulmonary gas exchange efficiency with 
V̇A/Q̇ inequality and diffusion limitation eliminated; 2) investigate the potential effect of 
pharmacologic interventions regulating this; and 3) to describe pulmonary gas exchange 
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efficiency in healthy humans with and without a PFO in acute hypobaric hypoxia and 
after acclimatization to hypobaric hypoxia. 
 
Aim #1: Determine Whether or Not Blood Flow Through Intrapulmonary 
Arteriovenous Anastomoses Contributes to Pulmonary Gas Exchange Efficiency 
 To establish IPAVA as physiologically relevant, we intend to demonstrate the 
potential for blood flow through IPAVA to impair pulmonary gas exchange efficiency. 
Previous work addressing this question was completed during conditions in which the 
role for IPAVA to be unequivocally involved in pulmonary gas exchange efficiency 
could not be determined (24, 143, 216). Accordingly, it remains unknown whether or not 
blood flow through IPAVA impairs pulmonary gas exchange efficiency. However, 
confirming that blood flow through IPAVA does contribute to pulmonary gas exchange 
efficiency could result in a paradigm shift in how we understand pulmonary gas 
exchange. As outlined in this dissertation we have developed a novel experimental design 
capable of isolating blood flow through IPAVA and all sources of right-to-left shunt, as 
the only contributing factor to pulmonary gas exchange efficiency. Thus, the first aim of 
this dissertation will be to utilize this experimental design and confirm or refute the 
potential for blood flow through IPAVA to contribute to pulmonary gas exchange 
efficiency. 
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Aim #2: Determine the Effect of Sildenafil, Nifedipine, and Acetazolamide on Blood 
Flow Through Intrapulmonary Arteriovenous Anastomoses During Exercise 
Breathing 100% O2 
 During exercise breathing room air, blood flow through IPAVA is known to 
increase (53, 54, 115, 143, 216), which has been quantified using nuclear imaging 
techniques (141). However, during exercise breathing a FIO2 = 1.0 blood flow through 
IPAVA is prevented or significantly reduced (54, 144). As previously described, the 
explanation for this hyperoxia-mediated reduction in blood flow through IPAVA is 
presumably via an active regulation of IPAVA. Suggesting the involvement of alterations 
in the tone of pulmonary vascular smooth muscle associated with IPAVA. Therefore, 
pharmacologic interventions known to act on pulmonary vascular smooth muscle, and 
specifically cause vasodilation and/or prevent vasoconstriction may be capable of 
preventing this hyperoxia-mediated reduction in blood flow through IPAVA. If so, 
knowledge of the pharmacologic mechanism of action may shed light on the potential 
regulation of IPAVA. Accordingly, the pharmacologic interventions utilized in this 
dissertation were sildenafil, nifedipine, and acetazolamide. Together these medications 
operate through unique cellular pathways, and either promote pulmonary vasodilation via 
augmenting the activity of nitric oxide (sildenafil), inhibiting vasoconstriction via 
blocking L-type calcium channels (nifedipine), or preventing an increase in intracellular 
calcium through a non L-type calcium channel mechanism (acetazolamide). Therefore, 
these pharmacologic interventions act through mechanisms with the potential to prevent 
or reduce the hyperoxia-mediated reduction in blood flow through IPAVA (9). Thus, the 
second aim of this dissertation is to investigate the effect of sildenafil, nifedipine, and 
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acetazolamide on the reduction in blood flow through IPAVA during exercise breathing a 
FIO2 = 1.0. 
 
Aim #3: Characterize Pulmonary Gas Exchange Efficiency in Healthy Humans With 
and Without a Patent Foramen Ovale in Acute and After Acclimatization to Hypobaric 
Hypoxia 
 Pulmonary gas exchange efficiency at rest and during exercise is impaired in 
healthy humans in acute hypoxia compared to when breathing room air at sea level, and 
is improved following acclimatization to hypobaric hypoxia compared to acute hypoxia. 
The mechanism explaining this initial impairment, and subsequent improvement in 
pulmonary gas exchange efficiency is likely driven by initial impairments, and 
subsequent improvements, in diffusion limitation. However, this prior work has 
presumably been done in subjects with and without a PFO, and as described, humans 
with a PFO have an additional source of right-to-left shunt that results in a measureable 
decrement in pulmonary gas exchange efficiency (145). Accordingly, it remains unknown 
how pulmonary gas exchange efficiency after acclimatization differs in humans with and 
without a PFO. Furthermore, although blood flow through IPAVA increases in acute 
normobaric hypoxia (134), it unknown if blood flow through IPAVA is altered following 
acclimatization to hypobaric hypoxia. Thus, the third aim of this dissertation is to 
characterize pulmonary gas exchange efficiency in healthy humans in acute, and after 
acclimatization to, hypobaric hypoxia; and secondarily to investigate effect of 
acclimatization to hypobaric hypoxia on blood flow through IPAVA. 
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 Chapter IV is in review with the Journal of Physiology and Joseph W. Duke, 
Jerold A. Hawn, John R. Halliwill, and Andrew T. Lovering are co-authors. I performed 
the experimental work, led the project, and the writing is entirely my own; Joseph W. 
Duke provided technical and editorial assistance; Jerold A. Hawn placed all radial artery 
catheters; and John R. Halliwill and Andrew T. Lovering helped develop the protocol, 
and provided guidance and editorial assistance. 
 Chapter V is in review with Respiration Physiology & Neurobiology and Joel E. 
Futral, Randall D. Goodman, and Andrew T. Lovering are co-authors. I performed the 
experimental work, led the project, and the writing is entirely mine; Joel E. Futral and 
Randall D. Goodman provided technical assistance with performing echocardiography 
during exercise; and Andrew T. Lovering helped develop the protocol, and provided 
guidance and editorial assistance. 
 Chapter VI is in review with the Journal of Applied Physiology and Steven S. 
Laurie, Julia P. Kern, Kara M. Beasley, Randall D. Goodman, Bengt Kayser, Andrew W. 
Subudhi, Robert C. Roach, and Andrew T. Lovering are co-authors. The data presented in 
this chapter come from a very large, multinational, field based project entitled 
“AltitudeOmics.” However, I performed the experimental work, led this aspect of 
AltitudeOmics, and the writing is entirely mine; Steven S. Laurie, Julia P. Kern, and Kara 
M. Beasley provided technical and editorial assistance; Randall D. Goodman provided 
technical assistance with performing echocardiography during exercise; and Bengt 
Kayser, Andrew W. Subudhi, Robert C. Roach, and Andrew T. Lovering helped develop 
the protocol, and provided guidance and editorial assistance.  
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CHAPTER II 
REVIEW OF THE LITERATURE 
INTRODUCTION 
 This review of the pertinent literature will track sequentially with Chapters IV, V, 
and VI with regard to the overall topic of each. However, areas of research that are 
pertinent across all Chapters are those pertaining to the presence of a patent foramen 
ovale and blood flow through IPAVA. Accordingly, I will begin by reviewing both of 
these subject areas. Following these sections, the subject matter will transition to 
pulmonary gas exchange efficiency, which represents a focal feature of this dissertation 
and is most pertinent to Chapters IV and VI. The factors related to pulmonary gas 
exchange efficiency will be reviewed, followed by the work that has developed our 
current understanding of these areas. Transitioning from pulmonary gas exchange will be 
to the regulation of blood flow through IPAVA including the reduction in blood flow 
through IPAVA during exercise breathing an FIO2 = 1.0.  
 
PATENT FORAMEN OVALE 
 Embryologic development of the fetal heart begins as a single common cavity that 
eventually separates into four distinct chambers (181). In doing so one-way valves 
develop that separate the right and left atria from the right and left ventricle, with the 
purpose being to permit uni-directional blood flow through them. In contrast, separation 
between the right and left atria and the right and left ventricle takes the form of a septal 
wall, with the purpose being to prevent blood flow across between them. However, 
crucial to the developing fetus is a non-fully formed septal division, particularly between 
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the right and left atria (71). Gas exchange occurs in utero at the level of the placenta, by 
way of the mother, and because of this, it is advantageous that blood flow to the 
developing pulmonary circulation be minimal. Maintaining an opening between the right 
and left atria allows blood flow to bypass the developing pulmonary circulation by 
flowing directly from the right-to-left atrium. This opening, called the foramen ovale, 
develops as the septum primum and septum secundum (named based their sequential 
appearance) develop (181). After birth, gas exchange in the infant occurs in the lung and 
no longer via the placenta, and thus, pulmonary blood flow increases from ~20% in utero 
to 100% of the Q̇T (191). This increase in pulmonary blood flow is associated with a fall 
in pulmonary vascular resistance, while systemic vascular resistance gradually increases 
(58). Once systemic vascular resistance exceeds pulmonary vascular resistance, the 
foraman ovale functionally closes by way of the septum primum being pushed against the 
septum secundum (71). Over time the septum secundum forms a permanent anatomic 
seal over the foramen ovale by fusing to the septum secundum (36). A fascinating 
description of the fetal atria from Claudius Galen was included in a review by Bradley 
Patten, originally from John Dalton’s text ‘Doctrine of the Circulation’ (44), providing an 
uncanny description of what we now know as the foramen ovale: 
 “There is a kind of orifice or fenestra common to both…at this orifice there is 
attached a membrane, like a lid or cover opening toward the pulmonary vessel [left 
atrium] so that it will yield to the influx of blood from the vena cava, but will prevent its 
regurgitation into that vessel. …Soon after birth, either within a day or two, or, in some 
animals after four or five days or a little longer, you will find the membrane at the 
foramen coalescing but not yet fully adherent. Looking at the same place in the adult 
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animal, you would say there had never been a time when it was open; and, on the other 
hand, in a foetus, before or immediately after birth when this membrane is attached so to 
speak, only by it’s root, the rest of it hanging free in the vascular cavity, you would 
hardly believe in it’s ever becoming agglutinated.” – (Opera Omnia, vol. IV, p.243; 
translation by Dalton, 1884, p.69 (44) – and quoted from (180)) 
 However, nearly 2 millennia have passed since Galen’s observation and we now 
know permanent anatomical closure of the foramen ovale fails to occur after birth in 
some individuals, and therefore remains ‘patent’ throughout life and is referred to as a 
patent foramen ovale (PFO). Studies examining the prevalence of PFO in the general 
population also have an interesting history and as described by Bradely Patten; 
 “Publications dealing with the failure of the foramen ovale to close have been 
appearing for more than three centuries (181).” - Bradley M. Patten, 1938 
 According to this report, summarizing data obtained on autopsy from 9 studies 
dating from 1837 – 1934, the presence of a PFO was identified in 864 out of the 
combined 4083 cases. The prevalence of PFO in these 9 studies ranged from 15% to 
43%, and averaged ~21% (181). Nevertheless, the publication generally cited as the 
classical reference for the prevalence of PFO is that by Hagen et al., (82) also determined 
on autopsy. This manuscript offers the additional details that describe the size of detected 
PFO that ranged from 1-19 mm and also suggested the prevalence of PFO declined from 
~35% in humans <29 years old to ~25% in humans >30 years old. However, more recent 
work has utilized a different, more sensitive technique (saline contrast echocardiography, 
described in Chapter III), in detecting the presence of a PFO and determined the 
 29 
prevalence to be 35-40% (55, 266), including one report in humans up to ~60 years old 
(156). 
 The right-to-left shunt provided by a PFO has been recognized clinically as a 
potential explanation for neurological insult, including stroke and particularly those that 
are otherwise unexplained i.e., cryptogenic. Lechat et al. (135) reported that the 
prevalence of PFO was significantly higher (40%) in patients with stroke compared to 
patients without stroke (10%). Furthermore, these data also reported that out of the 
patients with stroke, there was a 54% prevalence of PFO in patients with cryptogenic 
stroke. Webster et al. (248) also reported data suggesting the presence of a PFO may be 
an under recognized cause of stroke. In this study there was a 50% prevalence of PFO in 
patients with stroke while only a 15% prevalence of PFO in patients without stroke. 
Homma et al. (99) made the observation that patients with a PFO were at a significantly 
increased risk for cryptogenic stroke compared to subjects with a small PFO. Since these 
studies, the association between PFO and stroke has appeared many times in the literature 
(49, 50, 98, 99, 132, 178, 190, 211). 
 Nevertheless, there have also been several studies demonstrating the presence of 
recurrent paradoxical embolism in patients who have undergone surgical treatment for 
PFO closure. Messé et al. (165) reviewed several comprehensive publications in this area 
(20, 99, 157), and concluded that the risk of recurrent cryptogenic stroke in patients with 
a PFO, was no different than the risk for cryptogenic stroke in patients without a PFO. A 
similar conclusion was also reached by Meier et al. (160) in a recent superiority trial 
across 29 clinical centers in Europe, Canada, Brazil, and Australia, where closure of a 
PFO did not result in a significant reduction in the risk of recurrent embolic events. In a 
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study by Windecker et al. (264) 78 patients with a PFO who had a documented 
neurologic insult underwent surgical intervention for PFO closure, and 8 patients suffered 
recurrent paradoxical embolic events within the first year post-PFO closure. It was noted 
by these authors that the presence of ‘postprocedural shunt’ was a strong predictor for 
recurrent paradoxical embolic events. Postprocedural shunt is the presence of left-sided 
contrast using saline contrast echocardiography, after surgically closing the PFO, 
suggesting an alternative explanation for left-sided contrast. One plausible explanation 
for postprocedural shunt is blood flow through IPAVA, which has recently been 
suggested to be a potentially unrecognized cause of ischemic stroke and transient 
ischemic attack (TIA). Abushora et al. (2) demonstrated that the transpulmonary passage 
of saline contrast was an independent predictor, on the same order of magnitude as 
hypertension and hyperlipidemia, for stroke and/or TIA. 
 Furthermore, as reviewed by Kerut et al. (116) PFO has been implicated in 
several more pathologic process in addition to stroke, including decompression sickness 
in divers (73, 91, 168) and pilots (41), and may exacerbate arterial hypoxemia in patients 
with and chronic lung disease (81, 210). Lastly, it has been hypothesized that individuals 
with PFO may be at an increased risk for the development of high-altitude pulmonary 
edema (HAPE). Right-to-left intracardiac shunt across the PFO is dependent on right 
atrial pressure exceeding left atrial pressure, which can occur transiently during normal 
respiration (64), and is exacerbated during conditions of elevated pulmonary pressures. 
Exaggerated pulmonary hypertension is a hallmark of HAPE, and previous work has 
suggested the prevalence of PFO is >4 times higher in HAPE susceptible than HAPE 
resistant individuals (4). In this theory, the acute increase in pulmonary arterial pressure 
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associated with ascent to high-altitude facilitates right-to-left shunt across the PFO, 
thereby worsening arterial hypoxemia, resulting in a vicious downward spiral of 
increased shunt, leading to increased hypoxemia, leading to increased pressure, and the 
cycle continues (10). 
 Despite the presence of a PFO being recognized since the time of Galen and its 
appreciation in clinical disorders such as stroke, transient ischemic attack, migraine, 
decompression sickness and HAPE, its appreciation to contribute to pulmonary gas 
exchange efficiency is less widely accepted. Although previous research has suggested a 
role for PFO to explain the occurrence of systemic arterial oxygen desaturation or 
exaggerated arterial oxygen desaturation in patients with lung disease (81, 210), these 
studies do not have measures of pulmonary gas exchange efficiency. Lovering et al. 
(145) did investigate the effect of a PFO on pulmonary gas exchange efficiency and 
demonstrated that subjects with a PFO have an increased A-aDO2 at rest breathing room 
air and a FIO2 = 0.12. However, no difference was observed in the A-aDO2 between 
subjects with and without a PFO during exercise, which the authors reasoned, to be due 
to the possibility that the volume of blood flow through the PFO remained constant from 
rest to exercise. Interestingly, in light of recent work demonstrating that the degree of 
left-sided contrast visualized on release of a Valsalva maneuver correlates to the size of 
the PFO (64), of the 8 subjects with a PFO in the study by Lovering et al., 6 would be 
classified as having a ‘small’ PFO and 2 would be classified as having a ‘large’ PFO. 
Strictly speaking the size or diameter of the PFO is less important than the volume of 
blood flow across it, yet intuitively a larger PFO should confer a larger volume of right-
to-left shunt compared to a smaller PFO. This is illustrated both by the greater degree of 
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left-sided contrast visualized from a large PFO in the work by Fenster et al. (64) and by 
our data in Chapter VI. As will be described, those subjects with a large PFO (n = 6) had 
an increased A-aDO2 compared to those subjects with a small PFO (n = 5) at rest and 
throughout exercise at 70, 100, 130, and 160 Watts (Figure 6.2). 
 In summary, the prevalence of PFO in the general population is ~35-40% and 
blood flow across the PFO is an undisputed source of right-to-left shunt. Despite the 
appreciation of PFO pertaining to clinical disorders, the contribution of a PFO to 
pulmonary gas exchange efficiency is underappreciated. Interestingly, the prior work that 
has characterized the basis for our current understanding of pulmonary gas exchange 
efficiency has been carried out in subjects with and without a PFO. Thus, a priority in 
Chapter IV and V was to screen and exclude subjects for PFO, as the presence of a PFO 
would cloud our interpretation of blood flow through IPAVA using TTSCE as well as our 
interpretation of pulmonary gas exchange efficiency. In Chapter VI, per the study design, 
subjects with and without a PFO were included and the data analysis was separated for 
those with and without a PFO. 
 
INTRAPULMONARY ARTERIOVENOUS ANASTOMOSES 
Pre-capillary arteriovenous anastomoses form a direct connection between the 
arterial and venous circulation, and have been documented in the pulmonary circulation 
of the infant (226, 262) and adult human (225, 228), as well as in birds, dogs, cats, 
rabbits, and rats (12, 171, 179, 186, 188, 215). With the exception of the work done by 
Rahn, Stroud and Tobin in 1952, the remaining aforementioned studies used large 
diameter (15-500 µm) glass or synthetic microspheres to demonstrate the presence of 
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intrapulmonary arteriovenous anastomoses (IPAVA). This anatomic-based technique 
operates on the principle that anything larger than the diameter of the largest pulmonary 
capillary (≤13 µm) is filtered out and prevented from reaching the pulmonary venous 
circulation (75). Thus, microspheres injected into the pulmonary arterial circulation can 
only be recovered within the pulmonary venous effluent if a large diameter IPAVA, 
which bypasses the pulmonary capillary bed, is present and allows blood to flow through 
it. Criticism toward the majority of this seminal, anatomic-based work using large 
diameter microspheres has been due to the non-physiologic conditions the isolated lung 
models or animal preparations were studied under. However, more recently, Lovering et 
al. confirmed the presence of IPAVA using 25 and 50 µm microspheres in isolated 
healthy human and baboon lungs which were ventilated and perfused with physiologic 
pressures (146). 
 For ethical and medical reasons it is not possible to inject solid, non-
biodegradable microspheres into human subjects. However, gas-filled microbubbles 
(saline contrast), which pose no risk for permanent embolization of the lung, can be used 
in human subjects and are the basis for a technique called transthoracic saline contrast 
echocardiography (TTSCE). TTSCE is considered the gold standard, minimally invasive 
anatomic-based technique for detecting blood flow through IPAVA in humans (14, 30, 
71, 94, 128). Saline contrast is created by agitating saline and air together, which is then 
injected into a peripheral vein while the heart is visualized in the apical, four-chamber 
view using transthoracic ultrasound. Once injected, this microbubble replete blood very 
quickly opacifies the right-side of the heart, appearing as a “cloud of echos,” where it is 
then pumped through the pulmonary circulation (78, 79). Similar to microspheres, the 
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pulmonary microcirculation functions as a biological sieve to filter out bubbles >13 µm 
in diameter and prevent their appearance in the left heart (163, 164). Additionally, due to 
the physical properties governing the in vivo dynamics of gas-filled bubbles, those 
bubbles that are smaller than 13 µm rapidly dissolve before reaching the left heart (269, 
270). Accordingly, the appearance of saline contrast in the left heart, in subjects without a 
PFO post peripheral venous injection demonstrates blood flow through IPAVA (25, 26, 
46, 60, 94-96, 159, 189, 198, 231, 269-273). 
 Using TTSCE we have shown that ~30% of the general healthy population do not 
demonstrate blood flow through IPAVA at rest breathing room air, while ~40% have a 
PFO, and the remaining ~30% demonstrate no left-sided contrast (55). However, 
breathing hypoxic gas mixtures at rest (134) results in the recruitment of IPAVA and the 
transpulmonary passage of saline contrast. Data from Niden and Aviado in 1956 support 
these findings by demonstrating that in intact, anesthetized dogs using an over 
embolization model, the number of large diameter (60-420 µm) glass microspheres 
recovered from the pulmonary venous effluent increased during ventilation of hypoxic 
gas (FIO2 = 0.10) compared to room air (171). More recent work by Bates et al. in 2012 
demonstrates that in intact spontaneously breathing rats, the number of 15-70 µm 
microspheres that escape pulmonary filtration is significantly increased when breathing 
hypoxic gas (FIO2 = 0.08) compared to breathing room air (12). 
 Similarly, during exercise breathing room air IPAVA are also recruited and allow 
for the transpulmonary passage of saline contrast (53, 54, 115, 143, 173, 216). These data 
are supported by work done by Stickland, Lovering & Eldridge in 2007 which 
demonstrated that 25 µm microspheres escaped pulmonary filtration in 5/6 exercising 
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dogs, whereas at rest the pulmonary capillary bed prevented the transpulmonary passage 
of microspheres in 8/8 dogs (215). Furthermore, Lovering et al. in 2009 demonstrated 
that in healthy humans, exercise resulted in an increase in the transpulmonary passage of 
large diameter (15-105 µm) technetium-99m labeled macroaggregated albumin particles 
(141). 
 In contrast to exercise breathing room air, during exercise breathing 100% O2, 
IPAVA remain closed and the transpulmonary passage of saline contrast is prevented or 
significantly reduced (54, 144). Previous work by Niden and Aviado in 1956 also 
supports these data by demonstrating in intact, anesthetized dogs using an over 
embolization model, the number of large diameter (60-420 µm) glass microspheres 
recovered from the pulmonary venous effluent decreased during ventilation of 100% O2 
(171). Moreover, recent work from our lab using nuclear imaging techniques quantifies 
the reduction in blood flow through IPAVA during exercise breathing a FIO2 = 1.0 
(Duke, Elliott, et al., In Preparation). 
 To summarize, over the past 60 years a significant body of anatomic-based 
evidence has been collected to support the existence of large diameter IPAVA. In fact, 
Sirsi and Bucher stated in 1953 that, “It is now generally accepted that arteriovenous 
anastomoses exist in the lungs” (208). Additionally, these ex-vivo microsphere data are 
supported by in-vivo work done in healthy humans using TTSCE and macroaggregated 
albumin. Thus, not only is it clear that IPAVA exist using TTSCE, the general conditions 
in which blood flow through these vascular conduits occurs (i.e., during exercise, 
breathing hypoxic gas mixtures, and during the i.v. infusion of catecholamines) and is 
prevented (i.e., during conditions of alveolar hyperoxia) have now been described. 
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Nevertheless, the physiologic significance of blood flow through IPAVA remains 
controversial largely due to, 1) the undefined role for blood flow through IPAVA to 
contribute to pulmonary gas exchange efficiency by providing a source of right-to-left 
shunt, and 2) the undefined mechanistic regulation of blood flow through IPAVA. Both 
of these points will be expanded upon in the proceeding sections and Chapters. 
 
PULMONARY GAS EXCHANGE 
 Pulmonary gas exchange describes the transfer of gas between the atmosphere 
and pulmonary capillary blood, with a particular emphasis on the transfer of O2 from the 
alveolar air to the pulmonary capillary blood and the elimination of metabolically 
produced CO2 from the pulmonary capillary blood to the alveolar air. Fundamental to this 
process is adequately ventilating the alveolar air space, i.e., alveolar ventilation (V̇A). 
This differs from the more general term, minute ventilation (V̇E), by subtracting the 
volume of anatomic dead space from the tidal volume (149). In addition to anatomic dead 
space, if portions of the lung are ventilated but not receiving blood flow, these portions 
would also reflect physiologic dead space. As will be described later, these areas reflect 
an alveolar ventilation-to-perfusion (V̇A/Q̇) ratio equal to infinity (). The measurement 
of gas flow, i.e. V̇E, using modern equipment is relatively straightforward, and 
determining V̇A can be calculated as described in the classic text by Hermann Rahn and 
Wallace Fenn (187): 
V! = VCO!!×!KPACO!  
Equation 2.1. Alveolar Ventilation 
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where V̇CO2 represents the volume of CO2 produced, and K is a correction factor. In 
practice, PaCO2 can be used as a surrogate for PACO2, assuming complete end-capillary 
CO2 equilibration; an assumption with relatively minor error associated with it, 
particularly in healthy humans at rest (242). The correction factor K corrects V̇CO2 to 
body temperature and pressure: 
K = 273+ T! !× !760273  
Equation 2.2. Conversion Factor, K 
where TB is body temperature, 760 mm Hg is barometric pressure (PB) at sea level, and 
273 Kelvin is 0. At sea level and 37, K is equal to 863 mm Hg. 
 Alveolar ventilation at a given metabolic rate ultimately regulates PAO2, which is 
also a function of the inspired PO2. Direct measures of PAO2 are not possible, yet PAO2 
can be calculated with knowledge of PB, FIO2, PACO2, and V̇CO2/V̇O2. Of course the 
accuracy of this calculation depends on the accuracy of all of these measurements, and 
again, in practice PaCO2 can be used as a surrogate for PACO2 while PB should be 
corrected for water vapor pressure and body temperature, especially during exercise 
(196): 
PAO! = ! P! !− !e!.!"#$%#!$!×!!!! !!.!"#$"# !×!FIO! !− !PaCO!!× ! FIO! + 1!− !FIO!RER  
Equation 2.3. Alveolar Gas Equation 
 Finally, PaO2 can be directly measured using a blood gas analyzer (described 
further in Chapter III) and ultimately, the difference between PAO2 and PaO2, reflects the 
efficiency of pulmonary gas exchange for O2. This is referred to as the alveolar-to-arterial 
PO2 difference (A-aDO2), where an A-aDO2 = 0 mm Hg reflects perfect pulmonary gas 
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exchange efficiency and anything >0 mm Hg reflects an impairment in this process. In 
theory the A-aDO2 can never be <0 mm Hg, however in practice due to the 
aforementioned errors inherent to calculating PAO2 negative values are not uncommon in 
the literature, particularly when subjects are ‘resting’ before beginning exercise (112, 
142, 175, 216, 234). Potential factors that can impair pulmonary gas exchange efficiency 
are, 1) incomplete end-capillary O2 equilibration (diffusion limitation), 2) alveolar 
ventilation-to-perfusion (V̇A/Q̇) inequality, and 3) right-to-left shunt. Sources of right-to-
left shunt include, 1) postpulmonary shunt via the bronchial and Thebesian circulations, 
which drain the lungs and heart, respectively, 2) intracardiac shunt via the PFO, and 3) 
intrapulmonary shunt. 
Pulmonary Diffusion 
 Pulmonary O2 diffusion is a complex process mediated by several factors, 
including the gradient between PAO2 and capillary PO2 (PcO2) and the oxygen diffusing 
capacity of the lungs (DLO2). The oxygen diffusing capacity of the lungs is defined as the 
amount of oxygen transferred per minute (V̇O2) divided by the difference between PAO2 
and capillary PO2 (PcO2). Which rearranges to form the familiar equation of Fick’s First 
Law of Diffusion when applied to pulmonary gas exchange that was first conceptualized 
by Bohr (23): V̇̇O!(!) = !DLO![PAO! − PcO! ! ] 
Equation 2.4. Fick’s First Law of Diffusion 
 Therefore, this process is not instantaneous and based off of this principle it is 
clear that this process can be impaired if the mean pulmonary capillary erythrocyte transit 
time is insufficient to allow full equilibration between end-capillary PO2 (PcʹO2) and 
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PAO2. Furthermore, complete equilibration between PcʹO2 and PAO2 can be impacted by 
the partial pressure gradient between PAO2 and PcO2. As previously described, PAO2 is 
chiefly impacted by the inspired PO2 as well as the degree of alveolar ventilation (V̇A) 
and prevailing metabolic rate. Pulmonary capillary PO2 initially reflects mixed venous 
PO2 (Pv̅O2), and the gradient between Pv̅O2 and PAO2 plays a significant role in the rate 
at which O2 diffuses and binds with hemoglobin. Of note, although generally speaking a 
larger gradient confers a more rapid diffusion of O2, what is most important for 
determining the rate of O2 equilibration is the slope of the O2 dissociation curve (βO2) 
between the particular PAO2 and Pv̅O2 under study (182, 242, 243). 
 Finally, DLO2 can be separated into two distinct but related processes; 1) the 
diffusion of O2 across the blood gas barrier and through the plasma (i.e., the membrane 
component, Dm), and 2) the diffusion of O2 into the red cell and combining with 
hemoglobin (i.e., the red cell component, θ) (200). The membrane component is treated 
as applicable to the entire lung, however, for the same to be true of θ, it must be 
multiplied by the entire pulmonary capillary blood volume (Vc). Accordingly, the 
resistance to diffusion of O2 in the lung is the inverse of DLO2. Analogous to electrical 
theory (Ohms law), resistances are additive when in series and therefore the inverse of 
Dm and θ are additive to produce the entire resistance to diffusion of O2 in the lung. This 
relationship was derived rigorously by Roughton and Forster in 1957 (200): 1DLO! = 1DmO! + 1(θ!×!Vc) 
Equation 2.5. Roughton-Forster Equation 
 These two fundamental relationships form the basis of the current working “Bohr 
Integration” for calculating the rate of rise in PO2 of a ‘slug’ of blood moving through a 
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pulmonary capillary. Although a comprehensive review of the mathematical derivation is 
beyond the scope of this dissertation, it is worthwhile to briefly review the process as it 
still employed today to describe pulmonary capillary diffusion equilibration. Re-
expressing the left and right hand side of Equation 2.4 for O2 concentrations at time t, 
and incorporating Equation 2.5, respectively, produces the first order differential 
equation describing the rate of O2 diffusion as a function of time (240, 242): 
!CcO!∂! = 100Vc × 11DmO! + 1V!!×!θ × PAO! − PcO!  
Equation 2.6. Rate of Rise in Pulmonary Capillary PO2 
where !CcO2/!t is the O2 content in the pulmonary capillary blood at time t and is a 
function of the previously defined terms. Content is expressed as ml O2 per dL of blood 
as described by the content equation: 
O!!Content! = ! 1.39!×!Hb!× ! SO!100 + ! 0.003!×!PO!  
Equation 2.7. Oxygen Content Equation 
 Due to the non-linearity of the O2 dissociation curve and the fact that θ varies as a 
function of PcO2 (i.e., O2 saturation) this equation cannot be directly integrated and 
therefore must be numerically solved. This is accomplished using 4th order Runge-Kutta 
method of numerical integration that is optimized for a ‘large’ (in the computing sense) 
time step that maintains accuracy while reducing computing time. Doing so using 
previously published computer algorithms (240, 243) solves this equation for ‘small’ (in 
the physiological sense) time steps (0.001 sec). Where the number of necessary solutions 
depends on the pulmonary capillary transit time [(i.e., Vc/pulmonary blood flow)*60] 
which is 0.75 sec assuming pulmonary blood flow equals 6 L/min and Vc equals 75 ml. 
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The value for DmO2 is usually 40 ml O2/min/mm Hg, and that of θ depends on the initial 
PcO2 which is solved as a callable unit within Equation 2.6 according to Staub et al. 
(212, 213). In the previously published computer algorithms implementing this Bohr 
Integration, computing the corresponding PcO2 from the CcO2 for a given time step is 
done using a regula falsi in three dimensions method of iteration (177). Indeed, 
computing the PcO2 that corresponds to a given CcO2 is much more complicated than the 
reverse, which can be done using the callable unit described by Kelman (114). However, 
another way to convert CcO2 into PcO2 is to determine the O2 saturation (neglecting 
dissolved PO2) that would yield the given CcO2 using the first half of Equation 2.7. Then 
by way of assuming a value for the P50, the corresponding PO2 can be computed using the 
Hill equation (90): 
SO! = PO!!PO!! + P!"!  
Equation 2.8. Hill Equation 
where SO2 is the hemoglobin-O2 saturation corresponding to the calculated PO2, and 
corresponding P50 (i.e., the PO2 which results in a SO2 of 50%). The superscript ‘n’ is the 
Hill coefficient, which is equal to 2.7 in humans. By way of the Hill equation as 
described, I have recapitulated this Bohr Integration procedure described by Dr. Peter 
Wagner and Dr. John West using MatLab. However, through personal communication 
with Dr. Peter Wagner (email: 4/9/2013), the original Fortran code was provided to me, 
which can be easily implemented after building a Fortran compiler. The mathematical 
modeling of the rate of rise in pulmonary capillary PO2 was originally carried out using 
our MatLab code, and verified using the more rigorous Fortran version. 
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 According to this analysis complete PcʹO2 equilibration occurs within ~0.3 sec 
when PAO2 equals 100 mm Hg and Pv̅O2 equals 40 mm Hg, well below the mean 
pulmonary capillary transit time of 0.75 sec (described above). It should be appreciated 
that not all lung units will have this ‘mean’ transit time and some will be slower and 
some will be more rapid. Accordingly, it remains possible that the pulmonary capillary 
transit time in some lung units may be faster than 0.75 sec and if sufficient, there is the 
potential for a diffusion limitation to exist in that lung unit. Experimentally, it is not 
possible to directly measure diffusion limitation, and as described previously it is inferred 
based off of the portion of the A-aDO2 not explained by V̇A/Q̇ inequality and right-to-left 
shunt. 
Alveolar Ventilation-to-Perfusion 
 As mentioned in Chapter II, significant advancements in the study of V̇A/Q̇ 
inequality came from the work of Wallace Fenn, Arthur Otis, and Hermann Rahn during 
the World War II era (259) and stemmed from the development of the O2-CO2 diagram 
(187). The foundation behind understanding V̇A/Q̇ relationships is that when at steady 
state, pulmonary gas exchange follows the principles of mass conservation (246). The 
V̇A/Q̇ ratio for O2 and for CO2 can then be calculated and approximated using the 
following equations: 
V! Q = 8.63× (Cc!O! − CvO!)(PIO! − PAO!)  
Equation 2.9. V̇A/Q̇ Ratio for O2 
 V! Q = 8.63× (CvO! − Cc′O!)(PAO! − PICO!) 
Equation 2.10. V̇A/Q̇ Ratio for CO2 
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 As described by Dr. Peter Wagner, although these equations are seemingly 
straightforward they are remarkably difficult to solve and obtain an actual PO2 value 
based off a specific V̇A/Q̇ ratio (241, 246). Many of the same mathematical complexities 
encountered in the Bohr Integration surface here as well, namely the issue of processing 
the Kelman equation in reverse. However, when they are applied to an inert gas the 
complexity is dramatically reduced, because no longer must we consider a non-linear O2 
dissociation curve and the other confounding variables encountered in the Bohr 
Integration analysis (256). In doing so the fraction of inert gas that is retained in the 
capillary blood (i.e., not excreted via the lung), or vice versa, is a function of its blood-
gas partition coefficient (λ). Thus, the fraction of gas excreted by the lung, or retained in 
the blood, can be calculated using the following equation and is the foundation for the 
MIGET (236-238): PA!"Pv!" = λλ+ V!Q = Pc′!"Pv!"  
Equation 2.11. Retention/Excretion of Inert Gas 
where the subscript IG denotes ‘inert gas’, the left hand side is the fraction of inert gas 
excreted by the lung, while the right hand side is the fraction of inert gas retained in the 
blood. As a reminder, this relationship in its simplistic description is only valid assuming 
the alveolar and end-capillary concentrations of all gases are identical, i.e., complete end-
capillary inert gas diffusion equilibration. Nevertheless, considering inert gases are 
expected to equilibrate within a few hundredths of a second, this assumption seems 
reasonable. 
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 The MIGET employs this principle and based on the λ for any gas, the retention 
of that gas will fall (i.e., more will be excreted) as the V̇A/Q̇ ratio increases. Just as 
arterial blood can be collected and analyzed, so can mixed-expired air, and thus the 
retention (via the arterial blood sample) and excretion (via the mixed expired air sample) 
allow the measurement of the fraction of inert gas that is both retained and excreted. In 
theory, information about one yields information about the other; however, just as the 
retention of inert gases reflects the distribution of perfusion, the excretion of inert gases 
reflects the distribution of ventilation. 
 There are approximately 100,000 primary lobules or acini within the lung (249) 
and therefore, there are theoretically 100,000 different possible V̇A/Q̇ ratios. Meaning that 
in order to measure each, 100,000 different gases with a unique λ would be necessary 
(176). However, it is argued that sufficient resolution in the MIGET is obtained by the 
use of 6 inert gases, each with varying solubility’s, molecular weights and λ (sulfur 
hexafluoride, ethane, cyclopropane, halothane, diethyl ether, and acetone) (62). Sulfur 
hexafluoride has the lowest solubility, 0.0009 ml gas/dL blood/mm Hg and λ = 0.005, 
while acetone is the most soluble, 40 ml gas/dL blood/mm Hg and λ = 300. Based on 
these parameters the limits imposed by the MIGETs computer algorithm can detect V̇A/Q̇ 
ratios as low as 0.005 and as high as 100 (238). Additional assumptions required are for 
gas exchange in the lung to be in steady state, for ventilation and perfusion to be non-
pulsatile, complete diffusion equilibration between capillary blood and alveolar air, and 
for different lung compartments to function independently (97). Based on the retention 
and excretion of the 6 inert gases, the MIGET computer algorithm uses a 50-
compartment model, meaning it calculates the V̇A and Q̇ distributions across these 50 
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compartments optimized for a logarithmic scale. Controversy around the MIGET 
expressing V̇A/Q̇ ratios on a logarithmic scale has previously been an issue, with the 
proposed superior scale being one that is linear (223). Nevertheless, using these 
distributions, the MIGET provides a measure of ‘global’ V̇A/Q̇ inequality, while the 
logSDQ̇ and log SDV̇ are the standard deviation of the perfusion and ventilation 
distributions, respectively, providing an index of ‘dispersion’ for each parameter. 
Therefore, a larger value for either reflects greater dispersion. However, the values for 
logSDQ̇ and log SDV̇ explicitly do not take into account shunt (V̇A/Q̇ = 0) and dead space 
ventilation (V̇A/Q̇ = ) due the log of 0 and  being undefined values. However, shunt 
and dead space ventilation are generally thought of as separate issues from V̇A/Q̇ 
inequality (69). 
 Determination of shunt from MIGET only includes that from intrapulmonary and 
intracardiac shunt, and excludes right-to-left shunt from the bronchial and Thebesian 
circulations. Shunt is determined predominantly from the retention of sulfur hexafluoride 
(the least soluble gas), by extrapolation to a V̇A/Q̇ ratio (or λ) from 0.005 to 0. Therefore, 
any potential error or reason for the retention of sulfur hexafluoride to be underestimated 
will equate to an underestimation of shunt, while simultaneously an overestimation of 
perfusion to low V̇A/Q̇ units. As described by Hlastala, (97) without this mathematical 
extrapolation if shunt was determined based on the retention of sulfur hexafluoride alone, 
shunt would be overestimated because the λ of sulfur hexafluoride is high enough to be 
influenced by low and even normal V̇A/Q̇ units. The same issue of extrapolation to a 
V̇A/Q̇ from 100 to  for the determination of dead space ventilation also exists. 
Importantly, shunt measured by the MIGET includes intracardiac shunt via the PFO, and 
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excludes postpulmonary shunt via the bronchial and Thebesian circulations. As will be 
discussed in a proceeding section, in addition to the MIGETs inherent limitations and 
assumptions it “has never been validated against an independent technique” (as stated by 
Teplick et al., ref #223) over the past 40 years of practice. Perhaps one of the most 
difficult to reconcile findings is that there has never been one report of detecting a PFO 
using the MIGET. Yet, as has been pointed out, the prevalence of PFO in the general 
population is 35-40% and results in a measureable impact on pulmonary gas exchange 
efficiency detected via arterial blood gas analysis (145) a finding that has been replicated 
and extended in Chapter VI of this dissertation. 
 Despite the limitations in the MIGET it remains a very powerful tool for 
analyzing pulmonary gas exchange and is the current gold standard for quantifying global 
V̇A/Q̇ inequality. In theory measurement of the alveolar-to-arterial PN2 difference would 
solely reflect V̇A/Q̇ inequality (244), yet the use of this measurement is technically very 
difficult and not commonly employed (32). An alternative means to obtain a crude 
(compared to the MIGET) estimate of V̇A/Q̇ inequality is from the arterial-to-alveolar 
PCO2 difference (a-ADCO2). The theory is that with only V̇A/Q̇ inequality and no right-
to-left shunt or diffusion limitation there is predominantly an increase in both the a-
ADCO2 and A-aDO2. While without V̇A/Q̇ inequality, and only right-to-left shunt and/or 
diffusion limitation, there is predominantly only an increase in the A-aDO2 with very 
little change in the a-ADCO2. Accordingly, in theory if one were to measure an increase 
in the A-aDO2 while simultaneously detecting right-to-left shunt (e.g., using TTSCE), 
and no change was observed in the A-aDCO2, this would suggest that V̇A/Q̇ inequality 
was not significantly contributing to the increased A-aDO2. Importantly, at that point 
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there is still the problem of distinguishing between right-to-left shunt and diffusion 
limitation. Additionally, accurately measuring PACO2 is problematic, however in healthy 
humans at rest, end-tidal PCO2 (PETCO2) provides a good approximation of PACO2 (138, 
148, 232). Furthermore, it has been shown that the a-ADCO2 correlates well with dead 
space ventilation (VD/VT), which is calculated using the Bohr equation (22) modified by 
Enghoff (59): V!V! = PACO! − PĒCO!PACO!  
Equation 2.12. Bohr Dead Space Equation 
where, PACO2 is alveolar PCO2 and PĒCO2 is mixed expired PCO2. In practice, PaCO2 
can be used as a surrogate for PACO2 although it should be clear that the two are not 
necessarily interchangeable. Thus, measures of both the a-ADCO2 and VD/VT, should be 
linearly related and in the presence of significant V̇A/Q̇ inequality, both will increase. 
Right-to-Left Shunt 
 According to Riley and Cournand shunt is defined as blood flow that does not 
participate in gas exchange, therefore in the context of pulmonary gas exchange, shunt is 
blood flow that does not participate in pulmonary gas exchange (196). The ‘direction’ of 
shunt determines its role in impairing pulmonary gas exchange efficiency, where only a 
right-to-left shunt, meaning venous-to-arterial blood flow, will lower PaO2 (in contrast to 
a left-to-right shunt). As previously described, sources of right-to-left shunt include 
postpulmonary shunt via the bronchial and Thebesian circulations from the lungs and 
heart, intracardiac shunt (e.g., blood flow through a PFO), and intrapulmonary shunt 
(potentially including blood flow through IPAVA). Accordingly, all humans have this 
anatomic postpulmonary shunt resulting from the bronchial and Thebesian circulations 
 48 
returning their venous blood directly to the left side of the heart (6, 192, 227). 
Intracardiac shunt is most commonly thought of as blood flow through a PFO, though can 
also stem from defects in the atrial and ventricular septum and other congenital cardiac 
abnormalities. Intrapulmonary shunt is defined as an area of the lung with a V̇A/Q̇ ratio = 
0, though in practical terms is technically difficult to distinguish between areas of the 
lung with a V̇A/Q̇ ratio >0 but still being very low. For this reason issue with the 
semantics of ‘shunt’ have arisen in the literature with a elegant review of this provided by 
Eugene Robins (197). In Robins editorial, ‘shunt’ may reflect true shunt (i.e., mixed 
venous blood), blood flow through areas of very low V̇A/Q̇, or blood flow through 
vascular conduits that are diffusion limited. Accordingly, a term commonly used to 
reflect not only true shunt, but V̇A/Q̇ inequality and diffusion limitation is ‘venous 
admixture’ (5, 149, 260). Calculation of the fraction of Q̇T that represents shunt (Q̇S/Q̇T) 
and venous admixture (Q̇VA/Q̇T) is identical as described by the Berggren shunt equation 
(14): Q!Q! = Cc′O! − CaO!Cc!O! − CvO! = Q!"Q!  
Equation 2.13. Berggren Shunt Equation 
 The classical method for quantifying right-to-left shunt from all sources is the 
100% O2 technique (196). When breathing 100% O2 alveolar N2 is eliminated and 
therefore the PAO2 in all lung units must rise to that of the inspired PO2 less water vapor 
pressure and PACO2. There is then, theoretically, little discrepancy in PAO2 between 
ventilated lung units. Furthermore the driving gradient for O2 diffusion, and the slope 
between PAO2 and Pv̅O2 is optimized, and eliminates contributions from V̇A/Q̇ inequality 
and diffusion limitation (196). Based on this principle only right-to-left shunt quantified 
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using the 100% O2 technique will be referred to as Q̇S/Q̇T in this dissertation, and all 
other measures of pulmonary gas exchange efficiency will have the related Q̇VA/Q̇T 
parameter. However, when breathing 100% O2 accurately measuring and calculating 
PaO2 and PAO2, respectively, presents with additional technical challenges. Errors in the 
measured PaO2 can only result in a reduction in the PaO2 measured by the PO2 electrode, 
and can stem from room air bubbles forming in the sample syringe, heparin equilibrated 
with room air that has been added to the sample syringe, diffusion of O2 out of the 
syringe, consumption of O2 by white blood cells and the PO2 electrode itself. Thus, this 
technique always underestimates PaO2 and therefore, will likely overestimate the 
measured A-aDO2. 
 As has been mentioned and will be described further in Chapter V, during 
exercise when breathing a FIO2 = 1.0, blood flow through IPAVA is prevented or 
significantly reduced. Therefore, any potential venous admixture that could result from 
blood flow through IPAVA during exercise breathing room air or hypoxic gas mixtures, 
would go undetected when breathing 100% O2. Critics of this finding had postulated that 
the lack of left-sided contrast observed during exercise breathing 100% O2 was actually a 
function of altered in vivo gas-bubble dynamics due to the altered external partial 
pressure environment (i.e., significantly reduced PN2) compared to breathing room air 
(i.e., PN2 equilibrated with room air). In this view, the injected microbubbles would 
rapidly collapse and not survive long enough to reach the left heart. However, this 
concern was refuted in a study we performed in 2011, demonstrating that the lack of left-
sided contrast observed during exercise breathing 100% O2 is not a function of 
potentially altered in vivo gas-bubble dynamics (54). 
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 Accordingly and as detailed in Chapter IV, we propose that breathing an FIO2 
>0.21 but <1.0 has the potential to not significantly reduce the transpulmonary passage of 
microbubbles (i.e., blood flow through IPAVA) but still be sufficiently high to minimize 
contributions from V̇A/Q̇ inequality and diffusion limitation. For example, according to 
Forster (65), the ‘venous admixture’ component of V̇A/Q̇ inequality will become trivial 
once PAO2 reaches ~250 mm Hg, equal to an FIO2 of ~0.40. Implementing the 
previously described Bohr Integration the time required for complete end-capillary PO2 
equilibration when breathing an FIO2 = 0.40 is reduced to <0.1 sec, and is therefore 
approaching the rate of inert gas equilibration. Finally, recent work in our lab has 
demonstrated that the degree of left-sided contrast observed during exercise breathing an 
FIO2 = 0.40 is not different from room air (Davis, Elliott, et al. In Preparation). In 
summary, compared to breathing 100% O2, when breathing an FIO2 that elevates PAO2 
to the mid-200 range (i.e., 40% O2), accurate measures of PaO2 are more reliable, 
metabolic rate can be directly measured using commercial metabolic acquisition systems, 
V̇A/Q̇ and diffusion limitation can be minimized/eliminated, and blood flow through 
IPAVA is qualitatively unchanged. 
 
CLASSICAL PARADIGM 
 The preceding sections have described the theory and primary methods used to 
quantify each of the factors capable of impairing pulmonary gas exchange efficiency. 
Data collected with these methods, predominantly the functional gas exchange dependent 
ones (MIGET and 100% O2 technique) has shaped our current understanding of 
pulmonary gas exchange. The proceeding sections will now summarize the pertinent 
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literature relating to pulmonary gas exchange during exercise, in acute normobaric 
hypoxia, and after acclimatization to hypobaric hypoxia. 
Pulmonary Gas Exchange During Exercise at Sea Level 
 It has been well established that pulmonary gas exchange efficiency, although 
minimally impaired at rest (A-aDO2 = ~5 mm Hg) worsens with increasing exercise 
intensity, reaching a maximal value at V̇O2max. The normal resting A-aDO2 has almost 
always been entirely attributed to V̇A/Q̇ inequality from past studies using the MIGET 
(34, 69, 85, 102, 195, 229). From these data, although postpulmonary shunt via the 
bronchial and Thebesian circulations is present in 100% of humans, the contribution of 
this source of shunt has been considered to be small or non-detectable (236). Other 
attempts to quantify postpulmonary shunt using the 100% O2 technique report values 
ranging from 0.18-2.2% of the Q̇T (85, 229, 235). Cardús et al. (34) reports data using the 
MIGET from 64 subjects at rest (18-71 years old) and shows that in 90% of subjects 
~0.75% of the Q̇T was estimated to flow through areas of very low V̇A/Q̇ (<0.1). In this 
study, 7 of the 64 subjects (10%) had a higher value, ranging from 1-3% of the Q̇T. 
Interestingly, the individual data are plotted and there are 18 (28%) subjects with  ~0.5% 
or greater of the Q̇T estimated to flow through areas of very low V̇A/Q̇ (<0.1). It is 
tempting to speculate that these subjects may have an unidentified PFO. Despite these 
MIGET data, Robb Glenny has commented that the entire normal resting A-aDO2 can be 
accounted for by postpulmonary shunt (76). 
 It is generally taught from data obtained through the use of the MIGET that V̇A/Q̇ 
inequality contributes to the majority of the A-aDO2 at rest through submaximal exercise 
(V̇O2 <2.0 L/min) at sea level, while at higher levels of exercise intensity diffusion 
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limitation predominates. In this paradigm, right-to-left shunt does not significantly 
contribute to the A-aDO2 during exercise. Torre-Beuno et al. (229) demonstrated that 
during exercise at sea level the predicted A-aDO2 (i.e., that explainable by V̇A/Q̇ 
inequality) exceeded the measured A-aDO2 (i.e., that explainable by all sources of venous 
admixture) up to a V̇O2 of ~3.0 L/min, and no statistical differences were observed 
between the measured and predicted A-aDO2. In the companion paper by Gale et al. (69) 
there was also no statistical differences in the mean LogSDQ̇ and LogSDV̇ (indexes of 
dispersion), and no statistical differences in the dispersion of inert gas retention (DISPR), 
excretion (DISPE), or the difference in these parameters (DISPR-E). Briefly, DISPR, 
DISPE, and DISPR-E are derived directly from the inert gas retention/excretion data. 
DISPR and DISPE reflect the root-mean square difference between measured values of 
retention and excretion and those for a homogenous lung (with no V̇A/Q̇ inequality), and 
DISPR-E is the root-mean square difference between DISPR and DISPE. Only the slope of 
the individual regression lines for DISPR was found to be statistically different during 
exercise (up to a V̇O2 = 2.71 ± 0.53) at sea level. Hammond et al. (85) followed up on the 
studies by Gale et al. and Torre-Bueno et al. that suggested a trend for increasing V̇A/Q̇ 
inequality at higher levels of exercise intensity. In this study the predicted A-aDO2 
exceeded the measured A-aDO2 up to a V̇O2 of ~2.0 L/min, where thereafter the 
measured A-aDO2 was statistically greater than the predicted at a V̇O2 = 3 and 4 L/min. 
Wagner et al. (235) also reported data in 8 subjects during exercise at sea level and 
demonstrated no significant changes in the LogSDQ̇, LogSDV̇, DISPR, DISPE, and DISPR-
E, yet the measured A-aDO2 did exceed that of the predicted during exercise at a V̇O2 >35 
ml/kg/min. Of note only when these data from Wagner et al., (n = 8) were combined with 
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those data from Gale et al., (n = 8) significant differences in all indexes of V̇A/Q̇ 
inequality were observed. Hopkins et al. (102) contributed to this body of work by 
reporting data obtained using the MIGET in 10 highly trained endurance athletes. In this 
study the measured A-aDO2 only exceeded the predicted A-aDO2 at a V̇O2  = 5.0 L/min, 
and only LogSDQ̇ was shown to increase. The authors comment that at maximal exercise 
areas of low V̇A/Q̇ (<0.1) accounted for ~1% of the blood flow, although intrapulmonary 
shunt was not observed. They also comment on the fact that during exercise ventilation 
increases out of proportion to Q̇T (in this study ~20 fold increase in V̇E, and ~6 fold 
increase in Q̇T), and because of this, the effects of V̇A/Q̇ inequality on the A-aDO2 are 
minimized. Reeves et al., (193) have also made the comment that because of the 20 fold 
increase in V̇E and 6 fold increase in Q̇T, the overall V̇A/Q̇ ratio increases from ~1 at rest 
to as high as 5 or 6 at maximal exercise, and therefore even the lowest V̇A/Q̇ region 
during maximal exercise is higher than the highest V̇A/Q̇ region at rest. This fits with the 
data from Hopkins et al., (102) which report an improvement in LogSDV̇ from rest to 
exercise, and no difference during exercise. In contrast, Hopkins et al. (102) do report an 
increase in LogSDQ̇ at a V̇O2 of ~4.3 and ~5.1 L/min, yet only a significant difference 
between the measured and predicted A-aDO2 at the higher V̇O2. Rice et al. (195) 
investigated difference in V̇A/Q̇ inequality using the MIGET in high level endurance 
athletes with documented history of exercise-induced arterial hypoxemia (EIAH), and in 
controls subjects without EIAH. Although no difference was observed in the LogSDQ̇ and 
LogSDV̇, the measured A-aDO2 did exceed the predicted A-aDO2 at a V̇O2 of ~3.5 and 
4.5 L/min. 
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 To summarize, Torre-Beuno et al. demonstrated no increase in V̇A/Q̇ inequality 
and no evidence of diffusion limitation up to a V̇O2 of 3.5 L/min at sea level. Gale et al. 
found no significant differences in any index of dispersion up to a V̇O2 of 2.7 L/min at 
sea level. Hammond et al. showed evidence of a diffusion limitation at a V̇O2 of 3 and 4 
L/min and a corresponding increase in V̇A/Q̇ inequality, resulting from predominantly an 
increase in LogSDV̇ at a V̇O2 of 3 L/min and an increase in both LogSDQ̇ and LogSDV̇ at 
a V̇O2 of 4 L/min. Wagner et al. reported no increase in V̇A/Q̇ inequality or any index of 
dispersion from rest to a V̇O2 of ~3.7 L/min, and evidence of a diffusion limitation at a 
V̇O2 of ~2.7 and ~3.7 L/min. Hopkins et al. showed an increase in V̇A/Q̇ inequality at a 
V̇O2 of ~2, 4, and 5 L/min and evidence of a diffusion limitation only at a V̇O2 of ~5 
L/min, while LogSDV̇ decreased and LogSDQ̇ increased, from rest to exercise at sea level. 
Rice et al. reported no increase in V̇A/Q̇ inequality, LogSDQ̇, or LogSDV̇, from rest to 
exercise (up to V̇O2 of ~4.5 L/min) and evidence of a diffusion limitation at a V̇O2 of 
~3.5 and ~4.5 L/min. 
 Thus, from data using the MIGET during exercise up to a V̇O2 of ~5 L/min the 
results are somewhat inconsistent; with V̇A/Q̇ inequality and various indexes of 
dispersion increasing in some, and either not changing or decreasing in others. Of the 
studies by Hammond et al. and Hopkins et al. that demonstrate an increase in V̇A/Q̇ 
inequality up to a V̇O2 of ~5 L/min, V̇A/Q̇ inequality may account for 25-40% of the 
measured A-aDO2 (i.e., 5-10 mm Hg of the measured 25-30 mm Hg). Regardless of 
whether or not a diffusion limitation is developing at this high-intensity exercise, this 
increase in A-aDO2 due to V̇A/Q̇ inequality can easily be accounted for by a ~1% shunt 
(140, 214). As a reminder, the MIGET theoretically provides a measure of V̇A/Q̇ 
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inequality and intrapulmonary shunt, with the remaining portion of the A-aDO2 not 
explained by these factors being attributed to diffusion limitation. Therefore, diffusion 
limitation is never directly measured and always inferred by process of elimination. 
Clearly, this is only a limitation inasmuch as the MIGETs accuracy in measuring the 
other factors. Physiologically, the likelihood of a diffusion limitation developing even 
during heavy exercise seems improbable. As previously discussed (Pulmonary Diffusion, 
p. 43) complete end-capillary O2 diffusion equilibration occurs in ~0.3 sec of the ~0.75 
sec mean pulmonary capillary transit time. During exercise the increase in pulmonary 
blood flow and potential reduction in mean pulmonary capillary transit time is offset by a 
simultaneous increase in Vc owing to an increase in left-atrial pressure. Pulmonary 
capillary blood volume can increase ~3x, from ~70 to 210 ml, meaning that even when 
Q̇T is ~25 L/min, mean pulmonary capillary transit time is still ~0.5 sec. However, it 
should be appreciated that in elite athletes capable of attaining very high levels of 
exercise (i.e., V̇O2 ~5 L/min and Q̇T ~35 L/min), mean pulmonary capillary transit time 
would approach 0.35 sec, and therefore some degree of diffusion limitation would be 
expected. Data from Hsia et al. provide evidence against the possibility for a diffusion 
limitation, albeit in exercising foxhounds, demonstrating that with pneumonectomy of 
42% of their lung, a plateau in diffusing capacity is never reached and diffusion 
equilibration is maintained even at maximal exercise (104-106). 
 Importantly, when interpreting the data suggesting an increase in diffusion 
limitation during high intensity exercise, it is important to remember that it may not be 
mean pulmonary capillary transit time that is the defining factor. Instead it should be 
appreciated that there is likely a spectrum of pulmonary capillary transit times throughout 
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the lung and those that are sufficiently rapid may comprise the volume of blood necessary 
to explain the development of a diffusion limitation. 
Pulmonary Gas Exchange During Exercise in Acute Hypoxia 
 As previously described, hypoxia represents a useful tool for respiratory 
physiologists as it provides yet another means to challenge the pulmonary system for 
performing adequate gas exchange. Lilienthal et al. (137) measured a similar increase in 
the A-aDO2 in men during exercise at sea level and breathing an FIO2 equivalent to 
13000ft. The conclusions reached by these authors was that during exercise at sea level, 
shunt predominantly explains the measured A-aDO2 while at ‘altitude’, diffusion 
limitation predominantly explains the measured A-aDO2. Asmussen and Neilsen (5) 
studied pulmonary gas exchange efficiency during exercise breathing room air, an FIO2 = 
0.12, and 1.0. Their interpretation applied the entire shunt measured during exercise 
breathing an FIO2 = 1.0 to the other FIO2s, and concluded that diffusion limitation had no 
measurable impact on the A-aDO2, during exercise breathing any FIO2. Following the 
advent of the MIGET technique, Gale et al. (69) report measures of dispersion during 
exercise at 5000, 10,000, and 15,000ft with only LogSDQ̇ and the related DISPR index 
increasing during heavy exercise at 10,000 and 15,000ft (no differences were observed at 
5000ft). These data track with the companion paper by Torre-Bueno et al. (229) where 
the development of a diffusion limitation was inferred during exercise at 10000 and 
15000ft. Wagner et al. followed up on these studies, by collecting data in more subjects 
at rest and during exercise at 10000 and 15000ft. At rest, there was no increase in V̇A/Q̇ 
inequality or any index of dispersion, although during exercise overall V̇A/Q̇ inequality 
increased at 10000 and 15000ft. Specifically due to increases in LogSDQ̇ and DISPR, 
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while no differences were observed in LogSDV̇ and DISPE. Furthermore, an increase in 
diffusion limitation was detected at lower levels of exercise intensity compared to 
exercise at sea level. In contrast to the lack of an effect in LogSDV̇ and DISPE noted by 
Wager et al., (235) in the study by Hammond et al. (86) all of the indexes of dispersion 
increased during exercise breathing an FIO2 = 0.11. However again, significant diffusion 
limitation was detected during exercise. In the seminal work from ‘Operational Everest 
II’ by Wagner et al. (239) overall V̇A/Q̇ inequality increased during exercise as the 
altitude increased, although significant differences in indexes of dispersion were 
predominantly observed when PB = 282 (n = 5), and 240 mm Hg (n = 5) and were 
constrained only to LogSDQ̇ and DISPR. Again, diffusion limitation was detected during 
exercise, which occurred at lower exercise intensities as the altitude increased. 
 Although overall increases in V̇A/Q̇ inequality, particularly from perfusion 
dispersion are present in the literature it should be remembered that the contribution of 
V̇A/Q̇ inequality to the A-aDO2 decreases as the level of hypoxia increases (214, 239). 
The rationale for this is similar to why the effect of a given volume of right-to-left shunt 
on the A-aDO2 also decreases as the level of hypoxia increases. Just as the PaO2 becomes 
closer to Pv̅O2 (diminishing the effect of shunt) the V̇A/Q̇ ratios of individual lung regions 
are positioned on the steep portion of the O2 dissociation curve. Furthermore, V̇A 
increases even more out of proportion to Q̇T during exercise in hypoxia compared to 
exercise at sea level, further right-shifting the lung to an overall higher V̇A/Q̇ ratio. As 
described by Calbet et al. (31) the fact that V̇A, VT, and flow are all increased for a given 
VO2 compared to exercise at sea level, this should further reduce ventilatory 
inhomogeneities and result in improved V̇A/Q̇ matching. 
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 Rationale for an increase in diffusion limitation during exercise in hypoxia seems 
more plausible than at sea level with PAO2 being decreased and Q̇T being increased. 
Thus, for a given V̇O2, mean pulmonary capillary transit time is likely less than at sea 
level (100) despite the potential for the further recruitment of pulmonary capillaries (33). 
Furthermore, although DLO2 increases in hypoxia the effective slope between PAO2 and 
PvO2 increases which will function to reduce the rate of O2 uptake, as described by Piiper 
and Scheid (183, 184). Nevertheless Calbet et al. present an interesting interpretation of 
this theory, where according to the model of Piiper and Scheid (183) and data from 
Wagner et al. (229, 235) the increase in A-aDO2 for a given Q̇T should be more 
pronounced in hypoxia than when breathing room air at sea level, i.e., the slope of the A-
aDO2 vs. Q̇T relationship should be steeper. However, Calbet et al. (31) demonstrate that 
contrary to this expected relationship, the slope is only shifted upward, meaning for a 
given Q̇T the A-aDO2 is proportionally higher in hypoxia than breathing room air at sea 
level. Calbet et al. (30) have also demonstrated that after increasing Q̇T (by ~2 L/min) via 
hemodilution, no change was observed in the A-aDO2, which they use as further evidence 
that Q̇T may not be limiting pulmonary gas exchange in hypoxia. Together, these data 
suggest the possibility that the prevailing paradigm put forth by Piiper and Scheid may 
not entirely describe the measured response to pulmonary gas exchange efficiency during 
exercise in hypoxia. 
Pulmonary Gas Exchange After Acclimatization to Hypobaric Hypoxia 
 It is well established that pulmonary gas exchange progressively worsens in a 
workload dependent manner during exercise at sea level (48). This impairment in 
pulmonary gas exchange efficiency during exercise is exacerbated in acute hypoxia, such 
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that for any given V̇O2, the A-aDO2 is greater compared to exercise in normoxia (235). 
Following acclimatization to hypobaric hypoxia, pulmonary gas exchange efficiency is 
thought to improve compared to acute hypoxia (88, 203). The classic study from 
Dempsey et al. (47) reported a trend for an increased A-aDO2 during treadmill walking 
after 4 days at 3100 m compared to sea level, and a partial normalization during the same 
exercise protocol following 21 days at 3100m compared to that obtained after 4 days. 
Bebout et al. (13) subsequently demonstrated that, compared to acute normobaric 
hypoxia, acclimatization to 3800m for 2 weeks resulted in an ~3 mm Hg reduction in the 
A-aDO2 during submaximal cycle ergometer exercise. Calbet et al. (28) subsequently 
reported that, compared to acute normobaric hypoxia, acclimatization to 5260m for 9-10 
weeks resulted in an ~9 mm Hg reduction in the A-aDO2 during submaximal cycle 
ergometer exercise. Collectively, these data suggest that pulmonary gas exchange 
efficiency in non-acclimatized individuals improves with acclimatization to high-altitude 
compared to acute hypoxia. 
 Acclimatization to hypobaric hypoxia is characterized by a multitude of 
physiologic adaptations, notably a time-dependent increase in ventilation (250). 
Compared to acute hypoxia, ventilatory acclimatization helps to increase CaO2 by 
increasing PAO2 and the driving gradient for O2 diffusion at the alveolar-capillary 
interface, subsequently increasing PaO2 and therefore, SaO2. Consequently, compared to 
acute hypoxia the further increase in V̇A, and therefore PAO2 with acclimatization would 
theoretically reduce the relative contributions from V̇A/Q̇ inequality and diffusion 
limitation while increasing the relative contribution of right-to-left shunt on the A-aDO2. 
Indeed, as is the case in acute hypoxia, the greater increase in V̇A should equate to a 
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greater right-shifted mean V̇A/Q̇ ratio, thereby lessening potential disparities in the PO2 
between alveoli (63, 193, 204). Diffusion limitation would theoretically also be reduced 
compared to acute hypoxia by way of an increased driving gradient for O2 diffusion 
(243), increased Pv̅O2, and a potential improvement in diffusing capacity for O2 (3). 
Lastly, a given volume of right-to-left shunt would have a greater effect on the A-aDO2 
due to the difference between Pv̅O2 and PaO2 increasing after acclimatization compared 
to acute hypoxia. However, this possibility has not been directly investigated. 
 
REGULATION OF BLOOD FLOW THROUGH INTRAPULMONARY 
ARTERIOVENOUS ANASTOMOSES 
 In contrast to functional gas exchange dependent techniques, which do not report 
significant intrapulmonary shunt during exercise, there are several ‘anatomic based’ 
techniques that have been used to demonstrate blood flow through large diameter 
IPAVA, during various conditions (described below). These anatomic based techniques 
are based on the assumption that the lung provides a biological sieve and receives 100% 
of the Q̇T; therefore particles injected [microspheres, microbubbles or radiolabeled 
macroaggregates of albumin (MAA)] into the venous circulation will be filtered be the 
sieve action of the pulmonary capillaries, which have a mean diameter of 7-10 µm (75, 
199). However, these particles can escape pulmonary filtration if they bypass the 
pulmonary capillaries and flow through a large diameter vascular conduit, i.e., IPAVA. 
Thus, the transpulmonary passage of these particles demonstrates blood flow through 
IPAVA. It is worth mentioning that data collected using, either microspheres, 
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microbubbles or radiolabeled MAA, all report very consistent findings, as outlined 
below. 
Exercise 
 Blood flow through IPAVA, although trivial or absent at rest, was demonstrated 
to increase during exercise in the classic studies by Stickland et al. (216) and Eldridge et 
al. (53). Kennedy et al. (115) demonstrated that the transpulmonary passage of saline 
contrast during exercise was not different between men and women. While others have 
demonstrated the transpulmonary passage of saline contrast during exercise breathing 
room air (54, 115, 130, 131, 143), it should be noted that in the work by La Gerche et al. 
(130) and Lalande et al. (131) subjects were not screened for PFO. Neglecting to screen 
for PFO introduces the possibility that the appearance of left-sided contrast is due to 
blood flow across the PFO, in addition to blood flow through IPAVA. 
 The aforementioned data using TTSCE provide evidence of blood flow through 
IPAVA, but this technique does not quantify the volume of blood flow through IPAVA, 
nor does it provide us with information about the size/diameter of IPAVA. However, 
intravenously injected 25 and 50 µm microspheres in exercising dogs confirms that blood 
flow through IPAVA does occur during exercise and was calculated to be 1.4% (range 
0.2 to 3.1 %) of the Q̇T (215). Interestingly, the observation of increased blood flow 
through IPAVA in the exercising dog was less in the isolated dog lung preparation 
(<0.02% of the Q̇T). This suggests the possibility that either some blood borne factor or 
innervation to the lung is responsible for increasing blood flow through IPAVA. Studies 
in healthy humans using 99mTc-MAA and gamma camera imaging measured blood flow 
through IPAVA to be 1.3% (range −0.3 to 2.7%) of the Q̇T during maximal exercise 
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(141). These studies used MAA with a mean diameter of 20–40 µm and 90% of MAA 
between 10 and 90 µm in size. Studies prior to these used 99mTc albumin microspheres 
with a size range of 7-25 um in diameter and these authors found an increase in shunt to 
2.4% (range -2.4 to 5.9%) of Q̇T in 5 normal subjects during exercise (261). Furthermore, 
recent work from our laboratory demonstrates using 99mTc-MAA and gamma camera 
imaging that ~1.4% of the Q̇T flows through IPAVA during exercise in healthy humans 
(n = 10). 
To summarize these data, the finding that ~2% of the Q̇T flows through IPAVA 
during exercise appears to be a reproducible and consistent finding. The extent of the 
variability that exists in this area of the literature pertain to factors such as the exercise 
intensity where subjects begin to demonstrate blood flow through IPAVA, and the 
volume of blood flow through IPAVA. Nevertheless, using either microspheres, 
microbubbles or radiolabeled MAA, healthy human subjects demonstrate blood flow 
through IPAVA during exercise that is quantitatively and qualitatively very similar. The 
mechanisms regulating blood flow through IPAVA during exercise at sea level are 
unknown, although a recurring hypothesis is that blood flow through IPAVA may be 
responding passively to the increases in Q̇T and/or PASP (15, 216). In this way, IPAVA 
may serve a functional role of minimizing excessive increases in pulmonary pressure, 
however if this were true PASP would be expected to increase during exercise breathing 
a FIO2 = 1.0 when blood flow through IPAVA is prevented, and this finding has not been 
observed. 
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Normobaric Hypoxia 
 Compared to breathing room air at rest at sea level, where blood flow through 
IPAVA is trivial or non-detectable (55), breathing hypoxic gas at sea level (normobaric 
hypoxia) is known to increase blood flow through IPAVA at rest (134). During exercise 
in normobaric hypoxia qualitatively there is an increased degree of blood flow through 
IPAVA in healthy humans that occurs at lower workloads compared to breathing room 
air at sea level (54, 143). These data are supported from work by Niden and Aviado (171) 
demonstrating the number of large diameter microspheres recovered in the pulmonary 
venous effluent increased in intact dogs ventilated with a FIO2 = 0.10. More recently, 
Bates et al. (12) also demonstrated the transpulmonary passage of microspheres in intact 
rats ventilated with a FIO2 = 0.08. Interesting, similar to the work by Stickland et al. 
(215) using isolated dog lungs, Bates et al. (12) reports blood flow through IPAVA is 
minimal in the isolated rat lung preparation. Unpublished observations from our lab also 
demonstrate an increase in blood flow through IPAVA in healthy humans at rest 
breathing an FIO2 = 0.12, and report that ~1.3% of the Q̇T flows through IPAVA (Duke, 
Elliott, et al. In Preparation). Nevertheless, the mechanism(s) regulating hypoxia-
induced blood flow through IPAVA remain unknown. 
 Compared to exercise, hypoxia-induced blood flow through IPAVA occurs at 
lower Q̇T and before significant increases in PASP (<30-45 min). Therefore, it is possible 
the hypoxia-induced increase in blood flow through IPAVA is regulated differently. 
Work by Laurie et al. (134) showed a correlation between decreasing SpO2 and increases 
in blood flow through IPAVA. However to date, no study has investigated the effects of 
decreases in PaO2 independently of CaO2 (or vice versa) on the regulation of blood flow 
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through IPAVA. An attractive hypothesis is the reduction in PO2 secondary to breathing 
hypoxic gas mixtures, stimulates the release of ATP via red blood cells (56, 57, 77), 
which function as a vasodilatory signal for IPAVA. Arterial hypoxemia is also a 
sympathetic stimulant that increases levels of circulating catecholamines (61). However, 
data from Laurie et al. (134) show that in healthy humans breathing an FIO2 = 0.12, 
blood flow through IPAVA is unaffected after β-adrenergic receptor blockade via i.v. 
propranolol. Accordingly, the mechanisms responsible for hypoxia-induced blood flow 
through IPAVA remain elusive. 
Hypobaric Hypoxia 
 Few studies investigating blood flow through IPAVA in hypobaric hypoxia are 
present in the literature. Using transcranial Doppler, Imry et al. (107) investigated the 
occurance of emboli detected in the cerebral circulation post the peripheral venous 
injection of agitated saline contrast at rest and during exercise on acute ascent to 3450m 
and after 8 days at 3450m. Of the 8 subjects without PFO, no subjects demonstrated 
cerebral microbubbles at rest at altitude before or after acclimatization. During exercise, 
5/8 subjects demonstrated cerebral microbubbles on acute ascent to 3450m and no 
subjects did after acclimatization. More recent field studies to a higher altitude of 5050m 
using TTSCE to detect blood flow through IPAVA have also been carried out by Foster 
et al. (67). This work was done after 21 days of acclimatization to 5050m and 
demonstrated that in healthy sea level inhabitants after acclimatization to high-altitude 
blood flow through IPAVA at rest was qualitatively reduced compared to normobaric 
hypoxia. The authors speculated that several possibilities might explain the lower than 
expected blood flow through IPAVA including pulmonary vascular remodeling and/or 
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reduced Q̇T with acclimatization compared to acute normobaric hypoxia. Additionally, it 
remains possible that the in vivo microbubble dynamics of saline contrast are altered in 
hypobaric environments, a topic expanded upon in Chapter VI.  
Alveolar Hyperoxia 
 Of particular interest in this field are the studies in healthy humans breathing 
100% O2 demonstrating that blood flow through IPAVA is either prevented or 
qualitatively reduced as detected using TTSCE (144). One criticism of these findings is 
that the reduced appearance of left-sided contrast is due to changing the external partial 
pressure of the environment of the intravenously injected bubbles, but this criticism was 
experimentally refuted (54). These findings using TTSCE are also supported from work 
by Niden and Aviado (171) which demonstrate the reduction in large diameter 
microspheres collected in the pulmonary venous effluent in dogs ventilated with a FIO2 = 
1.0. Potential criticism with this work is that blood flow through IPAVA was increased 
secondary to pulmonary embolization.  
 The mechanism(s) responsible for the hyperoxia-mediated reduction in blood 
flow through IPAVA during exercise at sea level are unknown. Entertaining the 
hypothesized mechanism of exercise-induced blood flow through IPAVA being due to 
increases in Q̇T and PASP, it is likely that an alternative mechanism regulating the 
hyperoxia-mediated reduction in blood flow through IPAVA exists. This is because, 
during exercise breathing a FIO2 = 1.0 for any given V̇O2, Q̇T is reduced by ~10%. Yet 
blood flow through IPAVA during maximal exercise breathing a FIO2 = 1.0 is still less 
than blood flow through IPAVA during submaximal exercise breathing room air, when 
Q̇T is no different or even higher. 
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 The effect of oxygen tension on regulating blood flow through IPAVA is 
particularly provocative as these data suggest that some of the pulmonary vasculature 
may be regulated opposite that of the conventional pulmonary circulation, e.g. hypoxia 
increases, whereas hyperoxia reduces blood flow through IPAVA. However, this 
resemblance to the regulation of the systemic circulation is also present in the regulatory 
pathways controlling the vascular tone of the ductus arteriosus (251). Considering the 
ductus arteriosus is an important vessel in the fetal cardiopulmonary circulation, and that 
right-to-left shunt is an important factor for development in utero, it has been 
hypothesized by us and others that IPAVA may represent remnant vessels of the fetal 
circulation (134, 158). Interestingly, work by McMullan et al. (158) showed that blood 
flow through IPAVA occurred in developing sheep, but was reduced in the adult sheep. 
Therefore, it seems logical to speculate potential mechanism(s) regulating blood flow 
through IPAVA when breathing a FIO2 = 1.0 may resemble those that are known to 
regulate the tone of the ductus arteriosus. 
 Expansion on this theory and potential regulatory pathways is provided in Chapter 
V. However, contraction of the ductus arteriosus is stimulated by an increase in oxygen 
tension from fetal to neonatal levels, causing the inhibition of potassium (Kv) channels 
within ductus smooth muscle cells, membrane depolarization, and subsequent calcium 
entry via voltage gated L-type calcium channels (230). Pharmacologic blockade of L-type 
calcium channels via calcium channel blockers (e.g., nifedipine) may prevent the 
necessary increase in intracellular calcium for constriction of IPAVA. However, 
intracellular calcium levels may also be increased independently by calcium release from 
the sarcoplasmic reticulum and from non voltage gated calcium channels (252). 
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Nevertheless, nifedipine has been shown to reduce or prevent the increase in pulmonary 
artery pressure associated with acute hypoxia (207). 
 Endothelium-derived nitric oxide (NO) is a major endogenous agent regulating 
pulmonary vascular tone, which is primarily regulated by increases in cGMP via soluble 
guanylyl cyclase activation and subsequent activation of protein kinase G. The three 
isoforms of NO synthase, neuronal (nNOS), inducible (iNOS) and eNOS have all been 
identified in the lung (71). Breathing hyperoxia is also associated with an increase in 
reactive oxygen species (ROS), predominantly from cytochrome c oxidase subunit III in 
the electron transport chain, but also potentially from NADPH oxidase (252). This 
increase in ROS associated with hyperoxia has been demonstrated to attenuate 
endothelial mediated vasodilation in human skin (268). Additionally, hyperoxia has been 
shown to increase forearm vascular resistance, a finding that is abolished after high-dose 
i.v. ascorbic acid (153). Collectively, these data lend support that hyperoxia may reduce 
production of and/or bioavailability of NO and therefore, contribute to the hyperoxia-
mediated reduction in blood flow through IPAVA. 
 Another attractive hypothesis is the involvement of 20-hydroxyeicosatetraenoic 
acid (20-HETE), an ω-hydroxylation product of arachadonic acid from cytochrome P450. 
Interestingly, 20-HETE has been demonstrated to not only be a potent constrictor of 
multiple vascular beds (renal, cerebral and skeletal muscle), it has been shown to be 
produced in an O2-dependent fashion (89, 129, 167). Across a physiologic range of PO2, 
from 20 to 160 mm Hg, 20-HETE formation increases nearly linearly with the increasing 
PO2 (89). However, to my knowledge studies investigating the formation of 20-HETE in 
increasingly hyperoxic conditions have not been done. Moreover, there are many 
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isoforms of the cytochrome P450 enzyme with different families and subtypes 
predominating in different vascular beds, and a selective inhibitor for the ω-
hydroxylation arachadonic acid (i.e., the formation of 20-HETE) is not approved for 
human use (17-Octadecynoic acid) (167, 170).  
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CHAPTER III 
METHODS 
INFORMED CONSENT 
 The University of Oregon Institutional Review Board via Research Compliance 
Services and the Committee for Protection of Human Subjects formally approved the 
studies and protocols that constitute this dissertation (Chapters IV-VI). However, in 
Chapter VI, in addition to the University of Oregon, the institutional review boards from 
the University of Colorado Denver and the U.S. Department of Defense also formally 
approved the protocols therein. Prior to all studies, I verbally discussed procedures and 
risks with every subject and written informed consent was obtained from all subjects 
prior to participation. 
 
ECHOCARDIOGRAPHIC SCREENING 
 Through collaboration with the Oregon Heart & Vascular Institute one of two 
highly skilled (a combined 40+ years of experience) registered diagnostic cardiac 
sonographers works in our laboratory twice a week, and have performed all 
ultrasonography for the work in this dissertation (Randy Goodman, RDCS, BS, and Eben 
Futral, RDCS, MBA). All subjects underwent a comprehensive echocardiographic 
screening, performed by Randy Goodman or Eben Futral and overseen by myself. A 
three-lead electrocardiogram is placed and subjects are positioned in the left lateral 
decubitus position in a reclining chair with head resting on their left arm. This position 
not only allows the heart to move anteriorly and laterally against the subject’s ribcage, 
but also allows the ribs to spread apart and facilitate obtaining a clear apical, four 
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chamber view of the heart. For convenience and due to the ultrasound probe and required 
gel, male subjects are asked to go shirtless and female subjects are provided a scrub top. 
 The process begins with the sonographer thoroughly inspecting cardiac structures 
to rule out potential cardiac abnormalities. Including the right ventricular outflow tract to 
identify signs of obstruction, and the pulmonary artery and aorta for signs of stenosis. 
Left-ventricular function and all valves are inspected to rule out signs of congenital heart 
disease, and the pericardium is inspected to rule out signs of pericardial effusion. Once 
normal cardiac function and signs of heart disease are ruled out, the next step is 
identification of a PFO. 
Detection of Patent Foramen Ovale 
 The foramen ovale is a critical right-to-left shunt in the fetal cardiopulmonary 
circulation and is patent in 100% of healthy humans in utero. At birth, the reversal of 
pressure gradients between the right and left atria result in the septum primum covering, 
and therefore functionally closing, the foramen ovale within the septum secundum (71, 
82, 118). Over time fusion of the septum primum/secundum occurs in most infants (i.e., 
permanent anatomical closure of the foramen ovale); however, it has long been 
recognized that the foramen ovale does not permanently close in some adult humans and 
remains patent. The classic study by Hagen et al. (82) reported a  prevalence patent 
foramen ovale (PFO) of 25-35% identified using a probe during autopsy (n = 965). In 
these humans the septum primum/secundum offers a functional closure, rather than 
anatomical closure, but only when left atrial pressure exceeds right atrial pressure. In this 
condition blood flow across the foramen ovale is either prevented or allowed to flow 
from the left atrium to the right atrium, however when right atrial pressure exceeds left 
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atrial pressure blood in the right atrium flows directly into the left atrium. Identification 
of PFO in healthy, living humans is accomplished by exploiting the pressure dependence 
of right-to-left blood flow through the PFO using a technique called saline contrast 
echocardiography, and using this technique recent work has revealed ~35-40% of adult 
humans have a PFO (55, 156, 266). 
 Performing saline contrast echocardiography involves first placing an intravenous 
catheter (see Subject Instrumentation) in the antecubital fossa that is connected to an 
extension set and a three way stopcock. Attached to the stopcock are two 10 ml syringes, 
one with 3 ml of saline and one with 1 ml of air. This saline-air mixture is agitated back 
and forth, vigorously, for 10-15 sec creating a microbubble suspension that is then 
injected into the peripheral vein. With the subject breathing normally, the microbubbles 
are rapidly visualized as a “cloud of echoes” that opacify the right heart after traveling 
via the venous blood to the right heart. With the heart visualized in the apical, four-
chamber view, the left heart can be simultaneously monitored and the appearance of 
contrast in the left heart within 3 cardiac cycles is evidence for the presence of a PFO. 
Although past work has suggested that visualizing left heart contrast up to 5 cardiac 
cycles post right heart opacification is evidence for a PFO (267), recent work has 
demonstrated that the optimal timing of contrast appearing in the left heart is within 4 
cardiac cycles (18). 
 The rationale for concern over the optimal number of cardiac cycles for PFO 
detection is that there is a second mechanism by which microbubbles can enter the left 
heart, via flowing through the pulmonary circulation. In healthy humans at rest mean 
pulmonary (whole lung) transit time is ~9 sec (100), meaning for someone with a resting 
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heart rate of 40 bpm, 6 cardiac cycles must occur before contrast that has traveled 
through the pulmonary circulation can appear in the left heart. Thus, observing contrast in 
the left heart in ≤4 cardiac cycles is fairly conclusive evidence for a PFO, yet observing 
contrast in the left heart in >4 cardiac cycles is inconclusive for a PFO because it could 
have reached the left heart after flowing through the pulmonary circulation. As 
previously described this is most likely to occur by traversing the pulmonary circulation 
via large diameter IPAVA. 
 In order to conclusively identify the presence of a PFO, saline contrast injections 
are repeated in coordination with a Valsalva maneuver. The Valsalva maneuver is 
designed to transiently elevate right atrial pressure and create conditions that are optimal 
for detecting blood flow through the PFO. Performing a Valsalva maneuver is very 
simple, although proper coaching of the subjects is critical in order to accurately identify 
PFO. Subjects are instructed to take a small breath, “bear down” and exhale against a 
closed glottis, creating increased intra-abdominal pressure and preventing blood flow 
from returning to the right side of the heart via the inferior vena cava. This increase in 
pressure is maintained for ~15 sec, where just before release the agitated saline contrast is 
injected. Upon release of the Valsalva maneuver, the saline contrast microbubble 
suspension is immediately visualized in the right heart in coordination with the 
previously restricted, and therefore increased volume of blood. Right atrial pressure is 
then transiently elevated above that in the left atrium and any blood flow across the PFO 
will be accompanied by microbubbles that can be visualized in the left heart. This 
procedure is not only a very reliable method of detecting PFO but it has been recently 
demonstrated to correlate with the size of PFO as determined using intracardiac 
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echocardiography (64). Although not part of this dissertation we have recently published 
data on 176 subjects that have been screened within our laboratory that reports a 38% 
prevalence for PFO (55). These data are also in agreement with similar work using 
transthoracic saline contrast echocardiography that also demonstrate a 35-38% 
prevalence of PFO in the general population (156, 266). 
Pulmonary Artery Systolic Pressure 
 The next step in the echocardiographic screening process is the determination of 
pulmonary artery systolic pressure (PASP). This represents the peak blood pressure 
developed during systole in the pulmonary artery and can be estimated by measuring the 
peak velocity of retrograde blood flow across the tricuspid valve during systole. When 
the right ventricle contracts the tricuspid valve is forced closed, preventing blood flow 
into the right atrium, however a small volume of blood leaks past the tricuspid valve with 
every cardiac cycle in almost all individuals. The velocity of this blood flow is 
proportional to the pressure gradient between the right ventricle and right atrium that is in 
turn, dependent on the pressure within the pulmonary artery. All things equal, a higher 
pulmonary artery pressure will correspond to an increased peak velocity of blood flow 
across the tricuspid valve. Using Doppler ultrasound the sonographer carefully aligns the 
probe so as to direct the signal across the tricuspid valve and the resulting tricuspid 
regurgitate is visualized as inverted waveforms, representing the velocity of blood flow. 
The peak of each waveform corresponds to the peak velocity (v) of blood flow and an 
average of ≥3 measurements is taken. Right atrial pressure (PRA) is then estimated based 
on the collapsibility of the inferior vena cava as well as the diameter of the inferior vena 
cava. Collapsibility is determined by imaging the inferior vena cava in coordination with 
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subjects taking a quick inspiration. Right atrial pressure was determined to be: 3 mm Hg 
if the inferior vena cava collapses >50% and the diameter being ≤2.1 cm; 15 mm Hg if 
the inferior vena cava collapses <50% and the diameter is >2.1 cm, and; 8 mm Hg if 
either of these parameters is indeterminate. These values are then applied to the modified 
Bernoulli equation (202): PASP = !4v! + P!" 
Equation 2.14. Modified Bernoulli Equation 
 The gold standard method of measuring pulmonary pressure is via right heart 
catheterization and directly measuring pulmonary artery pressure. Doing so allows one to 
obtain mean pulmonary artery pressure, rather than peak systolic pulmonary artery 
pressure, and is subject to fewer limitations, however, prior work has demonstrated a very 
strong correlation between measurements of PASP and direct right heart catheterization 
(92, 275). Potential limitations in measuring PASP via echocardiography stem from this 
technique actually measuring the peak systolic pressure generated within the right 
ventricle. Thus, this is one prominent reason why we screen subjects for right ventricular 
outflow tract obstruction in the initial echocardiographic screening process. If present, the 
pressure generated in the right ventricle would be greater than the pressure in the 
pulmonary artery distal to the obstruction, and therefore, our measure of PASP would be 
erroneously high. 
Left Ventricular Outflow Tract 
 The final step in the echocardiographic screening process is the measurement of 
the diameter of the left ventricular outflow tract. While subjects were in the left lateral 
decubitus position, the left ventricular outflow tract diameter was measured using 2-
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dimensional echocardiography in triplicate and the average was used to determine the 
cross sectional area. Knowing the cross sectional area of the left ventricular outflow tract 
allows one to determine stroke volume based on the velocity of blood flow through the 
outflow tract determined using pulsed wave Doppler ultrasound. This estimate of stroke 
volume is then multiplied by heart rate determined via lead II of the 3-lead ECG to 
determine Q̇T. The left ventricular outflow tract diameter is assumed constant, and not to 
have changed through the duration of the studies and from rest to exercise. 
 
LUNG FUNCTION TESTING 
 The next step in the screening process, after we have completed the 
echocardiographic screening is to perform a series of pulmonary function tests. 
Collectively these tests are performed to ensure that all subjects have normal pulmonary 
function and no signs of lung disease are present. All tests are conducted according to the 
American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines (152, 
166, 247). 
Forced Vital Capacity 
 The forced vital capacity (FVC) maneuver is designed to determine the maximal 
volume of air exhaled from a maximal inspiration, performed with a maximally forced 
expiratory effort. Subject instrumentation consists of a nose-clip and a low resistance 
mouthpiece, which is fitted over a MedGraphics PreVent pneumotach connected to one 
of two primary pieces of equipment in our laboratory capable of performing spirometry: 
(the MedGraphics Ultima CardiO2 or Elite Series Plethysmograph). With subjects seated 
upright they are instructed to breathe quietly through the mouthpiece with their feet flat 
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on the floor and their hands on their knees. The maneuver begins when, at the end of a 
normal tidal inspiration, subjects are instructed to exhale all the air in their lungs and 
continue until reaching residual volume (RV). At that point in time subjects are then 
instructed to take a maximal inspiration, to total lung capacity (TLC), at which point they 
maximally exhale “blast” all of the air in their lungs to residual volume once again for ≥6 
sec. The resulting flow-volume loop recorded represents their forced vital capacity, and 
further analysis of this recording yields information pertaining to other important 
parameters. 
 The main secondary parameter is the volume of air exhaled during the first second 
of their maximal expiration from a maximal inspiration, the forced expiratory volume in 
1 sec (FEV1). In healthy, young individuals the ratio of this volume to their FVC (i.e., 
FEV1/FVC ratio) should be ~0.80. A reduced FEV1 and therefore FEV1/FVC ratio <0.80 
is one indication for air flow limitation/obstruction, which could be due to age or 
pathology (e.g., chronic obstructive pulmonary disease or asthma). Similar to FEV1 is the 
expiratory flow rate between 25% and 75% of their maximal expiration (i.e., FEF25-75). 
This middle portion of the expiratory volume is effort independent and offers an 
assessment of small airway reactivity and/or obstruction. In subjects with a reduced 
FEF25-75, the expiratory portion of the FVC maneuver will be curvilinear in this FEF25-75 
region and therefore can contribute to a reduced FEV1. 
 The ATS/ERS has clear guidelines on determining the validity and reproducibility 
of the FVC maneuver and requires a minimum of 3 successful trials. Acceptable 
repeatability is achieved when the difference between the largest and next largest FVC 
and FEV1 is ≤0.150 L. Each of these parameters also has defined predicted values based 
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on subjects age, sex and height. Subjects in this dissertation had no spirometric variable, 
particularly FVC, FEV1 and FEV1/FVC ratio, <90% predicted. 
Slow Vital Capacity 
 The slow vital capacity (SVC) is performed after the FVC maneuver and is 
essentially the same maneuver performed in a slow and controlled fashion with the intent 
to measure subject’s vital capacity. Performing a SVC begins with subjects positioned in 
the same manner as during the FVC. They are encouraged to breathe quietly at normal 
functional residual capacity (FRC), in some cases allowing subjects to relax by taking a 
sigh facilitates breathing at FRC. Subjects are required to take ≥4 tidal breaths at a 
constant FRC, at which point at the end of the next tidal expiration subjects are instructed 
to inhale slowly to TLC. This inhalation should not be forced, but also not unduly slow 
and verbal encouragement to fully reach TLC is imperative. Once at TLC subjects are 
instructed to relax and exhale passively from the natural recoil of the chest wall, again in 
a natural and not forced manner. Eventually effort is required to continue expiration at 
which point verbal encouragement to fully exhale to RV is similarly imperative. 
Performing the vital capacity in a slow manner reduces the rate of small airway collapse 
and therefore typically allows for a slightly larger vital capacity measurement when 
comparing to the FVC. Repeatability requirements for the SVC are similar to the FVC, 
≥3 SVC maneuvers with the largest and next largest being ≤0.150 L apart. 
Whole-Body Plethysmography 
 Spirometric variables are clinically very useful for detecting and quantifying the 
severity of lung disease, although the FVC and SVC maneuvers do not yield 
measurements of absolute lung volumes, specifically, TLC, FRC, and RV. Although 
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these are not clinically irrelevant, they technically more challenging to obtain, which 
limits their use in clinical practice outside of specialty pulmonology clinics. Nevertheless, 
whole body plethysmography is the gold standard method to measure lung volumes and 
is based on Boyle’s Law: P!V! = !P!V! 
Equation 2.15. Boyles Law 
which states that under isothermal conditions, when a constant mass of gas is compressed 
or decompressed, the gas volume decreases or increases, and the gas pressure changes 
such that the product of pressure and volume are constant. The pressure within, and 
volume of, subject’s thoracic cavity is then related to the pressure within, and volume of, 
the plethysmograph. The procedure for this test begins similar to that for the SVC 
maneuver where subjects are instructed to take ≥4 tidal breaths at a constant FRC, and 
again, subjects are encouraged to sigh to facilitate breathing at FRC. Once the subject 
reaches end-expiration, the subject is instructed to begin a series of gentle pants, which 
are essentially very shallow breaths that correspond to a specific mouth pressure 
generated by the panting maneuver and box pressure generated by the chest wall 
movement. The rate at which this panting maneuver is performed is important and must 
be between 70-90 pants per min. Once at the correct panting rate, the shutter within the 
mouthpiece closes for ~2-3 sec and 3-5 satisfactory panting maneuvers are recorded, 
which should appear almost superimposable on the pressure volume plot. The shutter 
then re-opens and the subject is instructed to perform a slow inspiratory vital capacity 
maneuver followed by an expiratory vital capacity maneuver. This procedure allows for 
the determination of the volume of gas within the thoracic cavity at FRC which when 
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subtracted from expiratory reserve volume will yield RV. Similarly, TLC can be 
computed by adding RV to the measured vital capacity. Repeatability is obtained when 
the measured values of FRC agree to within 5%, and ≥3 successful trials have been 
performed. 
Diffusion Capacity for Carbon Monoxide 
 Although there are several methods for determining the lungs diffusion capacity 
for carbon monoxide (e.g., steady state, intra-breath, and rebreathing techniques), the 
method used in our laboratory is the single-breath, breath hold technique. The procedure 
begins with subjects seated upright within the MedGraphics Elite Series Plethysmograph 
breathing normally through the mouthpiece with a nose-clip in place. Subjects are 
encouraged to breathe naturally and relaxed at a constant end expiratory volume, and 
after ≥4 breaths with a stable FRC, subjects exhale to RV in an unforced fashion. Once at 
RV there is an audible “clicking” noise from within the apparatus signifying that the 
expiratory outlet is pinched shut. Subjects are then quickly instructed to take a full breath 
in, all the way to TLC, which is delivered from the test gas cylinder (0.3% carbon 
monoxide, 21% oxygen, 0.5% neon, balanced nitrogen). Critical to accurate 
interpretation of the test results is that subjects inhale to >85% of their predicted TLC. 
The single-breath of test gas is held for 8 sec, after which the expiratory outlet opens 
signified by an audible “click” and subjects are instructed to exhale in a rapid but 
unforced fashion. A sample of this exhaled alveolar gas is then directed through a column 
of diatomaceous earth that allows for the separation of gases based on their size and is 
analyzed using a gas chromatograph. Neon serves as the tracer gas that is biologically 
inert, and is used to determine the initial alveolar carbon monoxide fraction, and the 
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alveolar volume at which carbon monoxide uptake is occurring. The computer then 
compares the volume of carbon monoxide delivered relative to the volume of carbon 
monoxide in the exhaled alveolar sample to calculate the volume of carbon monoxide 
that diffused from the alveolar air into the blood. This volume is standardized to the time 
of the breath hold (111), and presented as both an absolute diffusing capacity (DLCO) and 
a diffusing capacity relative to the calculated alveolar volume (DLCO/VA) determined 
during the test. Although differences in DLCO can arise from differences in lung volumes, 
based on differences in height and sex, these can be corrected for by comparing the 
DLCO/VA values across subjects. 
 
SUBJECT INSTRUMENTATION 
Intravenous Catheterization 
 On all studies involving the peripheral injection of agitated saline contrast, I 
placed an intravenous catheter (i.v.) in a peripheral vein in the antecubital fossa. For 
studies that also involved the i.v. infusion of epinephrine, a secondary i.v. was placed in 
the opposite arm. Briefly, a tourniquet is applied to the upper arm and subjects are 
instructed to squeeze a piece of foam to facilitate engorging the venous circulation in 
their forearm. If this process does not result in sufficient venous distension to visualize 
and/or feel a vein adequate for catheterization, a hot damp towel was laid over the area to 
further promote dilation. Once an adequate vein had been identified, an 18-22G 1.25” i.v. 
(ProtectIV Safety i.v. Catheter - radiopaque) was placed and connected to an extension 
set and one 3-way stopcock. Saline from a prefilled 10 ml syringe was used to ensure 
proper placement and adequate flushing of saline. Care was taken to pinch off the 
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extension set and turn the stopcock to the off position. Finally, a piece of tegaderm (2.75 
x 3.25 in) was set over the i.v. and extension set to maintain its placement. 
Arterial Catheterization 
 Arterial catheterization is a technically involved procedure and a critical piece of 
this dissertation, as the proper analysis of arterial blood is a fundamental skill set of 
respiratory physiologists that is essential to measuring pulmonary gas exchange 
efficiency. For the studies in this dissertation arterial catheterization was performed in the 
radial artery of all subjects. Due to the invasiveness and risk associated with procedure, 
radial artery catheters were placed in the subjects in Chapter IV by a licensed cardiologist 
(Dr. Jerold Hawn) and for the subjects in Chapter VI radial arterial catheters were placed 
by the physician currently on site (Drs. Christopher Davis, Morgen Eutermoser, and 
David Polaner). Prior to the placement of radial artery catheters an Allen’s test was 
conducted to ensure adequate collateral circulation in the hand. For all subjects in this 
dissertation, both hands were required to pass the Allen’s test in order to proceed with 
this procedure. Assessing adequate collateral circulation is important due to the rare but 
possible risk of occluding blood flow via the radial artery. Blood flow to the hand comes 
from two primary arteries, the radial and ulnar, and these two arteries anastomose in the 
palm. In some subjects the connection is very thorough, and both arteries supply 
sufficient blood flow to the hand on their own. However, in some subjects the connection 
is less thorough or relatively nonexistent, and in these subjects arterial catheterization 
carries the risk of preventing adequate blood flow to the hand. Thus, the Allen’s test is 
conducted by manually occluding blood flow via both the ulnar and radial arteries with 
the forefingers of both hands, and instructing the subject to firmly open and close their 
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fist. This causes their hand to become very pale, at which point they are instructed to 
open their hand and we then release pressure on the ulnar artery and count the number of 
seconds required for color to fully return to their hand, which must be in ≤7 sec. We 
preferentially chose to catheterize the non-dominate hand for subjects in Chapter IV, 
however for subjects in Chapter VI, arterial catheters were placed on three separate 
occasions, which necessitated using both wrists. Although I screened all subjects using 
the Allen’s test, the physician on site performed the test as well and always had the final 
decision. 
 All radial artery catheters (20G x 1.75” Arrow International, Reading, PA, USA) 
were placed under aseptic conditions following sterile techniques and under local 
anesthesia using 1% lidocaine with 2% by volume nitroglycerin (5 mg/ml) to minimize 
vasospasm. Subjects were positioned supine with their arm laid over a table covered in 
sterile drapes and their wrist in a support keeping it in an extended position. A secondary 
sterile drape with a 3” circular access hole was positioned with subject’s radial artery in 
the center of this access hole and unfolded to cover their arm. A 20G needle was used to 
gain access the radial artery, after which a guide wire was threaded through the needle 
into the radial artery. The needle was then removed and the catheter was threaded onto 
the guide wire and into the radial artery. Finally, the guide wire was removed and an 
extension set with 3-way stopcock that was pre-flushed with heparinized saline (1 
unit/ml) was connected to the catheter and proper placement was ensured by flushing the 
catheter with heparinized saline. This circuit was then connected to a pressurized flush 
system of heparinized saline that continuously and slowly dripped to maintain patency of 
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the catheter. Thereafter, arterial blood samples could be drawn for direct measurement of 
arterial PO2, PCO2, pH, SaO2, hemoglobin, hematocrit and lactate. 
Measures of Core Body Temperature 
 An important step in accurately measuring the true in vivo arterial PO2 and PCO2 
is to correct the arterial blood sample for subject’s core body temperature. When 
analyzed in the arterial blood gas machine, the temperature at the electrode interface is 37
, and therefore, the PO2/PCO2 of the sample will be reflective of 37. If subject’s 
body temperature is lower or higher than 37, the measured PO2/PCO2 will be lower or 
higher, respectively, compared to the true in vivo PO2/PCO2. It follows then that 
accurately measuring core body temperature is most important during conditions when 
body temperature would be expected to deviate from 37, such as during exercise.  
 Although various methods exist for measuring body temperature (tympanic, 
sublingual, rectal, esophageal, and via an ingestible pill) studies in this dissertation used 
the ingestible pill and esophageal method. For all visits in Chapter VI, the ingestible pill 
(HQinc., CoreTemp, Palmetto, FL, USA) was used and subjects were instructed to take 
the pill ~3 hours prior to the start of exercise. The pill is activated prior to ingestion by 
removing a magnetic connection and the correct serial number is entered into the wireless 
receiving device. With the handheld receiver near subject’s abdominal area, temperature 
recordings are transmitted and displayed to the nearest hundredth. Serial measures in at 
least triplicate were always taken and the average temperature was recorded. 
 For subjects in Chapter IV measures of esophageal temperature were primarily 
used, and I placed all of the temperature probes (Mon-a-therm General Purpose Probe, 7-
french). Subjects were positioned seated upright on the counter such that while standing, 
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I could see directly into their mouths using a headlight to assist with visualizing the back 
of the throat. The self-administration of 2 ml of 2% Lidocaine gel into the nasal cavity, 
was generally sufficient to temporarily anesthetize the area and back of the throat. 
However, an additional 1-2 sprays of HurriCaine spray (20% Benzocaine oral anesthetic) 
was used to further anesthetize the back of the throat and dampen subject’s gag reflex if 
necessary. The esophageal temperature probe was then inserted in the nasal cavity via 
nasal intubation and advanced until visualized in the back of the throat. At which point 
subjects were provided a glass of water with a straw, and instructed to take small sips of 
water in a consistent rhythmic order. With each sip of water, the probe was advanced 
another 1-2 inches until at the appropriate point estimated to be at the level of the atria 
based off of subjects sitting height (161). Four subjects in Chapter IV could not tolerate 
the placement of the temperature probe and instead were given an ingestible temperature 
pill ~2-3 hours prior to beginning data collection. 
Peripheral Oxygen Saturation and Heart Rate 
 A forehead pulse oximeter (Nellcor N600x, Covidien, Dublin, Ireland) was used 
to record peripheral estimates of arterial oxygen saturation (SpO2) and heart rate, which 
were continuously fed into our metabolic data acquisition system. The pulse oximeter is a 
adhesive oval shape with one red light emitting diode (LED) and another infrared LED, 
that when placed directly above the pupil record estimates of hemoglobin saturation. The 
wavelength of the red (660 nm) and infrared light (940 nm) are reflected differently based 
on the state of the hemoglobin molecule, i.e. bound or unbound. Although normally 
>97% of hemoglobin is bound with oxygen (HbO2) some hemoglobin, usually <2% is 
bound with carbon monoxide (HbCO) or is methemoglobin, which is interpreted via 
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pulse oximetry as bound (i.e. oxygenated) hemoglobin. Accordingly pulse oximetry 
provides an estimate that is usually ~2% higher than true in vivo HbO2. The gold standard 
method of measuring HbO2 is via CO-oximetry described in the arterial blood draw and 
analysis section. The pulsatile changes in color determined using pulse oximetry also 
provide an estimate of heart rate, however heart rate was also measured via lead II of 
either a 3-lead ECG (Chapters V and VI) or a 12-lead ECG (Chapter IV). 
12-Lead Echocardiogram 
 For all subjects in Chapter IV a 12-lead ECG was placed to continuously monitor 
electrical activity of the heart. Atrial through ventricular depolarization and repolarization 
is recorded via electrical impulses from electrodes on the skin and generates a waveform 
displayed real time (CardiO2, Mortara, MedGraphics). The placement of three limb leads, 
one on the left shoulder, right shoulder and left iliac crest give rise to the three bipolar 
limb leads (lead I, II, and III) and the three augmented unipolar limb leads (aVR, aVL, 
and aVF) that analyze the heart in the frontal place. The placement of six unipolar chest 
leads (V1, V2, V3, V4, V5 and V6) analyze the heart in the transverse plane with V1-3 
positioned in front of the heart to analyze posterior/anterior activity, and V4-6 positioned 
around the side of the chest to analyze right/left/lateral activity. The placement of V4 was 
repositioned ~2 in inferiorly to allow room for the ultrasound probe to reach the 
necessary location (139). 
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ECHOCARDIOGRAPHY MEASUREMENTS 
Transthoracic Saline Contrast Echocardiography 
 The detection of blood flow through intrapulmonary arteriovenous anastomoses 
(IPAVA) was done using transthoracic saline contrast echocardiography (TTSCE) in the 
same manner as was described in the echocardiographic screening procedure section. For 
subjects in Chapter V and VI subjects were positioned seated upright on a stationary 
cycle ergometer, and for subjects in Chapter IV, subjects were reclined in the left lateral 
decubitus position. In all cases, the sonographer (Randy Goodman or Eben Futral) 
obtained an apical, four-chamber view and individually adjusted the receiver settings for 
all subjects and for every injection to optimize the image. Care was taken to emphasize 
the image and optimize it on the left ventricle in a non-foreshortened view. Saline (3 ml) 
and air (1 ml) was agitated between two 10 ml syringes connected in series by two 3-way 
stopcocks. Connected to the first stopcock was a 250-1000 ml bag of saline via a solution 
set, and connected to the second stopcock was the extension set of the i.v. catheter. In this 
way saline could be easily and rapidly filled into the syringe. Saline and air were agitated 
together for ~15 sec for all injections, and after injection, the sonographer recorded the 
subsequent 20 cardiac cycles at >30 frames/sec post appearance of contrast in the right 
ventricle. Each injection was analyzed by individually advancing the recording frame-by-
frame and identifying the single frame with the greatest number and/or spatial 
distribution of microbubbles in the left ventricle. Based on this single frame, a 0-5 score 
was assigned; 0 = 0 microbubbles, 1 = 1-3 microbubbles, 2 = 4-12 microbubbles, 3 = >12 
microbubbles appearing as a bolus, 4 = >12 microbubbles heterogeneously filling the left 
ventricle, and 5 = >12 microbubbles homogenously filling the left ventricle. This scoring 
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system was first published in 2008 (144) and has subsequently been published in other 
work from our group (54, 55, 133, 134) and is not without precedent (11). 
 The sonographers were the primary scorers of each saline contrast injection, 
however we have previously reported very good agreement between bubble scores 
obtained when analyzed by a licensed cardiologist blinded to the conditions. In an effort 
to further validate reproducibility of this scoring system, the cardiologist reviewed 57 
echocardiogram recordings. There was 100% agreement on whether there was or was not 
contrast in the left ventricle, and 93% agreement on the bubble score between the 
sonographer and cardiologist. Of the 4 recordings with disparate scores, disagreement 
was between whether or not they should be scored a 0 or 1. Accurately identifying a 
single microbubble takes a very skilled eye, yet also represents in all likelihood a trivial, 
insignificant volume of blood flow through IPAVA. 
Pulmonary Artery Systolic Pressure 
 As described previously, PASP was determined by measuring the peak velocity 
(v) of the tricuspid regurgitation jet and estimating right atrial pressure (PRA) based on the 
collapsibility of the inferior vena cava, and applying these to the modified Bernoulli 
equation; see Equation 2.14 (42, 92, 202, 275). 
Cardiac Output 
 Cardiac output (Q̇T) was estimated using echocardiography and determined at the 
level of the left ventricular outflow tract (LVOT). Previously during the screening visit, 
subjects LVOT diameter had been determined and recorded. This value was used to 
estimate the cross sectional area of the outflow tract. Pulsed wave Doppler ultrasound 
was used in all studies to determine the LVOT velocity time integral (LVOTVTI) of blood 
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flow through the outflow tract. Measures of the LVOTVTI were recorded in triplicate and 
the average was multiplied by the previously determined cross sectional area of the 
LVOT. The product of the LVOTVTI and LVOT cross sectional area equals the stroke 
volume, which multiplied by heart rate provides an estimate of Q̇T.  
 Other echocardiographic methods exist to determine Q̇T, such as the modified 
Simpson’s method, however previous pilot work conducted in our laboratory has shown 
the modified Simpson’s method to be unreliable when heart rate is elevated. This was 
demonstrated by measuring Q̇T using modified Simpson’s and LVOT during exercise and 
comparing the measured Q̇T values to the predicted Q̇T based off of the measured V̇O2 
(8). Measured values using the modified Simpson’s method plateaued after ~10-12 
L/min, whereas measured values using LVOT tracked very well to the predicted values. 
 
OPEN CIRCUIT ACETYLENE UPTAKE 
 In Chapter IV Q̇T was also measured using the open circuit acetylene washin 
method as developed by Stout et al. (217), modified by Gan et al. (70), and subsequently 
validated in humans against the direct Fick approach (110). Subjects breathed through a 
non-rebreathing Hans-Rudolph mouthpiece connected to an automatic three-way sliding 
valve allowing rapid and non-interruptive transitions (i.e., during subjects expiration) 
between two different inspiratory ports. When breathing room air, one inspiratory port 
was open to room air and the other was connected to a normoxic acetylene gas mixture 
(0.6% acetylene, 9.0% helium, 20.9% O2, balance N2). When breathing 40% O2, one 
inspiratory port was connected to a hyperoxic gas mixture (40% O2, balance N2) and the 
other was connected to a hyperoxic acetylene gas mixture (0.6% acetylene, 9.0% helium, 
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40% O2, balance N2). During the washin phase, breath-by-breath acetylene and helium 
uptake was measured by a respiratory mass spectrometer (Marquette MGA 1100, MA 
Tech Services) and tidal volume was measured by a pneumotach (Hans Rudolph 3700) 
linearized by the method of Yeh et al. (274) and calibrated using test gas between before 
each study. Finally, it should be clear that the fundamental limitation of open circuit 
acetylene uptake is that blood flow through intrapulmonary right-to-left shunts is not 
detected using this method. 
 
DELIVERY OF INSPIRED GAS MIXTURES 
 In all studies in Chapters IV-VI, subjects breathed through a low resistance, non-
rebreathing mouthpiece and they expired to room air. When subjects inspired room air, 
the inspiratory port was also open to room air. However when the FIO2 was manipulated, 
and subjects either breathed 40% O2 (Chapter IV) and 100% O2 (Chapter V) the 
inspiratory port was connected to a non-diffusing Mylar Douglas bag. This Douglas bag 
was connected to a compressed gas blender that is connected to two compressed gas 
cylinders; medical grade room air, and medical grade 100% O2. By adjusting the blender 
the appropriate FIO2 could be obtained and verified using our metabolic data acquisition 
system. The gas analyzer in our metabolic data acquisition system is a zirconia O2 cell 
that we calibrate prior to all studies using a known gas mixture. In series between the 
hosing that delivers gas to the Douglas bag and the gas blender, is a flow regulator that 
can be adjusted to manipulate the flow rate into the bag based off of subject’s minute 
ventilation. 
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In Chapter IV the mouthpiece subject breathed through was a custom built two-
way non-rebreathing mouthpiece with a pneumatic sliding valve allowing rapid and non-
interruptive transitions (i.e., during subjects expiration) between two different inspiratory 
ports. When breathing room air, one inspiratory port was open to room air and the other 
was connected to a normoxic acetylene gas mixture (0.6% acetylene, 9.0% helium, 
20.9% O2, balance N2). When breathing 40% O2, one inspiratory port was connected to a 
hyperoxic gas mixture (40% O2, balance N2) and the other was connected to a hyperoxic 
acetylene gas mixture (0.6% acetylene, 9.0% helium, 40% O2, balance N2). 
 
MEASUREMENT OF ARTERIAL BLOOD GASES 
Arterial Blood Draw and Analysis 
 Although analyzing arterial blood is a technically straightforward procedure, 
substantial care must be taken to obtain accurate measures, particularly when subjects are 
breathing >21% O2. As described in the arterial catheterization section, patency of 
arterial catheters was maintained using a pressurized flush system of heparinized saline, 
and connected in series to this circuit, between the solution set and extension set, were 
two 3-way stopcocks. Arterial blood samples were obtained by first wasting ~1 ml of 
blood because the extension set and stopcock have a combined dead space of ~0.5 ml. A 
new, heparinized 3 ml syringe was then connected to the stopcock and arterial blood was 
withdrawn over an ~15 sec window. Care was taken to include several respiratory cycles 
when subjects were resting, however this was less of a concern during conditions of 
elevated ventilation (i.e., during exercise or the i.v. infusion of epinephrine). Additionally 
the precise duration of the blood draw was noted, from start to finish, so as to accurately 
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align the blood draw with metabolic data. The arterial sample was withdrawn in such a 
way as to keep any small air bubble at the tip of the syringe, which was immediately 
expelled after passing the sample to the investigator in charge of analyzing the samples. 
During the analysis investigators were careful to maintain a positive pressure on the 
sample syringe during the analysis to pre-emptively prevent the production of an air 
bubble. Additionally, all arterial samples were held with a firm seal over the tip of the 
syringe, rocked back and forth to facilitate mixing, and prior to their immediate analysis a 
small volume of blood near the tip of the syringe was wasted to continually rid the 
sample of blood that is most at risk for room air contamination. All arterial blood samples 
analyzed in Chapters IV and VI were done using a Siemens RAPIDLab248 containing a 
Clarke electrode for measurement of PO2 and a Severinghaus electrode for measurement 
of PCO2. After obtaining the arterial sample, the investigator in charge of monitoring the 
arterial catheter resumed the pressurized flush system of heparinized saline to flush the 
arterial catheter. The blood gas analyzer requires ~60 sec to analyze each sample, and 
during this period, the sample was analyzed using CO-oximetry via a Radiometer OSM3 
to determine arterial O2 saturation and hemoglobin concentration. Arterial blood samples 
were analyzed in duplicate and triplicate if time permitted or if the difference between the 
first two measurements exceeded 5%. After which the arterial blood was analyzed for 
hematocrit using the microcapillary tube centrifugation method, and for lactate 
concentration (YSI 1500 Sport).  
 All arterial blood samples were corrected for body temperature and were collected 
using a blood gas analyzer calibrated daily using tonometered whole human blood (see 
below). 
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Tonometry 
 The process of tonometry is similar, but superior, to using standard quality control 
methods in that it allows for the correction of day-to-day fluctuations and inherent errors 
in measuring the exact PO2 and PCO2. Samples of whole human blood are positioned 
within a heated block (37 ) and equilibrated for ~120 min with gases of known 
concentrations of O2 and CO2 that are anticipated to reflect the expected arterial PO2 and 
PCO2. These samples are then analyzed in duplicate and triplicate if the difference 
between the first to measurements exceeds 5%. A correction factor based off of the 
inverse slope of the measured versus predicted values was applied to the measured values 
in this dissertation. 
 For Chapter IV, the gases chosen were expected to span the range of arterial PO2 
and PCO2 anticipated in subjects breathing room air and 40% O2 at rest (PO2 = 100, 210, 
and 245 mm Hg; PCO2 = 21, 35, 48 mm Hg). Consistent inherent errors with handling 
and analyzing blood with PaO2 in the 220-230 mm Hg range are also present during the 
process of tonometry, and therefore this correction factor will help offset these. 
 For Chapter VI, the gases chosen were expected to span the range of arterial PO2 
and PCO2 anticipated in subjects at rest and during exercise breathing room air in 
Eugene, OR (130m, PB = 750 mm Hg) and on Mt. Chacaltaya, Bolivia (5260m, PB = 410 
mm Hg). For data collected at sea level the gases chosen spanned arterial PO2 = 40, 70, 
110 mm Hg and arterial PCO2 = 15, 35, 50 mm Hg. For data collected at altitude the 
gases chosen spanned arterial PO2 = 25 and 50 mm Hg, and PCO2 = 15 and 30 mm Hg. 
Only two tonometry gases were used at altitude due to the extreme difficulty and cost 
associated with obtaining these gases and transporting them to the research lab. 
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ALTITUDEOMICS 
 AltitudeOmics represents a very large, multinational collaborative research 
expedition investigating human acclimatization to hypoxia with the ultimate goal to 
marry the physiological adaptations to high-altitude with the accompanying genomic, 
proteomic, metabalomic, and epigenetic changes. Much of the prior methodological 
descriptions apply to this part of the AltitudeOmics project that represents Chapter VI of 
this dissertation, however considering the size and scope of this project a more detailed 
description is warranted that has largely been paraphrased from our recent publication 
describing the overview of this project (218). 
Subject Recruitment and Screening 
 All subjects were recruited from Eugene, OR (130m, PB = ~750 mm Hg) and only 
screened if they met the following exclusion criteria; born at >1500m, having traveled to 
altitudes >1000m in the past three months (including air travel), using prescription 
medications, smoking, pregnant, having a history of serious head injury, personal or 
familial history of migraine, cardiovascular or respiratory disease, hematologic 
abnormalities such as sickle cell trait, pulmonary function of diffusing capacity for 
carbon monoxide <90% predicted, or failing to meet the requirements of the army 
physical fitness test (push-ups, sit-ups, and 2 mi run). After excluding subjects for the 
aforementioned criteria, a total of 79 subjects were screened, that included additional 
testing identifying the presence of a PFO, a V̇O2max test and short bout of breathing 14% 
O2 to determine the baseline level of left-sided contrast at this level of acute normobaric 
hypoxia. The final group of 24 subjects that met the combined screening criteria 
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participated in the study, however two subjects dropped out for non-medical reasons, and 
one subject suffered from a non-altitude related gastrointestinal illness such that this 
subject was never fully healthy. These three subjects were excluded from the data 
analysis and the remaining 21 subjects participated in the project. 
Timeline 
 Baseline testing occurred in our Cardiopulmonary and Respiratory Physiology lab 
in the Spring of 2012. However, prior to the experimental study visit, all subjects 
completed a familiarization visit, in which a mock study visit was carried out. In both the 
familiarization protocol and experimental study visit (i.e., sea level testing, Figure 3.1), 
two subjects were completed each day. Experimental study visits were ~14 hour work 
days for investigators and occurred over a 14 day period, with a two day ‘break’ between 
the first 6 (12 subjects) and last 6 (12 subjects) experimental study days. Approximately 
one month later, study investigators (including myself) traveled to La Paz, Bolivia, to 
prepare/improve the housing conditions and laboratory setting. 
 Due to our laboratory equipment being held in Bolivian customs until the day 
prior to the first study visit, we set-up the entire laboratory for physiologic testing and 
laboratory space for omics analyses that night (before the first subjects); a process that 
took ~7 days to complete for baseline testing at sea level (SL). From this day forward, 
subjects traveled to Bolivia in pairs, on successive days (i.e., two subjects arrived each 
day). Upon arrival in El Alto, subjects were escorted from the airport at 4300m to 
Coroico at 1525m where they rested for ~48 hours. After this, subjects traveled in pairs 
from Coroico, via car, while breathing supplemental O2 to Mt. Chacaltaya at 5260m, an 
elevation gain of 3735m. The first subject immediately began instrumentation after being 
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Figure 3.1. AltitudeOmics Overview Timeline 
As published in the project overview paper of this series (218) the time course for each 
subject with respect to altitude. Arrows indicated experimental study days. Data in 
Chapter VI comes from experiments at SL, ALT1 and ALT16. 
 
removed from supplemental O2, while the second subject remained breathing 
supplemental O2. After the first subject was almost done with the physiologic testing 
protocol, the second subject was removed from supplemental O2 and began 
instrumentation, after which the physiologic protocol was repeated again. This study visit 
occurring after acutely and rapidly being transported to 5260m was referred to as ALT1 
(the first day at 5260m, Figure 3.1). These two subjects then slept overnight at 5260m 
breathing supplemental O2, with an emergency medicine physician in the same room. The 
following morning, these subjects completed a 3.2km field ‘run’, after which they 
descended to La Paz at 3800m where they remained for 3 days. On the fourth day in 
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Bolivia (ALT4) subjects returned to Mt. Chacaltaya for ~6 hours to promote 
acclimatization, and then returned to La Paz, after which they returned again to Mt. 
Chacaltaya on ALT5 where they remained for the following 12 days. This process was 
repeated for all 24 subjects, such that the number of residents on Mt. Chacaltaya 
increased by 2 per day, until all 24 subjects resided on Mt. Chacaltaya.  
 After the 11 day period of acclimatization spent at 5260m, the first subjects who 
arrived were the first subjects to be tested on ALT16 (Figure 3.1). These subjects then 
spent one last night on Mt. Chacaltaya before performing the 3.2km field run again and 
afterwards descending to Coroico for either 7 (n = 14) or 21 (n = 7) days. The same 
physiologic protocol was carried out at ALT16 as was done at ALT1 and SL. After the 
first study visit for ALT1, there were 12 sequential study visits, with a one day break in 
the middle, allowing investigators to descend to La Paz to shower and replenish snacks. 
Thus, there was also a ~2 day break before the first ALT16 study visit.  
 The general experimental protocol for SL, ALT1 and ALT16 (Figure 3.1) was to 
first instrument subjects with a radial artery and antecubital vein catheter, have subjects 
complete a series of cognitive function tests, perform a series of blood draws for analyses 
of omics data, and perform a muscle biopsy of the vastus lateralis. Subjects remained 
seated upright and ventilatory responses to different CO2 levels were recorded, they then 
performed a cycle ergometer VO2peak test and a 5km time trial. 
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CHAPTER IV 
INCREASED CARDIAC OUTPUT, NOT PULMONARY ARTERY SYSTOLIC 
PRESSURE, INCREASES INTRAPULMONARY SHUNT IN HUMANS 
BREATHING ROOM AIR AND 40% O2 
 This chapter is in review at the Journal of Physiology and Joseph W. Duke, Jerold 
A. Hawn, John R. Halliwill, and Andrew T. Lovering are co-authors. I performed the 
experimental work, led the project, and the writing is entirely my own; Joseph W. Duke 
provided technical and editorial assistance; Jerold A. Hawn placed all radial artery 
catheters; and John R. Halliwill and Andrew T. Lovering helped develop the protocol, 
and provided guidance and editorial assistance. All co-authors formally approved this 
manuscript for submission. 
 
INTRODUCTION 
 In healthy humans without a patent foramen ovale (PFO), blood flow through 
intrapulmonary arteriovenous anastomoses (IPAVA) can be detected using saline contrast 
echocardiography (159, 163, 198). Although blood flow through IPAVA is absent or 
trivial at rest (55), blood flow through IPAVA increases during exercise (53, 54, 143, 
216), while breathing hypoxic gas mixtures at rest (134), and during the intravenous (i.v.) 
infusion of inotropic drugs (24, 133). The physiological significance of these findings 
remains controversial (103) but it has been hypothesized that blood flow through IPAVA 
could provide a source of venous admixture and impair pulmonary gas exchange 
efficiency, i.e. increase the alveolar-to-arterial difference in PO2 (A-aDO2) (143, 216). 
 98 
 Bryan et al. (24) demonstrated that during the i.v. infusion of dobutamine and 
dopamine in healthy humans at rest breathing room air, the degree of left-sided contrast 
increased, yet the A-aDO2 remained unchanged (24). However, in accordance with the 
Fick principle of mass balance, this necessitates an increase in the calculated shunt 
fraction (Q̇S/Q̇T) due to an increase in mixed venous O2 content (Cv̅O2) secondary to an 
increased QT and constant whole body V̇O2. In that study, increases in left-sided contrast, 
which never exceeded intermittent boluses of contrast in the left ventricle, corresponded 
to increases in Q̇T that increased by ~50% above resting values. Similar work by Laurie et 
al. (133) without measurements of the A-aDO2, has demonstrated in healthy humans 
without a PFO that at rest breathing room air during the i.v. infusion of epinephrine (EPI) 
blood flow through IPAVA is increased. In that study the highest dose of EPI (320 
ng/kg/min) corresponded to an ~2-fold increase in Q̇T and pulmonary artery systolic 
pressure (PASP) the qualitative degree of left-sided contrast ranged from intermittent 
boluses to heterogeneous filling of the left ventricle. Accordingly, the data from Bryan et 
al. support the potential that blood flow through IPAVA may provide a source of venous 
admixture, yet in light of the work by Laurie et al., it remains possible that higher Q̇T and 
PASP would have corresponded to greater degrees of left-sided contrast and therefore, 
potentially more blood flow through IPAVA resulting in a measurable increase in the A-
aDO2. 
 In addition to potential contributions from blood flow through IPAVA, pulmonary 
gas exchange efficiency may also be impaired by alveolar ventilation-to-perfusion 
(V̇A/Q̇) inequality, incomplete end-capillary O2 diffusion equilibration (diffusion 
limitation), and right-to-left shunt via the bronchial and Thebesian circulations. 
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Determination of the A-aDO2 via arterial blood gas analysis and calculation of alveolar 
PO2 (PAO2) does not yield information concerning the relative contribution of each of 
these factors. This is particularly relevant during interventions known to increase blood 
flow through IPAVA (e.g., during exercise, breathing hypoxic gas mixtures, or the i.v. 
infusion of catecholamines) where the pulmonary capillary transit time required for 
complete end-capillary O2 equilibration, mixed venous PO2, and driving gradient for O2 
across the alveolar-capillary interface may vary considerably. As a result, contributions 
from V̇A/Q̇ inequality, diffusion limitation, and shunt may differ during these different 
interventions, and thus obscure the ability to draw conclusions regarding the potential 
contributions from each on the A-aDO2 unless some of these contributions are held 
constant. 
 Accordingly, an experimental paradigm that would eliminate V̇A/Q̇ inequality and 
diffusion limitation while increasing blood flow through IPAVA in healthy humans at 
rest would be optimal to determine if blood flow through IPAVA contributed to 
pulmonary gas exchange efficiency. Elevating PAO2 via breathing 100% O2 at sea level 
theoretically eliminates V̇A/Q̇ inequality and diffusion limitation (196), however, blood 
flow through IPAVA during exercise and the i.v. infusion of EPI has been shown to be 
significantly reduced or eliminated when breathing 100% O2 (24, 54, 133, 144). Thus, 
breathing 100% O2 isolates the contribution of right-to-left shunt, but this would not 
include the contribution of blood flow through IPAVA, and therefore may not represent 
the same volume of right-to-left shunt when breathing room air. Instead, breathing 
<100% O2 but, >21% O2 has the potential to sufficiently elevate PAO2 such that the 
contributions of V̇A/Q̇ inequality and diffusion limitation are minimized or prevented, yet 
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still permits blood flow through IPAVA. According to theoretical analyses describing the 
rate of O2 uptake across the alveolar-capillary interface (240) and unpublished 
observations in our laboratory (Davis et al.), breathing 40% O2 satisfies both of these 
requirements. Compared to breathing room air, when breathing 40% O2, blood flow 
through IPAVA is qualitatively unchanged, PAO2 is increased >2 fold, and mean end-
capillary O2 equilibration time is reduced to ~0.1 sec. 
 The purpose of the current study was to investigate the potential for blood flow 
through IPAVA to provide a source of venous admixture and impair pulmonary gas 
exchange. To this end, we employed the aforementioned experimental paradigms by 
quantifying the A-aDO2 in healthy humans at rest, breathing room air and 40% O2 during 
the i.v. infusion of EPI. Additionally, to increase Q̇T with lower doses of i.v. EPI, this 
protocol was repeated following vagal blockade via atropine. We hypothesized that the 
A-aDO2 would increase during the i.v. infusion of EPI when breathing room air, and the 
resulting increase in A-aDO2 would not be ameliorated during the i.v. infusion of EPI 
when breathing 40% O2. 
 
METHODS 
 The University of Oregon Office for Protection of Human Subjects approved this 
project and all subjects provided verbal and written informed consent prior to 
participation. All studies were performed in accordance with the Declaration of Helsinki. 
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Subjects 
 Nine subjects (4 female) volunteered to participate in this study, all of which were 
healthy, young, non-smoking and without a history of cardiopulmonary or respiratory 
disease. 
 According to the American Thoracic Society and European Respiratory Society 
standards (ATS/ERS) all subjects demonstrated normal pulmonary function, lung 
volumes and capacities, and diffusion capacity for carbon monoxide. Pulmonary function 
was assessed using computerized spirometry (MedGraphics Ultima CardiO2, St. Paul, 
MN, USA) and involved forced and slow vital capacity manoeuvres (166). Lung volumes 
and capacities were determined using whole body plethysmography (MedGraphics Elite 
Plethysmograph) (247). Lung diffusion capacity for carbon monoxide (DLCO) was 
determined by the single-breath, breath hold method (119, 152) using the Jones and 
Meade method for timing (111). 
 All subjects underwent a comprehensive echocardiographic screening procedure 
performed by a registered diagnostic cardiac sonographer in both adult and paediatric 
echocardiography with 25 years of experience (Philips iE33, The Netherlands). The 
purpose of this screening procedure was to confirm that subjects were without cardiac 
abnormalities, including a PFO. To this end, subjects were rigorously screened using 
transthoracic saline contrast echocardiography (TTSCE) as described previously (55, 
139) and did not have a PFO. 
Instrumentation 
 Following local anesthesia [1% lidocaine, 2% by volume nitroglycerine (5 mg/ml) 
to minimize vasospasm] a 20 Ga x 1.75 in radial artery catheter (Arrow International, 
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Reading, PA, USA) was placed under aseptic conditions by a board certified cardiologist. 
Patency of the arterial catheter was maintained using a pressurized flush system of 
normal saline. Intravenous catheters (i.v.) (18-22 Ga) were placed in the antecubital fossa 
of each arm, one for the injection of agitated saline contrast and one for the infusion of 
epinephrine and atropine. All catheters were connected to an extension set (7.0 inch, 0.3 
mL volume) followed by a three-way stopcock. Measures of core body temperature were 
made using an esophageal temperature probe (Mon-A-Therm), which was inserted via 
nasal intubation following the application of an anesthetic gel (2 mL of 2% lidocaine gel) 
into the nasal cavity. In subjects who could not tolerate the esophageal temperature probe 
placement (4/9 subjects), an ingestible core temperature pill (HQInc) was used. 
Unpublished observations from our laboratory demonstrate that temperature obtained 
using esophageal and the core temperature pill is in good agreement at rest (R2 = 0.85). 
Lastly, a 12-lead ECG (MedGraphics, Mortara, CardiO2) was placed with V4 
repositioned ~5 cm inferiorly as described previously (139). 
Protocol 
 Subjects reported to the laboratory at 0700 hours and after familiarization with the 
study procedure began instrumentation. Thereafter, subjects were repositioned in a 
reclining chair in the left lateral decubitus position, and remained in this position for the 
duration of the protocol. The first set of measurements (Figure 4.1A) were made 
breathing room air and 40% O2 before and during the i.v. infusion of epinephrine (EPI). 
The second set of measurements (Figure 4.1B) were made breathing room air and 40% 
O2 following vagal blockade via atropine (ATR) before and during the i.v. infusion of 
epinephrine. In both sets of measurements, before and after ATR, the order of breathing 
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room air or 40% O2 was done in a random and balanced fashion. However, measurements 
with ATR always occurred second due to the ½ life of ATR being ~120 min. 
 Epinephrine was diluted in sterile saline to 4,000 ng/mL and depending on 
subjects body weight, was delivered at a constant rate for 5 min, using a continuous 
infusion syringe pump (Harvard Apparatus, Pump 22) as described previously (133). In 
the first set of measurements, before vagal blockade, EPI was infused at 320 ng/kg/min 
(320 EPI). In the second set of measurements, after vagal blockade, EPI was infused at 80 
ng/kg/min (ATR+80 EPI). Vagal blockade was accomplished via the i.v. infusion of 2 
mg of atropine, diluted in 10 mL of sterile saline, at a constant rate of 1 mL/min for 10 
min. 
 In both sets of measurements, before and after ATR, subjects were allowed ~20 
min for EPI to be metabolized and a final measurement without i.v. EPI was made. In this 
measurement, subjects reproduced the respiratory rate and tidal volume they had during 
the i.v. infusion of EPI. Respiratory rate was coached using a metronome and tidal 
volume was coached by verbal feedback while observing real time ventilatory data. 
 Thus, the first set of measurements (Figure 4.1A) were made breathing room air 
and 40% O2 at baseline (Pre EPI), during the i.v. infusion of EPI at 320 ng/kg/min (320 
EPI) and subsequently while reproducing the ventilation (V̇A) they had at 320 EPI (V̇A @ 
320 EPI). Following vagal blockade, the second set of measurements (Figure 4.1B) were 
made breathing room air and 40% O2 at baseline (Pre EPI (ATR)), during the i.v. infusion 
of EPI at 80 ng/kg/min (ATR+80 EPI) and subsequently while reproducing the 
ventilation they had at ATR+80 EPI (V̇A @ ATR+80 EPI). 
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Figure 4.1. Protocol Schematic 
Schematic of the overall protocol, with dark grey boxes indicating the time points where 
measurements were made (see below). EPI, epinephrine; ATR, atropine; 320 EPI, 320 
ng/kg/min epinephrine; V̇A (320 EPI), iso-alveolar ventilation after break from 320 EPI; 
ATR+80 EPI, 80 ng/kg/min of epinephrine with atropine; V̇A (ATR+80 EPI), iso-alveolar 
ventilation after break from ATR+80 EPI. 
 
Measurements 
Respiratory Variables. Breath-by-breath metabolic data was collected (MedGraphics, 
CardiO2) and presented as the mid 5 of 7 (i.e., the moving average of five breaths 
excluding the low and high). In this way continuous measures of pulmonary V̇O2, V̇CO2, 
minute ventilation (V̇E), and associated parameters, including end tidal and mixed expired 
PO2 and PCO2 values, were collected. Gases with known O2 and CO2 concentrations 
were used to calibrate the gas analyzer before every test and change from breathing room 
air or 40% O2. 
Cardiac Output and Pulmonary Artery Systolic Pressure. Cardiac output was 
measured using the open circuit acetylene washin method developed by Stout et al. (217), 
modified by Gan et al. (70), and subsequently validated in humans using direct Fick 
(110). Subjects breathed through a non-rebreathing Hans-Rudolph mouthpiece connected 
to an automatic three-way sliding valve allowing rapid and non-interruptive transitions 
(i.e., during subjects expiration) between two different inspiratory ports. When breathing 
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room air, one inspiratory port was open to room air and the other was connected to a 
normoxic acetylene gas mixture (0.6% acetylene, 9.0% helium, 20.9% O2, balance N2). 
When breathing 40% O2, one inspiratory port was connected to a hyperoxic gas mixture 
(40% O2, balance N2) and the other was connected to a hyperoxic acetylene gas mixture 
(0.6% acetylene, 9.0% helium, 40% O2, balance N2). During the washin phase, breath-by-
breath acetylene and helium uptake was measured by a respiratory mass spectrometer 
(Marquette MGA 1100, MA Tech Services) and tidal volume was measured by a 
pneumotach (Hans Rudolph 3700) linearized by the method of Yeh et al. (274) and 
calibrated using test gas before each study. 
 Pulmonary artery systolic pressure was determined by measuring the peak 
velocity (v) of the tricuspid regurgitation jet and estimating right atrial pressure (PRA) 
based on the collapsibility of the inferior vena cava, and applying these to the modified 
Bernoulli equation 4v2 + PRA (42, 92, 202, 275). 
Blood Flow Through Intrapulmonary Arteriovenous Anastomoses. Transthoracic 
saline contrast echocardiography (TTSCE) was used to detect blood flow through IPAVA 
as before (133). Briefly, agitated saline contrast was produced by combining 3 ml room 
air with 1 ml of normal saline and agitating for ~15 sec prior to injecting. Each agitated 
saline contrast injection was visualized in the apical, four-chamber view and recorded at 
>30 frames per second for 20 cardiac cycles post-appearance of saline contrast in the 
right ventricle. The single frame within the 20 cardiac cycle recording with the greatest 
density and spatial distribution of contrast was qualitatively assessed using a previously 
published scoring system (144) similar to others (11); 0 = no bubbles, 1 = 1-3 bubbles, 2 
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= 4-12 bubbles, 3 = >12 bubbles appearing as a bolus, 4 = >12 bubbles heterogeneously 
filling the left ventricle, and 5 = >12 bubbles homogeneously filling the left ventricle. 
Arterial Blood Gas Analysis. Arterial blood (3 mL) was drawn anaerobically via the 
radial artery over 10-15 sec into a heparinized syringe and immediately analyzed in 
duplicate (and triplicate if necessary) for arterial PO2 (PaO2), arterial PCO2 (PaCO2), and 
pH. The blood-gas analyzer (Siemens RAPIDLab 248, Germany) was calibrated daily 
with tonometered whole human blood by equilibrating three 6 ml samples of human 
blood, positioned within a heated block (37 ), with gases of known concentrations of 
O2 and CO2 for ~120 min. The gases were chosen to span the expected range of PaO2 and 
PaCO2 anticipated in subjects breathing room air and 40% O2 at rest (PO2 = 100, 210, 
and 245 mm Hg; PCO2 = 21, 35, 48 mm Hg). Each sample was run in triplicate, and the 
values were used to create a predicted versus measured slope. A correction factor based 
off of the inverse slope of this relationship was applied to measured values in this study. 
Arterial blood gases were also corrected for body temperature (48, 113, 205). Arterial O2 
saturation (SaO2) and hemoglobin (Hb) were measured with CO-oximetry (Radiometer 
OSM3, Copenhagen, Denmark). Hematocrit was analyzed using the microcapillary tube 
centrifugation method (M24 Centrifuge, LW Scientific, Lawrenceville, GA, USA). Blood 
lactate was analyzed in duplicate using an electrochemical analyzer (YSI 1500 Sport, 
Yellow Springs, OH, USA). 
Calculations 
 Alveolar PO2 (PAO2) was calculated using the ideal gas equation, using 
temperature/tonometry corrected PaCO2, and a respiratory quotient (RER) from a 15 sec 
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average of breath-by-breath metabolic data corresponding to the time and duration of the 
arterial blood draw: 
PAO! = ! P! !− !e!.!"#$%#!$!×!!!! !!.!"#$"# !×!FIO! !− !PaCO!!× ! FIO! + 1!− !FIO!RER  
Equation 2.3. Alveolar Gas Equation 
where TB is core body temperature for temperature correction of water vapor pressure, 
RER is the respiratory exchange ratio (V̇CO2/V̇O2), and PB is barometric pressure 
measured daily using a solid-state transducer barometer (7400 series Perception II, Davis 
Instruments). Pulmonary gas exchange efficiency (A-aDO2) was then determined at rest 
and during i.v. infusion of EPI with and without ATR by subtracting the 
temperature/tonometry corrected PaO2 from the corresponding calculated PAO2.  
 Measures of O2 content were calculated from the standard content equation: 
O!!Content! = ! 1.39!×!Hb!× ! SO!100 + ! 0.003!×!PO!  
Equation 2.7. Oxygen Content Equation 
using an O2 carrying capacity of 1.39 ml O2/g Hb and subjects directly measured 
corresponding Hb (g Hb/dL). For arterial O2 content (CaO2) SO2 represents CO-oximetry 
measured arterial O2 saturation (SaO2) and temperature/tonometry corrected PaO2. For 
end-capillary O2 content (CcʹO2) SO2 represents calculated end-capillary O2 saturation 
(ScʹO2) via the Kelman equation (114) assuming end-capillary PO2 (PcʹO2) was equal to 
PAO2. Mixed venous O2 content was calculated using the Fick equation (V̇O2 = Q̇T × 
(CaO2 − Cv̅O2)) and rearranging such that, Cv̅O2 = CaO2 − (V̇O2/QT). 
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 Total venous admixture (QVA/QT) required to account for the entirety of the 
AaDO2 was calculated from the shunt equation using the previously calculated O2 
contents: Q!"Q! = !CcʹO! − CaO!CcʹO! − CvO! 
Equation 2.13. Berggren Shunt Equation 
 Alveolar ventilation (V̇A) was calculated using the directly measured V̇CO2 and 
temperature corrected PaCO2: 
V! = VCO!!×!863PaCO!  
Equation 2.1. Alveolar Ventilation 
Statistical Analyses 
 Statistical analyses using GraphPad Prism (v. 5.0d) were done using a one-way 
analysis of variance comparing measured and calculated variables within an FIO2 (room 
air or 40% O2) without and with ATR. A Tukey’s multiple comparison post hoc test was 
used to determine specific pairwise differences within variables. Non-parametric analyses 
(bubble scores) were done using a Friedman’s test with a Dunn’s multiple comparison 
post-hoc test. All comparisons were determined a priori and significance was set to p < 
0.05. 
 
RESULTS 
 Subject anthropometric and pulmonary function data are presented in Table 4.1. 
Cardiopulmonary and respiratory data when breathing room air are presented in Table 
4.2, and when breathing 40% O2 are presented in Table 4.3. 
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Table 4.1. Anthropometric and Pulmonary Function Data  
 Absolute % Predicted 
Age, yr 24.6 ± 4.9  
Height, cm 172 ± 11  
Weight, kg 73.3 ± 11.2  
FVC, L 5.12 ± 1.09 (103.6 ± 5) 
FEV1, L 4.19 ± 0.86 (101.5 ± 6.9) 
FEV1/FVC, % 82 ± 5 (97 ± 5) 
FEF25-75 4.18 ± 1.2 (95.4 ± 6.4) 
SVC, L 5.43 ± 1.1 (111.4 ± 6.7) 
TLC, Lpleth 6.55 ± 1 (106 ± 7.3) 
DLCO, mL?min-1?mmHg-1 36.56 ± 7.46 (122.5 ± 17.9) 
DLCO/VA, mL?min-1?mmHg-1 5.69 ± 0.62 (117.1 ± 15.6) 
Values are mean ± standard deviation. FVC, forced vital capacity; FEV1, 
forced expiratory volume in 1 s; SVC, slow vital capacity; FEF25-75, forced 
expiratory flow from 25 to 75% of FVC; TLC, total lung capacity; DLCO, 
uncorrected diffusion capacity for carbon monoxide; DLCO/VA, DLCO per 
alveolar volume; 
 
Transpulmonary Passage of Saline Contrast and Pulmonary Gas Exchange Efficiency 
 When breathing room air, from Pre EPI to 320 EPI, the transpulmonary passage 
of saline contrast increased (Figure 4.2A) concomitant with an increase in the A-aDO2 
(Figure 4.2B) that corresponded with an increase in calculated Q̇VA/Q̇T (Figure 4.2C). 
Similarly, when breathing 40% O2, from Pre EPI to 320 EPI, the transpulmonary passage 
of saline contrast increased (Figure 4.2D) concomitant with an increase in the A-aDO2 
(Figure 4.2E) that corresponded with an increase in calculated Q̇VA/Q̇T (Figure 4.2F). As 
expected, when breathing 40% O2 the magnitude of the increase in A-aDO2 was greater 
compared to breathing room air, however, importantly, calculated Q̇VA/Q̇T increased to 
the same extent and averaged 2 ± 1%. 
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Table 4.2. Cardiopulmonary and Respiratory Data Breathing Room Air, During the I.V. Infusion of EPI With and Without Atropine 
 
Pre EPI 320 EPI VA @ 320 EPI 
 
Pre EPI (ATR) ATR+80 EPI VA @ ATR+80 EPI 
V̇E, L?min-1 10.5 ± 2.2 16.4 ± 2.9* 15.5 ± 2.8* 
 
11.4 ± 2.1 15.7 ± 3.2* 15.5 ± 2.9* 
V̇A, L?min-1 5.9 ± 1.7 9.5 ± 3.1* 9.4 ± 2.6* 
 
5.5 ± 1.3 8.4 ± 2.1* 8.0 ± 1.6* 
RR 14.3 ± 3.6 19.3 ± 2* 17.5 ± 4  18.2 ± 3.7 21.6 ± 3.4 20.6 ± 3.8 
VT, mL 764 ± 158 851 ± 141 937 ± 384 
 
640 ± 112 730 ± 104 757 ± 117 
VD/VT 0.44 ± 0.09 0.43 ± 0.08 0.39 ± 0.08 
 
0.51 ± 0.07 0.47 ± 0.05 0.48 ± 0.05 
V̇O2, L?min-1 0.32 ± 0.08 0.35 ± 0.08 0.34 ± 0.06 
 
0.30 ± 0.06 0.33 ± 0.09 0.31 ± 0.06 
V̇CO2, L?min-1 0.28 ± 0.08 0.41 ± 0.10* 0.39 ± 0.08 
 
0.27 ± 0.07 0.38 ± 0.09* 0.35 ± 0.07 
RER 0.87 ± 0.04 1.21 ± 0.22* 1.15 ± 0.28* 
 
0.89 ± 0.05 1.17 ± 0.1* 1.13 ± 0.14* 
HR, bpm 63 ± 6 80 ± 16* 73 ± 10 
 
82 ± 15 97 ± 20 83 ± 13 
PaO2, mm Hg 99 ± 4 107 ± 7 110 ± 8* 
 
101 ± 4 107 ± 2* 110 ± 5* 
PaCO2, mm Hg 41 ± 4 38 ± 5 36 ± 4 
 
41 ± 4 39 ± 3 37 ± 3 
PAO2, mm Hg 99 ± 5 113 ± 7* 112 ± 8* 
 
99 ± 4 111 ± 3* 112 ± 5* 
SaO2, %  96.9 ± 0.4 97.2 ± 0.4 97.4 ± 0.3 
 
96.9 ± 0.3 97.2 ± 0.3 97.4 ± 0.2 
CaO2, ml O2?dL-1 17.46 ± 1.62 18.47 ± 1.69 17.51 ± 1.8 
 
17.2 ± 1.77 18.07 ± 1.84 17.72 ± 1.93 
pH 7.392 ± 0.017 7.402 ± 0.028 7.418 ± 0.023 
 
7.387 ± 0.018 7.391 ± 0.01 7.405 ± 0.015 
Hct, % 39 ± 3 41 ± 3 40 ± 4 
 
39 ± 5 40 ± 4 41 ± 3 
Hb, g?dL-1 13.2 ± 1.3 13.9 ± 1.3 13.2 ± 1.4 
 
13 ± 1.4 13.6 ± 1.4 13.3 ± 1.5 
Core Temp, °C 36.8 ± 0.3 36.7 ± 0.3 36.8 ± 0.3 
 
36.9 ± 0.3 36.7 ± 0.3 36.7 ± 0.3 
Lactate, mmol?L-1 0.94 ± 0.32 1.59 ± 0.38* 1.28 ± 0.34 
 
1.12 ± 0.3 1.35 ± 0.32 1.42 ± 0.3 
Values are mean ± standard deviation. V̇A, minute ventilation, V̇A, alveolar ventilation; RR, respiratory rate; VT, tidal volume; VD/VT, 
dead space to tidal volume ratio; a-PETCO2, arterial-to-end tidal PCO2 difference; V̇O2, volume of O2 consumed; V̇CO2, volume of CO2 
produced; RER, respiratory exchange ratio; HR, heart rate; PaO2, arterial PO2; PaCO2, arterial PCO2; PAO2, alveolar PO2; SaO2, arterial 
oxygen saturation; CaO2, arterial oxygen content; Hct, hematocrit; Hb, hemoglobin. *, p < 0.05, Pre EPI compared to 320 EPI and V̇A @ 
320 EPI; *, p < 0.05, Pre EPI (ATR) compared to ATR+80 EPI and V̇A @ ATR+80 EPI. 
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Table 4.3. Cardiopulmonary and Respiratory Data Breathing 40% O2, During the I.V. Infusion of EPI With and Without Atropine 
 
Pre EPI 320 EPI VA @ 320 EPI 
 
Pre EPI (ATR) ATR+80 EPI VA @ ATR+80 EPI 
V̇E, L?min-1 10.4 ± 2.5 15.6 ± 4.7* 14.6 ± 4.2 
 
11.3 ± 2.1 15 ± 3 14.9 ± 4.5 
V̇A, L?min-1 5.3 ± 1.3 10.9 ± 9.0 9.9 ± 8.0 
 
5.4 ± 1.2 8.8 ± 2.5 7.7 ± 3.1 
RR 15.9 ± 3.8 19.2 ± 5.5 18.2 ± 5 18.2 ± 2.8 21.6 ± 4.4 20.3 ± 4.6 
VT, mL 656 ± 59 830 ± 221 840 ± 294 
 
620 ± 62 702 ± 78 740 ± 177 
VD/VT 0.48 ± 0.05 0.45 ± 0.05 0.46 ± 0.08 
 
0.53 ± 0.06 0.43 ± 0.06 0.49 ± 0.08 
V̇O2, L?min-1 0.30 ± 0.08 0.33 ± 0.08 0.31 ± 0.09 
 
0.28 ± 0.07 0.31 ± 0.07 0.27 ± 0.09 
V̇CO2, L?min-1 0.26 ± 0.06 0.39 ± 0.12* 0.35 ± 0.10 
 
0.26 ± 0.06 0.37 ± 0.09 0.34 ± 0.14 
RER 0.86 ± 0.1 1.16 ± 0.21* 1.05 ± 0.14* 
 
0.93 ± 0.12 1.24 ± 0.13* 1.25 ± 0.19* 
HR, bpm 58.2 ± 7.6 81.3 ± 22.2* 72.1 ± 11.3 
 
83.2 ± 23.6 92.2 ± 24.2 81 ± 18.2 
PaO2, mm Hg 223 ± 12 222 ± 8 232 ± 11 
 
220 ± 9 225 ± 4 230 ± 11 
PaCO2, mm Hg 42 ± 5 37 ± 9 36 ± 9 
 
42 ± 4 38 ± 4 39 ± 3 
PAO2, mm Hg 235 ± 10 245 ± 8 245 ± 12 
 
230 ± 6 243 ± 8* 241 ± 9* 
SaO2, %  98.01 ± 0.29 97.93 ± 0.27 98 ± 0.24 
 
97.96 ± 0.2 97.96 ± 0.19 98.03 ± 0.2 
CaO2, ml O2?dL-1 18.1 ± 1.84 18.92 ± 1.77 18.21 ± 1.7 
 
18.02 ± 1.95 18.59 ± 2.05 18.07 ± 1.94 
pH 7.388 ± 0.017 7.400 ± 0.026 7.406 ± 0.04 
 
7.386 ± 0.015 7.384 ± 0.014 7.407 ± 0.018† 
Hct, % 40 ± 4 41 ± 4 40 ± 4 
 
40 ± 3 41 ± 4 39 ± 3 
Hb, g?dL-1 13.3 ± 1.4 13.9 ± 1.4 13.3 ± 1.3 
 
13.2 ± 1.5 13.7 ± 1.6 13.2 ± 1.5 
Core Temp, °C 36.7 ± 0.2 36.8 ± 0.3 36.8 ± 0.2 
 
36.8 ± 0.2 36.7 ± 0.3 36.8 ± 0.2 
Lactate, mmol?L-1 0.83 ± 0.19 1.54 ± 0.4* 1.42 ± 0.32† 
 
1.03 ± 0.32 1.28 ± 0.21 1.28 ± 0.29 
Values are mean ± standard deviation. See Table 4.2 for definitions of abbreviations and symbols.  
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 When breathing room air, from Pre EPI (ATR) to ATR+80 EPI, the 
transpulmonary passage of saline contrast increased (Figure 4.2A) concomitant with an 
increase in the A-aDO2 (Figure 4.2B) that corresponded with an increase in calculated 
(Figure 4.2C). When breathing 40% O2, from Pre EPI (ATR) to ATR+80 EPI, the 
transpulmonary passage of saline contrast increased (Figure 4.2D) concomitant with an 
increase in the A-aDO2 (Figure 4.2E) that corresponded with an increase in calculated 
Q̇VA/Q̇T (Figure 4.2F). Similarly, as expected when breathing 40% O2 the magnitude of 
the increase in A-aDO2 was greater compared to breathing room air, however, 
importantly, calculated Q̇VA/Q̇T increased to the same extent and averaged 2 ± 1%. 
Therefore, both before and after ATR, the i.v. infusion of EPI at either 320 or 80 
ng/kg/min corresponded to an impairment in pulmonary gas exchange efficiency and an 
increase in calculated Q̇VA/Q̇T that all averaged 2 ± 1%. 
 The respiratory rate and tidal volume, and therefore V̇A, subjects had during 320 
EPI was reproduced for the V̇A @ 320 EPI measurement. Accordingly, per experimental 
design there was no difference in V̇A or dead space ventilation (VD/VT) between 320 EPI 
and V̇A @ 320 EPI when breathing room air and 40% O2 (Table 4.2 and 4.3). Prior to the 
V̇A @ 320 EPI measurement, EPI from the preceding infusion (i.e., 320 EPI) was allowed 
time to be metabolized and as such the transpulmonary passage of saline contrast was 
reduced to Pre EPI values at this time point when breathing room air (Figure 4.2A) and 
40% O2 (Figure 4.2D). Similarly, at V̇A @ 320 EPI the A-aDO2 was reduced to Pre EPI 
values when breathing room air (Figure 4.2B) and 40% O2 (Figure 4.2E) which also 
corresponded to calculated Q̇VA/Q̇T being reduced to Pre EPI values when breathing room 
air (Figure 4.42C) and 40% O2 (Figure 4.2F). 
 113 
 
Figure 4.2. Bubble Scores and Pulmonary Gas Exchange Efficiency 
The transpulmonary passage of saline contrast (bubble scores, panel A and B), 
pulmonary gas exchange efficiency (A-aDO2, panel C and D) and calculated venous 
admixture (Q̇VA/Q̇T, panel E and F) before (non-hatched) and after (hatched) vagal 
blockade breathing room air (open symbols) and 40% O2 (shaded symbols). * = Pre EPI 
compared to 320 EPI and V̇A @ 320 EPI; Pre EPI (ATR) compared to ATR+80 EPI and 
V̇A @ ATR+80 EPI. † = 320 EPI compared to V̇A @ 320 EPI; ATR+80 EPI compared to 
V̇A @ ATR+80 EPI. 
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When breathing room air, during V̇A @ ATR+80 EPI the transpulmonary passage of 
saline contrast was reduced to Pre EPI (ATR) values (Figure 4.2A), corresponding to a 
reduction in calculated Q̇VA/Q̇T to Pre EPI (ATR) values (Figure 4.2C). When breathing 
40% O2, from ATR+80 EPI to V̇A @ ATR+80 EPI, the transpulmonary passage of saline 
contrast was reduced to Pre EPI (ATR) values (Figure 4.2D) corresponding to a 
reduction in the A-aDO2 (Figure 4.2E) and calculated Q̇VA/Q̇T (Figure 4.2F) to Pre EPI 
(ATR) values. 
 
Cardiac Output and Pulmonary Artery Systolic Pressure 
When breathing room air and 40% O2, Q̇T increased during 320 EPI and ATR+80 EPI, 
however there was no difference between 320 EPI and ATR+80 EPI (Figure 4.3A and 
4.3B). Pulmonary artery systolic pressure (PASP) increased during 320 EPI (Figure 4.3C 
and 4.3D) when breathing room air and 40% O2. However, PASP was not increased 
during ATR+80 EPI when breathing room air and 40% O2 (Figure 4.3C and 4.3D).  
 
DISCUSSION 
The main finding of this study was that the i.v. infusion of EPI in healthy humans 
resulted in an increase in the transpulmonary passage of saline contrast and a concomitant 
increase in the A-aDO2 and calculated Q̇VA/Q̇T; when breathing room air and 40% O2. 
Neither the transpulmonary passage of saline contrast, nor the calculated Q̇VA/Q̇T differed 
during the i.v. infusion of EPI when breathing room air and 40% O2. The increase in A-
aDO2 observed during the i.v. infusion of EPI before or after vagal blockade was not due 
to the associated increase in ventilation. Furthermore, these findings were present during 
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the i.v. infusion of EPI at 320 ng/kg/min before vagal blockade, and during the i.v. 
infusion of EPI at 80 ng/kg/min after vagal blockade. Lastly, these data lend support that 
blood flow through IPAVA is mediated primarily by increases in Q̇T. 
 
 
Figure 4.3. Cardiac Output and Pulmonary Artery Systolic Pressure 
Cardiac output (Panel A and B) and pulmonary artery systolic pressure (PASP, panel C 
and D) before (non-hatched) and after (hatched) vagal blockade breathing room air 
(open symbols) and 40% O2 (shaded symbols). * = Pre EPI compared to 320 EPI and V̇A 
@ 320 EPI; Pre EPI (ATR) compared to ATR+80 EPI and V̇A @ ATR+80 EPI. † = 320 
EPI compared to V̇A @ 320 EPI; ATR+80 EPI compared to V̇A @ ATR+80 EPI. 
 
Experimental Design 
 Pulmonary gas exchange efficiency is defined and quantified by the A-aDO2 
where an A-aDO2 >0 mm Hg reflects imperfect pulmonary gas exchange that could be 
caused by three distinct mechanisms; 1) incomplete end-capillary O2 diffusion 
equilibration (diffusion limitation), 2) alveolar ventilation-to-perfusion (V̇A/Q̇) inequality, 
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and 3) right-to-left shunt. Importantly, subjects in the current study were rigorously 
screened and did not have an intracardiac shunt (i.e., a PFO). Therefore, sources of right-
to-left shunt present in subjects in the current work are postpulmonary shunt (e.g., venous 
blood from the bronchial and Thebesian circulations) and intrapulmonary shunt. Previous 
work has hypothesized that blood flow through IPAVA, inferred from the 
transpulmonary passage of saline contrast, provides a source of intrapulmonary shunt (24, 
143, 216). However, this remains a controversial topic (103) and therefore was the focus 
of the current investigation. 
 As outlined in the introduction, the experimental paradigm used to address this 
question was to increase blood flow through IPAVA in healthy humans at rest when 
breathing room air and 40% O2. When breathing 40% O2 the potential contributions from 
diffusion limitation and V̇A/Q̇ inequality to the A-aDO2 are prevented, and therefore, the 
contribution of postpulmonary and intrapulmonary shunt will be the only remaining 
factor capable of explaining an increase in the A-aDO2 and calculated Q̇VA/Q̇T. 
Effect of breathing 40% O2 on diffusion limitation. Compared to breathing room air, 
when breathing 40% O2 PAO2 increased from ~100 mmHg to ~235 mm Hg, 
corresponding to an increase in calculated mixed venous PO2 (Pv̅O2) of ~40 mm Hg 
when breathing room air, to ~45 mm Hg when breathing 40% O2. Accordingly, the 
partial pressure gradient of O2 across the alveolar-capillary interface was ~60 mm Hg 
when breathing room air, which increased >3 fold to ~190 mm Hg when breathing 40% 
O2. The result of this increased driving gradient for the diffusion of O2 across the 
alveolar-capillary interface is a markedly increased rate of end-capillary O2 equilibration. 
Using a computer algorithm implementing a Bohr integration for the lung, similar to 
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previously published work (240, 243), the rate of O2 uptake across the alveolar-capillary 
interface can be model-predicted. According to this model, in subjects at rest breathing 
room air, complete end-capillary O2 equilibration is predicted to occur within ~0.4 sec, 
whereas when breathing 40% O2 complete end-capillary O2 equilibration is predicted to 
occur within ~0.1 sec. Importantly, in these same conditions, mean pulmonary capillary 
transit time is predicted to be ~0.7 sec, which is unchanged between breathing room air 
and 40% O2. Although on average complete end-capillary O2 equilibration is expected to 
occur when breathing room air at rest (235), it remains possible that some lung units 
might have a pulmonary capillary transit time <0.4 sec, such that these lung units would 
potentially be diffusion limited. However, this possible scenario is much less likely when 
breathing 40% O2 considering the pulmonary capillary transit time in a diffusion limited 
lung unit would need to be <0.1 sec. Therefore, when breathing 40% O2, the potential 
contribution from diffusion limitation to the A-aDO2 is minimized compared to breathing 
room air. 
Effect of breathing 40% O2 on V̇A/Q̇ inequality. When breathing 40% O2, the potential 
contribution from V̇A/Q̇ inequality on the A-aDO2 would also be expected to be 
minimized compared to breathing room air, based on the same principles as those which 
define the 100% O2 technique. With the removal of alveolar N2, as occurs when breathing 
100% O2, the PAO2 in all lung units must increase to that of the inspired PO2 less 
PACO2. There is then, very little discrepancy in PAO2 between lung units, regardless of 
their respective V̇A/Q̇ ratios, and how poorly ventilated they may be. Following this same 
logic, although alveolar N2 is not eliminated when breathing 40% O2, it’s further reduced 
compared to breathing room air and the venous admixture component of V̇A/Q̇ inequality 
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is nearly eliminated when PAO2 reaches ~250 mm Hg (65). Although regional atelectasis 
resulting in V̇A/Q̇ inequality may be a concern when breathing a high FIO2, prior work in 
humans breathing 40% O2 has been shown to not be associated with an increase in V̇A/Q̇ 
inequality (45). 
Effect of breathing 40% O2 on blood flow through IPAVA. The effect of breathing 
40% O2 on blood flow through IPAVA has not been directly investigated and more 
extensive work in this area would be of interest. However, it is known that breathing 
100% O2 during exercise (54, 144) and during the i.v. infusion of catecholamines (24, 
133) significantly reduces, or eliminates the transpulmonary passage of saline contrast. 
This has been demonstrated to not be a product of O2 breathing altering the in vivo 
dynamics of saline contrast (54) and is also in agreement with work using solid 
microspheres to detect a reduction in blood flow through IPAVA in anesthetized dogs 
ventilated with 100% O2 (171). Conversely, bubble scores during 320 EPI and ATR+80 
EPI were not different between breathing room air and 40% O2 (Figure 4.2A and 4.2B) 
yet bubble scores have been shown to be reduced or eliminated during 320 EPI when 
breathing 100% O2 (133). Thus, our experimental paradigm allows for blood flow 
through IPAVA while preventing contributions from V̇A/Q̇ inequality and diffusion 
limitation. 
Pulmonary Gas Exchange Efficiency During the I.V. Infusion of Epinephrine 
 When breathing room air the A-aDO2 increased by 6 mm Hg at 320 EPI 
compared to Pre EPI, which corresponded to an increase in calculated Q̇VA/Q̇T of 2%. 
This 2% increase in calculated Q̇VA/Q̇T necessary to explain the measured A-aDO2 could 
in theory include contributions from diffusion limitation, V̇A/Q̇ inequality, and right-to-
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left shunt. When breathing 40% O2 the A-aDO2 increased by 12 mm Hg at 320 EPI 
compared to Pre EPI, which corresponded to a similar increase in calculated Q̇VA/Q̇T of 
2%. However, unlike when breathing room air, this 2% increase in calculated Q̇VA/Q̇T 
when breathing 40% O2 is only explained by an increase in right-to-left shunt. Prior work 
in dogs has also demonstrated an increase in intrapulmonary shunt during the i.v. infusion 
of EPI using microspheres (172) to detect blood flow through IPAVA and by arterial 
blood gas analysis to determine the impact on pulmonary gas exchange efficiency; a 
finding that was also demonstrated to be eliminated in dogs ventilated with 100% O2 (16) 
demonstrating that 100% O2 prevented blood flow through IPAVA as we have suggested 
occurs in humans (54, 144). 
 During the i.v. infusion of EPI at either 320 EPI or ATR+80 EPI, Q̇T was 
similarly increased by ~2 fold above Pre EPI values. Assuming no change in pulmonary 
capillary blood volume, this should correspond to a decrease in mean pulmonary 
capillary transit time from ~0.7 sec to ~0.35 sec. As previously discussed, when breathing 
room air and 40% O2 complete end-capillary O2 equilibration is expected to occur within 
~0.4 sec and ~0.1 sec, respectively. Therefore, if pulmonary capillary blood volume 
remained constant, some degree of diffusion limitation would be possible when breathing 
room air, although breathing 40% O2 should sufficiently minimize this potential. That 
said, it seems unlikely that pulmonary capillary blood volume would not increase to some 
degree in response to the ~2-fold increase in pulmonary blood flow and any increase in 
pulmonary capillary blood volume would mitigate reductions in mean pulmonary 
capillary transit time. Furthermore, as expected based on the Fick principle of mass 
balance, calculated Pv̅O2 increased secondary to the ~2 fold increase in Q̇T and constant 
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whole body V̇O2. Specifically, calculated Pv̅O2 would have increased from ~40 mm Hg 
at Pre EPI to ~50 mm Hg at 320 EPI when breathing room air, and from 45 mm Hg at Pre 
EPI to ~55 mm Hg at 320 EPI when breathing 40% O2. In both cases, the ~10 mm Hg 
increase in Pv̅O2 would help to accelerate end-capillary O2 equilibration (243). 
 The potential that V̇A/Q̇ inequality was increased during the i.v. infusion of EPI at 
320 EPI or at ATR+80 EPI cannot be excluded, although as discussed it would likely be 
minimized when breathing 40% O2 compared to room air. Prior work investigating the 
effect of inotropic drugs on V̇A/Q̇ inequality in healthy humans is lacking. However, in 4 
patients admitted to the intensive care unit for acute respiratory failure from pulmonary 
embolism, Manier and Castaing (154) showed a non-significant decrease in mean V̇A/Q̇ 
for blood flow distribution (0.67 to 0.57) and non-significant decrease in Log SDQ (1.19 
to 1.11) during the i.v. infusion of dobutamine at 10 µg/kg/min. In 2 of these patients 
shunt (V̇A/Q̇ = 0) increased, one of which was also assessed during the i.v. infusion of 
dobutamine when breathing 40% O2 and shunt was unchanged compared to breathing 
room air. In another study, Rennotte et al. (194) studied 10 patients admitted to the 
intensive care unit for a variety of reasons and found a significant increase in log SDQ 
during the i.v. infusion of dopamine, but not during the i.v. infusion of dobutamine (both 
drugs at 5 µg/kg/min). Work in dogs with pulmonary edema secondary to oleic acid 
infusion, has demonstrated that an increase in Q̇T via the i.v. infusion of isoproterenol 
(136) and dopamine (151) resulted in a significant increase in shunt. Of note, in the work 
by Lynch et al., the changes in shunt occurred whether Q̇T was pharmacologically or 
mechanically altered. Therefore, as concluded by these authors, the increase in shunt 
from pharmacologically increased Q̇T is likely not due to vasoconstrictor or vasodilator 
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activity of these drugs as the increase in shunt is observed when Q̇T is increased via 
mechanical means as well. The current study in healthy humans lends support to this 
conclusion, by demonstrating the same increase in shunt in response to the same increase 
in Q̇T during both 320 EPI and ATR+80 EPI. 
 If it is accepted that diffusion limitation and V̇A/Q̇ inequality are likely not 
significantly contributing to the measured A-aDO2 in healthy humans breathing room air 
and 40% O2 during 320 EPI and ATR+80 EPI, one possibility other than an increase in 
intrapulmonary shunt remains; an increase in postpulmonary shunt. The chronotropic and 
inotropic effects of EPI, and chronotropic effects of ATR may increase Thebesian blood 
flow, and similarly the increase in ventilation may increase bronchial blood flow. In an 
attempt to control for the potential confounding effects of increased ventilation, 
measurements were made in iso-alveolar ventilation conditions after EPI had been 
allowed time (~20 min) to be metabolized [i.e., V̇A @ 320 EPI and V̇A @ ATR+80 EPI]. 
At these time points, tidal volume and respiratory rate were matched to their respective, 
preceding condition during the i.v. infusion of EPI (Table 4.2 and 4.3). Accordingly, the 
increase in calculated QVA/QT during V̇A @ 320 EPI and V̇A @ ATR+80 EPI may serve 
as a measure of predominantly bronchial shunt. Therefore, subtracting the increase in 
Q̇VA/Q̇T during V̇A @ 320 EPI and V̇A @ ATR+80 EPI, from 320 EPI and ATR+80 EPI, 
respectively, would yield the increase in total right-to-left shunt less the contribution 
from bronchial blood flow. Doing so reveals an ~1% increase in Q̇VA/Q̇T during 320 EPI 
breathing room air and 40% O2, and an ~1% increase in Q̇VA/Q̇T during ATR+80 EPI 
breathing room air and 40% O2 (Table 4.4), of which could be either Thebesian and/or 
intrapulmonary shunt. 
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Table 4.4. Difference in Q̇VA/Q̇T With I.V. EPI and During 
Conditions of Iso-Alveolar Ventilation Without I.V. EPI 
  
QVA/QT 
 
QVA/QT 
Room Air 320 EPI 2% ATR+80 EPI 2% 
 
V̇A @ 320 EPI 1% V̇A @ ATR+80 EPI 1% 
  Difference = 1% Difference = 1% 
     40% O2 320 EPI 2% ATR+80 EPI 2% 
 
V̇A @ 320 EPI 1% V̇A @ ATR+80 EPI 1% 
  Difference = 1% Difference = 1% 
       Mean = 1% Mean = 1% 
 
Reconciling Anatomic and Gas Exchange Dependent Data 
 Neither work using the multiple inert gas elimination technique nor the 100% O2 
technique, both gas exchange dependent methods, have reported detecting significant 
intrapulmonary right-to-left shunt in healthy humans during exercise. Pooling data from 
several studies using the MIGET (101, 112, 175, 195), intrapulmonary shunt averages 0.2 
± 0.7% of the Q̇T. Work by Vogiatzis et al. (233) reports right-to-left shunt from all 
sources measured during exercise in subjects breathing 100% O2 to average 0.5 ± 0.5%. 
Data from the current study, particularly when breathing 40% O2, challenges these data 
by reporting a calculated Q̇VA/Q̇T of 2% during conditions of increased blood flow 
through IPAVA while contributions from diffusion limitation and V̇A/Q̇ inequality are 
minimized. However, breathing 100% O2 has been demonstrated to reduce or eliminate 
blood flow through IPAVA as detected using TTSCE (24, 54, 133, 144). If true, then the 
impact of blood flow through IPAVA on pulmonary gas exchange efficiency would be 
minimal when breathing 100% O2. However, when breathing 40% O2 blood flow through 
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IPAVA can be detected using TTSCE, and there is also a significant and measureable 
impact on pulmonary gas exchange efficiency. 
Cardiac Output and Pulmonary Artery Systolic Pressure 
 Cardiac output and PASP have previously been hypothesized as potential 
mechanisms responsible for regulating blood flow through IPAVA (24, 130, 133, 173, 
216). The primary purpose of the ATR+80 EPI measurement was to facilitate increasing 
Q̇T to a similar extent as 320 EPI, with a lower dose of EPI. However, it has also been 
shown that the chronotropic effects of ATR are associated with no change in mean 
pulmonary artery pressure measured using right heart catheterization in patients with 
asthma and emphysema at rest (263) and in a different group of patients (1). In support of 
these observations, although in healthy human subjects, PASP in the current study was 
unchanged during Pre EPI (ATR) compared to Pre EPI, despite Q̇T increasing by ~2 
L/min when breathing room air and 40% O2 (Figure 4.3). Furthermore, unlike during 320 
EPI which resulted in an ~20 mm Hg increase in PASP, during ATR+80 EPI, PASP only 
increased by ~10 mm Hg when breathing room air and 40% O2 (Figure 4.3). In both 
conditions, 320 EPI and ATR+80 EPI, Q̇T was not different (~12.5 L/min) when 
breathing room air and 40% O2 (Figure 4.3). Therefore, both 320 EPI and ATR+80 EPI 
produced similar increases in Q̇T, yet PASP was less during ATR+80 EPI, and there was 
no difference in bubble scores during 320 EPI and ATR+80 EPI (Figure 4.2). Although 
bubble scores do not represent a means to quantify blood flow through IPAVA and are a 
semi-quantitative, non-distributed variable, the calculated Q̇VA/Q̇T was ~2% during both 
320 EPI and ATR+80 EPI when breathing room air and 40% O2. These data suggest that 
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blood flow through IPAVA is more dependent on increases in pulmonary blood flow, 
rather than increases in pulmonary artery systolic pressure. 
Limitations 
Saline contrast echocardiography. The detection of blood flow through IPAVA using 
TTSCE is based on the rationale that the pulmonary circulation functions as a biological 
sieve, filtering out bubbles that are larger than the diameter of a pulmonary capillary. 
Although the size of the injected bubbles remains unknown, it is estimated that based on 
the minimum size necessary for bubbles to be stable enough to survive the pulmonary 
transit time, their initial diameter would need to be >60 µm (53). To date, there is no 
direct evidence that either pulmonary capillaries or corner vessels can distend to 
diameters >20 µm, even under pulmonary pressures that are supra-physiologic for 
humans. For example at pulmonary pressures up to 73 mm Hg in isolated greyhound 
lungs the mean capillary diameter was found to be 6.5 µm and the maximum capillary 
diameter measured was 13 µm (75, 199). Thus, the transpulmonary passage of bubbles 
larger than the diameter of a pulmonary capillary indicates these bubbles have escaped 
pulmonary capillary filtration by traversing the pulmonary circulation via large diameter 
IPAVA. However, this technique does not quantify the volume of blood flow through 
IPAVA; therefore, the bubble scoring system which is not without precedent (11), offers 
a qualitative assessment of the degree and spatial distribution of left-sided contrast. 
 In subjects without a PFO, the alternative explanation for observing left-sided 
saline contrast is the possibility that bubbles are, by some means, travelling through 
pulmonary capillaries and/or corner vessels. In this way, left-sided contrast would not 
reflect blood flow through IPAVA. However, this possibility should be considered with 
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several points in mind. First, bubbles small enough to traverse pulmonary capillaries (<10 
µm) have an estimated survival time of 180-550 msec (164, 269, 270) and in healthy 
humans at rest, mean pulmonary transit time is ~9 sec, that decreases to ~3 sec at 
maximal exercise with Q̇T in excess of 30 L/min (100). Second, Roelandt et al. (198) 
demonstrated that an injection pressure of 300 mm Hg through a firmly wedged 
pulmonary artery catheter was needed to observe left-sided contrast, by forcing bubbles 
to deform and squeeze through pulmonary capillaries. Third, pulmonary capillary 
disruption, not distension has been predicted to be the more likely result of pulmonary 
capillary pressures sufficient to distend pulmonary capillaries to >20 µm in diameter 
(253). 
 Although we cannot definitely rule out the possibility that microbubbles are, by 
some means, traversing pulmonary capillaries, the transpulmonary passage of 25 and 50 
µm microspheres has been demonstrated in isolated human lungs ventilated and perfused 
with physiologic pressures (146). And work in animals during exercise (215) and 
breathing hypoxic gas at rest (12) demonstrate the transpulmonary passage of >25 µm 
and 70 µm microspheres, respectively. Importantly, the transpulmonary passage of non-
deformable, large diameter microspheres can only be explained by blood flow through 
IPAVA, and for these aforementioned studies using microspheres, studies using saline 
contrast microbubbles demonstrate the same findings (54, 134, 143). 
Accurately Measuring Arterial PO2 >200 mm Hg. Accurate measurements of PaO2 are 
critically important to the interpretation of these data, and several precautions were taken 
to ensure very high standards. When breathing room air PaO2 at Pre EPI was ~100 mm 
Hg (Eugene, OR; 130 m above sea level), which increased to ~220 mm Hg when 
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breathing 40% O2. During 320 EPI and ATR+80 EPI when V̇A was doubled, PaO2 
increased to ~110 mm Hg and ~230 mm Hg when breathing room air and 40% O2, 
respectively. Accordingly, this >2-fold increase in PaO2 when breathing 40% O2 
amplifies several potential sources of error compared to when breathing room air, all of 
which can only decrease the measured PO2, and therefore, increase the measured A-
aDO2. Perhaps the most significant error is that air bubbles within the sampling syringe, 
will be composed of room air, and thus contain a PO2 of ~150 mm Hg, ~70 to 80 mm Hg 
lower than PaO2 when breathing 40% O2. This was minimized by withdrawing all arterial 
blood samples in such a way as to keep any small air bubble at the top of the sample, 
which was immediately expelled, and by maintaining a positive pressure on the sample 
syringe during the analysis to pre-emptively prevent the production of an air bubble.  
 Additional potential issues are, 1) the possible diffusion of O2 from the sample 
through the syringe, 2) the consumption of O2 by white blood cells, and 3) the 
consumption of O2 by the PO2 electrode during the analysis. The impact of the first two 
concerns increases over time, and therefore, we minimized this by immediately analyzing 
each sample. All of these concerns can also, at least partially, be corrected for by 
calibrating the blood gas analyzer on each study day using tonometered human blood, as 
before (142). This practice is similar, but superior, to using standard quality control 
methods in that it allows for the correction of day-to-day fluctuations and inherent errors 
in measuring the exact PO2 and PCO2, of which, include aforementioned concerns. 
Consistent inherent errors with handling and analyzing blood with PaO2 in the 220-230 
mm Hg range are also present during tonometry, and therefore this correction factor will 
help offset these. After correcting PaO2 and PaCO2 for core body temperature, the 
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tonometry correction resulted in an average increase in PaO2 of <1 mm Hg and <2 mm 
Hg when breathing room air and 40% O2, respectively. The minimal change in PaO2, 
particularly when breathing 40% O2 is reflective of our careful handing and immediate 
analysis of all arterial blood samples. 
 Lastly, although potential errors related to measuring PaO2 can result in large 
errors in the measured A-aDO2, these are less of a concern in the calculation of Q̇VA/Q̇T. 
As described in the methods, Cc’O2 is calculated assuming complete end-capillary O2 
equilibration with PAO2 that is calculated using the ideal alveolar gas equation, and from 
this the Kelman equation is used to compute Sc’O2. Therefore, the calculation of PAO2 is 
independent of the measured PaO2 and is instead dependent on accurate measures of 
metabolic rate, the fraction of inspired O2, and PaCO2. In contrast, calculation of CaO2 is 
affected by the measured PaO2 inasmuch as the dissolved concentration of PO2 
contributes, which corresponds to <0.5 and <1 ml O2/dL of blood or ~2% and ~4% of the 
CaO2, when breathing room air and 40% O2, respectively. Without direct measures of 
mixed venous blood, Cv̅O2 is calculated using measured CaO2, V̇O2, and QT according to 
the Fick principle of mass balance [Cv̅O2 = CaO2 − (V̇O2/Q̇T)]. Therefore, although CaO2 
is directly affected by errors in the measured PaO2, Cv̅O2 is affected to an equal 
magnitude in the same direction, which all else being equal, will offset error in the 
measured PaO2 on the calculation of Q̇VA/Q̇T. 
Summary 
 The current study investigated the potential that blood flow through IPAVA 
provides a source of venous admixture that can contribute relevantly to pulmonary gas 
exchange efficiency. These data demonstrate that during the i.v. infusion of EPI (i.e., 
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during conditions of elevated pulmonary blood flow) the transpulmonary passage of 
saline contrast is increased concomitant with an increase in calculated Q̇VA/Q̇T and A-
aDO2. Furthermore, this impairment in pulmonary gas exchange efficiency was present to 
the same extent, with Q̇VA/Q̇T averaging ~2% during 320 EPI and ATR+80 EPI, not only 
when breathing room air, but also when breathing 40% O2 when contributions from V̇A/Q̇ 
inequality and diffusion limitation were minimized. When the potential contribution from 
predominately bronchial shunt is subtracted from this total, the average Q̇VA/Q̇T is again 
similar between breathing room air and 40% O2 and averages 1% which may be the result 
of Thebesian shunt and/or blood flow through IPAVA. The current paradigm describing 
mechanisms of impaired pulmonary gas exchange efficiency does not include blood flow 
through IPAVA, particularly during exercise. However, the transpulmonary passage of 
saline contrast is also observed during exercise and thus, blood flow through IPAVA 
during exercise may also provide a source of venous admixture.  
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 Although during exercise breathing 40% O2 blood flow through IPAVA is not 
reduced, during exercise breathing 100% O2, blood flow through IPAVA is reduced. This 
has been repeatedly demonstrated using TTSCE, radiolabeled MAA, and microspheres. 
However, the explanation for this remains unknown and the purpose of the next chapter 
was to investigate the pharmacologic effect of sildenafil, nifedipine and acetazolamide, 
on the hyperoxia-mediated reduction in blood flow through IPAVA. This study marks the 
first investigation into this area.   
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CHAPTER V 
PHARMACOLOGIC INVESTIGATIONS INTO THE MECHANISTIC REGULATION 
OF INTRAPULMONARY ARTERIOVENOUS ANASTOMSES 
 This chapter is in review with Respiration Physiology & Neurobiology and Joel E. 
Futral, Randall D. Goodman, and Andrew T. Lovering are co-authors. I performed the 
experimental work, led the project, and the writing is entirely mine; Joel E. Futral and 
Randall D. Goodman provided technical assistance with performing echocardiography 
during exercise; and Andrew T. Lovering helped develop the protocol, and provided 
guidance and editorial assistance. 
 
INTRODUCTION 
 Blood flow through intrapulmonary arteriovenous anastomoses (IPAVA) is trivial 
or non-detectable in healthy humans at rest breathing room air (55), yet increases during 
exercise and the intravenous (i.v.) infusion of catecholamines when breathing room air as 
detected by the transpulmonary passage of saline contrast (24, 53, 54, 133, 143, 216). 
However, blood flow through IPAVA is prevented or significantly reduced during 
exercise and the i.v. infusion of catecholamines when breathing 100% O2 (24, 54, 133, 
144). This particular finding is controversial, in that it implies blood flow through the 
pulmonary circulation can be regulated by the fraction of inspired O2 (FIO2), and that 
IPAVA appear to be regulated opposite of the conventional pulmonary circulation. 
Specifically, IPAVA respond to changes in the FIO2 similar to the systemic circulation 
and constrict in response to hyperoxia. However, previous work supports this supposition 
by demonstrating an active regulation of the pulmonary circulation as measured by an 
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increase in perfusion heterogeneity using 15 µm microspheres, in sheep ventilated with a 
FIO2 = 0.4 (162) and pigs ventilated with a FIO2 = 0.5 (93) compared to room air. 
Additionally, the transpulmonary passage of solid microspheres has been demonstrated to 
decrease in anesthetized dogs ventilated with 100% O2 compared to room air (171). 
Furthermore, considering previous work demonstrating IPAVA dilate in response to 
hypoxia (134), the regulation of IPAVA bears a striking resemblance to the fetal 
cardiopulmonary circulation; and although patent in fetal sheep, blood flow through 
IPAVA decreases in juvenile sheep and is absent in adult sheep (158). 
 Regulated similar to IPAVA, constricting and dilating in response to increases 
and decreases in O2 tension, respectively, is the ductus arteriosus that is also a vital 
component of the fetal cardiopulmonary circulation. Closure of the ductus arteriosus at 
birth is initiated by an increase in O2 tension, a process regulated by O2 sensitive 
potassium channels that are inhibited by increases in O2 tension, leading to membrane 
depolarization and a subsequent increase in intracellular calcium through L-type voltage-
gated calcium channels (230). In utero the tone of the ductus arteriosus is reflective of 
competing vasodilator and vasoconstrictor influences, with the primary vasodilating 
mechanisms being the production of endothelium-derived nitric oxide and prostaglandin 
E2 (37, 38). Accordingly, the mechanistic regulation of IPAVA may also resemble that of 
the ductus arteriosus. Specifically, the reduction in blood flow through IPAVA during 
exercise breathing a FIO2 = 1.0, presumably via vasoconstriction of IPAVA, may also in 
part be regulated by L-type calcium channels or reductions in the bioavailability of nitric 
oxide. If so, pharmacologic interventions known to block L-type calcium channels 
(nifedipine) and augment the action of nitric oxide (sildenafil) may reduce or prevent the 
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potential O2 mediated constriction of IPAVA and thereby allow for the transpulmonary 
passage of saline contrast during exercise breathing a FIO2 = 1.0. Regardless of the 
mechanism, constriction of vascular smooth muscle is dependent on an increase in 
intracellular calcium and acetazolamide has been shown to prevent intracellular calcium 
from increasing in pulmonary vascular smooth muscle cells by a non L-type voltage-
gated calcium channel mechanism (206). Thus, acetazolamide may also prevent the 
potential O2 mediated constriction of IPAVA, and allow blood flow through IPAVA 
during exercise breathing a FIO2 = 1.0. 
 Therefore, the purpose of this study was to investigate the independent effects of 
sildenafil, nifedipine, and acetazolamide on the regulation of blood flow through IPAVA 
during exercise breathing a FIO2 = 1.0. To this end we studied 8 healthy human subjects 
at rest and during submaximal exercise breathing room air and a FIO2 = 1.0, at baseline 
without any pharmacologic intervention, with a single dose of sildenafil (100 mg, p.o), 
with a single dose of nifedipine (20 mg, p.o), and after acetazolamide (250 mg, p.o., t.i.d 
for 3 days). 
 
METHODS 
 The University of Oregon Office for Protection of Human Subjects approved this 
project and all subjects provided verbal and written informed consent prior to 
participation. All studies were performed in accordance with the Declaration of Helsinki.  
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Subjects 
 Eight subjects (2 female) volunteered to participate in this study, all of which 
were healthy, young, non-smoking and without a history of cardiopulmonary or 
respiratory disease. 
 According to the American Thoracic Society and European Respiratory Society 
standards (ATS/ERS) all subjects demonstrated normal spirometry, lung volumes and 
capacities, and diffusing capacity for carbon monoxide. Pulmonary function was assessed 
using computerized spirometry (MedGraphics Ultima CardiO2, St. Paul, MN, USA) and 
involved forced and slow vital capacity maneuvers (166). Lung volumes and capacities 
were determined using whole body plethysmography (MedGraphics Elite 
Plethysmograph) (247). Lung diffusion capacity for carbon monoxide (DLCO) was 
determined by the single-breath, breath hold method (119, 152) using the Jones and 
Meade method for timing (111). 
 All subjects underwent a comprehensive echocardiographic screening procedure 
performed by a registered diagnostic cardiac sonographer in both adult and pediatric 
echocardiography with 25 years of experience (Philips iE33, The Netherlands). The 
purpose of this screening procedure was to confirm that subjects were without cardiac 
abnormalities, including a patent foramen ovale (PFO). To this end, subjects were 
rigorously screened using transthoracic saline contrast echocardiography (TTSCE) as 
described previously (55, 139) and did not have a PFO. 
Protocol 
 For each visit, subjects performed two bouts of cycle ergometer exercise (Lode 
Excalibur), separated by a 30 min rest period, at 50, 100, 150, 200, and 250 W for 3 min 
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each, breathing room air and 100% O2. All subjects completed the aforementioned 
exercise protocol on four separate visits separated by >5 days; 1) without pharmacologic 
intervention (i.e., baseline); 2) with a single dose of 100 mg p.o. sildenafil, 3) with a 
single dose of 20 mg p.o. nifedipine, and 4) after 3 days of 250 mg p.o. acetazolamide, 
every 8 hours t.i.d. The order of pharmacologic intervention, as well as the order of 
exercise bouts breathing room air and 100% O2, were randomized. 
Detection of Blood Flow Through Intrapulmonary Arteriovenous Anastomoses 
 Transthoracic saline contrast echocardiography (TTSCE) was used to detect blood 
flow through IPAVA as before (133). However, briefly, agitated saline contrast was 
produced by combining 3 ml room air with 1 ml of normal saline and agitating for ~15 
sec prior to injecting. Each agitated saline contrast injection was visualized in the apical, 
four-chamber view with subjects on the cycle ergometer in the forward leaning aerobar 
position, and recorded at >30 frames per second for 20 cardiac cycles post-appearance of 
saline contrast in the right ventricle. The single frame within the 20 cardiac cycle 
recording with the greatest density and spatial distribution of contrast was qualitatively 
assessed using a previously published scoring system (144) similar to others (11); 0 = no 
bubbles, 1 = 1-3 bubbles, 2 = 4-12 bubbles, 3 = >12 bubbles appearing as a bolus, 4 = 
>12 bubbles heterogeneously filling the left ventricle, and 5 = >12 bubbles 
homogeneously filling the left ventricle. 
Respiratory Variables 
 Breath-by-breath metabolic data was collected (MedGraphics, CardiO2) and 
presented as the mid 5 of 7 (i.e., the moving average of five breaths excluding the low 
and high). In this way continuous measures of pulmonary V̇O2, V̇CO2, minute ventilation 
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(V̇E), and associated parameters, including end tidal PO2 and PCO2 values, were 
collected. Gases with known O2 and CO2 concentrations were used to calibrate the gas 
analyzer before every exercise test. 
Cardiac Output and Pulmonary Artery Systolic Pressure 
 Cardiac output was estimated using echocardiography and determined at the level 
of the left ventricular outflow tract (LVOT). Previously during the screening visit, 
subjects LVOT diameter had been determined and recorded. This value was used to 
estimate the cross sectional area of the outflow tract. Pulsed wave Doppler ultrasound 
was used in all studies to determine the LVOT velocity time integral (LVOTVTI) of blood 
flow through the outflow tract. Measures of the LVOTVTI were recorded in triplicate and 
the average was multiplied by the previously determined cross sectional area of the 
LVOT. The product of the LVOTVTI and LVOT cross sectional area equals the stroke 
volume, which multiplied by heart rate, provides an estimate of cardiac output. 
 Pulmonary artery systolic pressure was determined as before (133, 134) by 
measuring the peak velocity (v) of the tricuspid regurgitation jet and estimating right 
atrial pressure (PRA) based on the collapsibility of the inferior vena cava, and applying 
these to the modified Bernoulli equation; 4v2 + PRA (42, 92, 202, 275). 
 Total pulmonary resistance (TPR) was calculated as previously described (120), 
by pulmonary artery systolic pressure divided by cardiac output, and has been previously 
published by our group (173). 
Statistics 
Statistical analyses were done using GraphPad Prism (v5.0d) and all comparisons were 
determined a priori. Comparisons of data from rest to exercise, within an FIO2 and 
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pharmacologic intervention, were done using a one-way analysis of variance with a 
Tukey’s multiple comparison post-hoc test. Comparisons of data at rest and during 
exercise within an FIO2, with and without pharmacologic intervention were done using a 
paired t-test with alpha adjusted for the number of comparisons made. The 
aforementioned analyses were done for non-parametric data (i.e., bubble scores) using a 
Kruskal Wallis one-way analysis of variance and a Mann-Whitney t-test. 
 
RESULTS 
Subject Characterization and Pulmonary Function 
 Anthropometric, pulmonary function, lung volumes/capacities, and diffusion 
capacity for carbon monoxide are presented in Table 5.1. All subjects demonstrated 
normal pulmonary function, and were ≥85% predicted on all parameters. 
Table 5.1. Anthropometric and Pulmonary Function Data 
 Absolute % Predicted 
Age, yr 24.5 ± 5.5  
Height, cm 162.5 ± 39.6  
Weight, kg 72.6 ± 10.1  
FVC, L 5.1 ± .08 (94.7 ± 7) 
FEV1, L 4.1 ± 0.6 (94.1 ± 3.9) 
FEV1/FVC, % 81.1 ± 6.6 (97 ± 7.9) 
FEF25-75 3.9 ± 1.0 (95.6 ± 10) 
SVC, L 5.2 ± .7 (102.3 ± 9.4) 
TLC, Lpleth 6.9 ± 1.1 (105.1 ± 6.6) 
DLCO, mL・min-1・mmHg-1 39.1 ± 7.2 (123.6 ± 21.5) 
DLCO/VA, mL・min-1・mmHg-1 5.9 ± 0.9 (122.5 ± 23.9) 
Values are mean ± standard deviation. FVC, forced vital capacity; FEV1, 
forced expiratory volume in 1 s; SVC, slow vital capacity; FEF25-75, forced 
expiratory flow from 25 to 75% of FVC; TLC, total lung capacity; DLCO, 
uncorrected diffusion capacity for carbon monoxide; DLCO/VA, DLCO per 
alveolar volume; 
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Hemodynamic and Ventilatory Effects of Pharmacologic Interventions 
 Room air: The hemodynamic and ventilatory response to exercise was not 
different during exercise at baseline and with all pharmacologic interventions, with the 
exceptions noted below (Table 5.2). However, with nifedipine, cardiac output was 
significantly elevated at rest and during exercise at 50 W, concomitant with an increased 
heart rate at rest and throughout exercise compared to baseline. Although no difference 
was observed at rest with sildenafil, similar to nifedipine, heart rate was increased during 
exercise compared to baseline. Despite the peripheral circulatory hemodynamic changes 
associated with sildenafil and nifedipine, no significant ventilatory changes were 
observed. In contrast, no significant hemodynamic changes were observed with 
acetazolamide, however, minute ventilation was increased at rest and during exercise. 
100% O2: During The hemodynamic and ventilatory response to exercise was not 
different during exercise at baseline and with all pharmacologic interventions, with the 
exceptions noted below (Table 5.3). However, similar to exercise breathing room air, 
nifedipine resulted in an increased Q̇T at rest and during exercise at 50 and 100 W. 
Similarly, compared to baseline, heart rate was increased at rest and during exercise with 
nifedipine. This increase in Q̇T was also accompanied with an increase in pulmonary 
artery systolic pressure, yet total pulmonary vascular resistance was not different 
compared to baseline. Unlike when breathing room air, with sildenafil no significant 
hemodynamic changes were measured. However, the augmented ventilation at rest and 
during exercise with acetazolamide was also present when breathing 100% O2 and no 
significant hemodynamic changes were observed. 
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Table 5.2. Hemodynamic and Ventalitory Data During Exercise Beathing Room Air 
  
Rest 50 W 100 W 150 W 200 W 250 W 
Q̇T, L min Baseline 4.3 ± 0.9 7.3 ± 1.5* 9.8 ± 2.1* 10.8 ± 2.4* 12.5 ± 2.2* 15 ± 2.4*† 
 
Sildenafil 4.5 ± 1.2 7.7 ± 1.9 9.9 ± 2.6* 11.7 ± 3.5* 13.3 ± 4.2* 15.1 ± 4.1* 
 
Nifedipine 5.6 ± 1.3† 8.2 ± 1.9† 10.2 ± 2.9* 10.5 ± 2.9* 13 ± 3.6* 15.1 ± 4.2* 
 
Acetazolamide 4.6 ± 1.2 7.9 ± 1.5 9.7 ± 1.6* 11.9 ± 2.2* 15.3 ± 2.8* 16.5 ± 1.5* 
SV, mL Baseline 69 ± 13 76 ± 22 85 ± 25 82 ± 27 83 ± 22 90 ± 22 
 
Sildenafil 60 ± 16† 76 ± 21 78 ± 22 84 ± 31 85 ± 30 90 ± 28 
 
Nifedipine 68 ± 20 78 ± 22 83 ± 27 74 ± 25 82 ± 27 89 ± 27 
 
Acetazolamide 69 ± 18 76 ± 15 85 ± 20 86 ± 18 96 ± 17 97 ± 8 
HR, bpm Baseline 65 ± 18 99 ± 15* 117 ± 15* 137 ± 19* 153 ± 19* 165 ± 16* 
 
Sildenafil 75 ± 15 103 ± 18*† 128 ± 23*† 145 ± 22*† 159 ± 18*† 171 ± 15* 
 
Nifedipine 86 ± 18† 108 ± 22* 126 ± 25* 146 ± 23*† 162 ± 18*† 172 ± 18*† 
 
Acetazolamide 71 ± 15 105 ± 13* 118 ± 20* 140 ± 20* 160 ± 15* 170 ± 13* 
SpO2, % Baseline 98.4 ± 1.7 98.1 ± 2.2 97.5 ± 2.7 97.3 ± 2.1 96.7 ± 2.4 94.5 ± 2.4 
 
Sildenafil 98.5 ± 1.8 98.1 ± 1.9 97.9 ± 2.2 98.3 ± 1.5 98 ± 1.4 96.1 ± 1.4 
 
Nifedipine 98.7 ± 0.9 99 ± 0.9 98.6 ± 0.8 98.8 ± 0.8 98.7 ± 0.8 97 ± 1.3 
 
Acetazolamide 98.7 ± 1.2 98.8 ± 1.3 98.8 ± 1.3 98.4 ± 1.5 97.5 ± 1.6 96.3 ± 1.5 
PASP, mm Hg Baseline 27.9 ± 6.7 40 ± 5.7 43.2 ± 8* 49.4 ± 10.1* 55.2 ± 11.3* 56.6 ± 9.2* 
 
Sildenafil 27.4 ± 6 38.4 ± 7.9 46.4 ± 13.1* 51.3 ± 8.4* 56.3 ± 8.8* 58.4 ± 8.8* 
 
Nifedipine 31.5 ± 6.2 40.2 ± 9.2 44.6 ± 11.7 51.6 ± 13.2* 58 ± 10* 60.3 ± 12.5* 
 
Acetazolamide 29.5 ± 7.2 37.8 ± 9.1 40.7 ± 6.6 45.6 ± 8.8* 48.9 ± 8.8* 57.1 ± 4.4* 
TPR, mm Hg/L/min Baseline 6.7 ± 2.3 5.7 ± 1.4 4.5 ± 1* 4.7 ± 1.1 4.5 ± 0.9* 3.9 ± 1.3* 
 
Sildenafil 6.5 ± 2.1 5.3 ± 1.9 4.8 ± 1 4.9 ± 2.2 4.6 ± 1.6 4.2 ± 1.6 
 
Nifedipine 5.7 ± 1 5 ± 1.1 4.5 ± 1.2 5.1 ± 1.4 4.8 ± 1.5 4.2 ± 1.2 
 
Acetazolamide 6.9 ± 2 5 ± 0.8* 4.2 ± 0.5* 3.9 ± 0.6* 3.3 ± 1* 3.5 ± 0.4* 
V̇E, L min Baseline 11.4 ± 2.2 25.7 ± 4.4* 35.9 ± 5.2* 49.8 ± 5.2* 66.5 ± 8.7* 88.2 ± 14.8* 
 
Sildenafil 11.9 ± 1.4 25.3 ± 2.7* 38.3 ± 4.2* 52.7 ± 5* 71.2 ± 10.5* 92.1 ± 14.2* 
 
Nifedipine 13.1 ± 3.7 27.5 ± 3.4* 37.2 ± 6.4* 54.6 ± 11.7* 72.6 ± 12.7* 89.8 ± 18.6* 
 
Acetazolamide 14.7 ± 1.6† 32.7 ± 4.7*† 46.9 ± 7.2*† 63.8 ± 9.4*† 81.1 ± 11.4*† 105.2 ± 17.9*† 
Values are mean ± standard deviation. Q̇T, cardiac output; SV, stroke volume; HR, heart rate; SpO2, peripheral arterial O2 saturation; 
PASP, pulmonary artery systolic pressure; TPR, total pulmonary resistance; RR, respiratory rate; VT, tidal volume; V̇E, minute 
ventilation. *, significantly different from rest within a given pharmacologic condition; †, significantly different from baseline without 
pharmacologic intervention for that specified workload.  
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Table 5.3. Hemodynamic and Ventalitory Data During Exercise Beathing 100% O2 
  
Rest 50 W 100 W 150 W 200 W 250 W 
Q̇T, L min Baseline 4.9 ± 0.7 6.9 ± 1.9 9 ± 2.5* 10.9 ± 2.2* 13.1 ± 2.8* 13.7 ± 2.2* 
 
Sildenafil 4.4 ± 1.3 7.2 ± 1.6 8.5 ± 2.2* 11.7 ± 2.5* 12.8 ± 3.1* 15 ± 3.4*† 
 
Nifedipine 6.3 ± 1.4† 8.8 ± 1.5† 11.1 ± 2.1*† 11.7 ± 2.7* 13.2 ± 3* 15.5 ± 5* 
 
Acetazolamide 4.4 ± 1.4 7.7 ± 2 10.2 ± 2.2* 12.4 ± 2.7* 14.2 ± 2.7* 17.5 ± 2.3* 
SV, mL Baseline 63 ± 14 73 ± 20 79 ± 31 83 ± 26 88 ± 25 84 ± 20 
 
Sildenafil 59 ± 15 79 ± 17 79 ± 19 94 ± 24* 90 ± 23* 96 ± 20* 
 
Nifedipine 66 ± 19 78 ± 18 87 ± 24 82 ± 23 84 ± 23 93 ± 29 
 
Acetazolamide 60 ± 16 78 ± 18 87 ± 23 92 ± 24* 93 ± 21* 106 ± 14* 
HR, bpm Baseline 81 ± 19 97 ± 27* 118 ± 16* 136 ± 21* 152 ± 19*  166 ± 16* 
 
Sildenafil 75 ± 16 93 ± 22* 108 ± 25* 129 ± 23* 145 ± 22*  156 ± 18* 
 
Nifedipine 99 ± 19† 116 ± 25*† 132 ± 22*† 145 ± 22*† 160 ± 19*† 168 ± 18* 
 Acetazolamide 75 ± 17 87 ± 35* 120 ± 17* 138 ± 19* 154 ± 18* 166 ± 16* 
SpO2, % Baseline 99.3 ± 0.7 99.3 ± 0.7 98.9 ± 0.5 99.2 ± 0.7 99.1 ± 1.1 99 ± 0.8 
 
Sildenafil 99.4 ± 0.5 99.2 ± 0.4 99.7 ± 0.4 99.5 ± 0.4 99.6 ± 0.4 99.5 ± 0.5 
 
Nifedipine 99.3 ± 0.3 99.5 ± 0.5 99.3 ± 0.4 99.5 ± 0.4 99.5 ± 0.5 99.5 ± 0.5 
 
Acetazolamide 99.3 ± 0.6 99.6 ± 0.4 99.5 ± 0.4 99.5 ± 0.4 99.7 ± 0.5 99.2 ± 0.7 
PASP, mm Hg Baseline 27.6 ± 4.8 35 ± 5.8 42.5 ± 4.6* 43.2 ± 8.8* 51.8 ± 7.7* 55.4 ± 11.1* 
 
Sildenafil 27.6 ± 7.5 35.7 ± 8.4 41.6 ± 10.3* 49.4 ± 10.4* 51.1 ± 8* 58.6 ± 6.3* 
 
Nifedipine 31 ± 7.2 45.6 ± 15.3† 48.9 ± 11.1* 55.1 ± 10.8* 55.4 ± 7.5* 61.9 ± 11.9* 
 Acetazolamide 26.2 ± 4.8 31.5 ± 2.6 39.7 ± 2.2* 44.5 ± 8.1* 49 ± 7.4* 56.7 ± 9* 
TPR, mm Hg/L/min Baseline 5.8 ± 1.5 5.9 ± 4 5.1 ± 1.5 4 ± 0.6 4.2 ± 1.2 4.1 ± 0.8 
 
Sildenafil 6.6 ± 1.8 5.1 ± 1.2 5 ± 1.1 4.5 ± 1.7* 4.2 ± 1.3* 4 ± 0.6* 
 
Nifedipine 5.1 ± 1.6 5.2 ± 1.9 4.5 ± 1.1 5.1 ± 1.9 4.4 ± 1 4.6 ± 1.7 
 
Acetazolamide 6.2 ± 1.1 4.3 ± 1 3.8 ± 0.8 3.7 ± 1 3.6 ± 0.8 3.3 ± 0.7 
V̇E, L min Baseline 13.4 ± 2.8 23.7 ± 4.4* 35.7 ± 3.6* 47.8 ± 3.7* 61.6 ± 4.3* 79.3 ± 11.7* 
 
Sildenafil 12.8 ± 2.8 24.6 ± 2.1* 36.7 ± 3* 50.3 ± 6.8* 63.2 ± 8.9* 81.1 ± 15.3* 
 
Nifedipine 13.5 ± 2.4 13.1 ± 3.7* 27.5 ± 3.4* 37.2 ± 6.4* 54.6 ± 11.7* 72.6 ± 12.7* 
 
Acetazolamide 17.2 ± 3.3† 30.8 ± 3.6* 44.8 ± 5.1*† 59.2 ± 10.7*† 75.8 ± 11.9*† 91 ± 22* 
Values are mean ± standard deviation. See Table 5.2 for definitions of terms and acronyms.  
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 100% O2: During exercise at baseline and with all pharmacologic interventions, 
the expected hemodynamic and ventilatory response occurred to similar degrees (Table 
5.3). However, similar to exercise breathing room air, nifedipine resulted in an increased 
Q̇T at rest and during exercise at 50 and 100 W. Similarly, compared to baseline, heart 
rate was increased at rest and during exercise with nifedipine. This increase in Q̇T was 
also accompanied with an increase in pulmonary artery systolic pressure, yet pulmonary 
vascular resistance was not different compared to baseline. Unlike when breathing room 
air, no significant hemodynamic changes were associated with sildenafil. However, the 
augmented ventilation at rest and during exercise with acetazolamide was also present 
when breathing 100% O2 and no significant hemodynamic changes were observed. 
Transpulmonary Passage of Saline Contrast 
 Room air: During exercise at baseline and with all pharmacologic interventions, 
the transpulmonary passage of saline contrast progressively increased and was 
significantly elevated during exercise at 150, 200, and 250 W (Figure 5.1A). Bubble 
scores during exercise with sildenafil (Figure 5.1C) and acetazolamide (Figure 5.1G) 
were similar compared to baseline. Although not statistically different from baseline, 
mode bubble scores were the highest during exercise with nifedipine from rest through 
200 W (Figure 5.1E). Furthermore, consistent with the elevated Q̇T at rest and 50 W with 
nifedipine, there was a trend (p = 0.08) for bubble scores to be higher compared to 
baseline.  
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Figure 5.1. Bubble Scores During Exercise Breathing Room Air and 40% O2 
Bubble scores during exercise breathing room air and 100% O2; at baseline without 
pharmacologic intervention (A and B), after 100 mg p.o. Sildenafil (C and D), after 20 
mg p.o. nifedipine (E and F), and after three days of 250 mg p.o. t.i.d. acetazolamide (G 
and H).  
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 100% O2: As expected, the transpulmonary passage of saline contrast was trivial 
during exercise at baseline and only significantly increased from rest breathing a FIO2 = 
1.0 during exercise at 200 W. During exercise with sildenafil, nifedipine, and 
acetazolamide, the transpulmonary passage of saline contrast was not different compared 
to baseline. Similar to baseline without pharmacologic intervention, significant increases 
in bubble scores were only observed at 200 and 250 W. 
 
DISCUSSION 
 The current study investigated the pharmacologic influence of sildenafil, 
nifedipine, and acetazolamide on the regulation of blood flow through IPAVA during 
exercise in healthy humans breathing a FIO2 = 1.0. The primary finding of the current 
study was that the general absence of blood flow through IPAVA during exercise 
breathing a FIO2 = 1.0 was not significantly altered following administration of a single 
dose of sildenafil (100 mg, p.o), a single dose of nifedipine (20 mg, p.o), or after 
acetazolamide (250 mg, p.o., t.i.d. for 3 days). 
 We have previously shown that during exercise breathing a FIO2 = 1.0 blood flow 
through IPAVA is prevented or significantly reduced. The current study found similar 
results during exercise breathing a FIO2 = 1.0 with pharmacologic interventions that are 
known modulators of pulmonary vascular tone. All of these pharmacologic interventions 
act through mechanisms with the potential to prevent or reduce the O2 induced 
constriction of IPAVA (9). Nifedipine and acetazolamide have the potential to prevent or 
limit pulmonary vascular smooth muscle contraction, while sildenafil augments the 
potential relaxation of pulmonary vascular smooth muscle. The increase and decrease in 
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blood flow through IPAVA during exercise breathing room air and a FIO2 = 1.0, may at 
least partially be a result of IPAVA vasodilation and vasoconstriction, respectively. 
Accordingly, by preventing the potential vasoconstriction of IPAVA or augmenting the 
vasodilation of IPAVA, these pharmacologic interventions could have allowed blood 
flow through IPAVA to occur during exercise breathing a FIO2 = 1.0, as occurs during 
exercise breathing room air. However, this was not the case and potential explanations 
for this are discussed below. 
  
Sildenafil 
 Endothelium derived or exogenous nitric oxide (NO) promotes smooth muscle 
relaxation by activation of soluble guanylate cyclase and the subsequent production of 
cyclic guanosine monophosphate (cGMP), and via activation of protein kinase G, 
decreased intracellular calcium levels. The type-5 phosphodiesterase (PD-5) isoform, 
located primarily in the penis and lungs, rapidly degrades cGMP and thereby limits the 
NO mediated relaxation. Sildenafil citrate inhibits PD-5, prolonging the survival cGMP, 
and thus promotes vascular relaxation by allowing the effects of NO to persist longer, 
rather than increasing the bioavailability of NO. 
 Previous work has demonstrated a correlation between increases in blood flow 
through IPAVA when breathing room air and increases in Q̇T (24, 133, 216) that may be 
in part due to the associated increase in sheer stress and increased release of NO. If so, 
the possibility that blood flow through IPAVA is NO mediated should be interpreted in 
light of recent work demonstrating the i.v. infusion of nitroglycerin in healthy humans at 
rest did not increase the transpulmonary passage of saline contrast (147). However, the 
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i.v. infusion of nitroglycerin did not increase Q̇T, and therefore, it remains possible that 
IPAVA were open but the transpulmonary passage of saline contrast did not occur due to 
potential factors such as mean pulmonary transit time being to long for in vivo 
microbubbles to survive. Furthermore, prolonging the action of cGMP with sildenafil 
ingestion did not significantly change the transpulmonary passage of saline contrast 
during exercise breathing room air. Nevertheless, it remains possible that during exercise 
breathing room air, IPAVA are open without augmenting the vasodilatory effects of NO 
with sildenafil. 
 During exercise breathing a FIO2 = 1.0 with sildenafil, also did not result in an 
increase in the transpulmonary passage of saline contrast. The explanation for this may be 
due to an increase in the production of reactive oxygen species, known to occur during O2 
breathing, which may limit the bioavailability of NO (201). Thus, the vasodilatory effects 
of NO during exercise breathing a FIO2 = 1.0 may be diminished, similar to hyperoxia 
attenuating endothelial mediated vasodilation in peripheral vascular beds (268). 
However, these data suggest that even when augmenting the action of NO that is present, 
no significant increase in blood flow through IPAVA is detected. 
Nifedipine 
 Nifedipine is a dihydropyridine that blocks the activation of voltage gated (L-
type) calcium channels (207), that when open allow for the influx of calcium down the 
concentration gradient (2 mM extracellular vs. 100 nM intracellular). L-type calcium 
channels are critical to the control of vascular tone and have been demonstrated to be 
integral in facilitating the O2 induced constriction of the ductus arteriosus (230). 
Additionally, and also via blockade of L-type calcium channels, nifedipine has been 
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shown to prevent hypoxic pulmonary vascoconstriction using the same dosage (20 mg, 
p.o.) as the current study (10, 174). Accordingly, considering the pervasive influence of 
L-type calcium channels in regulating vascular tone and their documented role in 
mediating both O2 induced constriction of the ductus arteriosus and hypoxic pulmonary 
vasoconstriction it seemed plausible that IPAVA may be similarly regulated. 
Nevertheless, no effect was observed during exercise breathing a FIO2 = 1.0 with 
nifedipine, suggesting that the O2 induced constriction of IPAVA is not primarily 
mediated via L-type calcium channels. 
Acetazolamide 
 Acetazolamide is a carbonic anhydrase inhibitor, most commonly known for it’s 
utility in preventing acute mountain sickness (66) owing to it’s respiratory stimulating 
properties secondary to renal excretion of bicarbonate (i.e., metabolic acidosis) and 
carbonic anhydrase inhibition in central chemoreceptors (155, 221). However, a 
secondary property of acetazolamide is a reduction/prevention of increases in pulmonary 
artery pressure in acute hypoxia (222). The mechanism explaining the prevention of 
hypoxic pulmonary vasoconstriction via acetazolamide has been shown to not be a result 
of intracellular acidification or changes in membrane potential and is independent of 
carbonic anhydrase inhibition (206). Accordingly, acetazolamide prevents increases in 
intracellular calcium via a non L-type calcium channel mechanism. Importantly, the 
dosage used in the current study (250 mg, p.o. every 8 hours, t.id.) has also been shown 
to prevent hypoxic pulmonary vasoconstriction in acute hypoxia (224). Despite the 
efficacy of acetazolamide in preventing hypoxic pulmonary vasoconstriction, these data 
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suggest that the O2 induced constriction of IPAVA is not mediated by a similar 
mechanism. 
Limitations 
 Blood flow through IPAVA was detected using transthoracic saline contrast 
echocardiography, and previous work has discussed the associated limitations (24, 53, 54, 
134, 216). However, particularly pertinent to the current study is addressing the potential 
concern that blood flow through IPAVA is not detected during exercise breathing a FIO2 
= 1.0 due to O2 breathing altering the partial pressure environment of in vivo 
microbubbles and destabilizing them (103). In this way, blood flow through IPAVA may 
be occurring during exercise breathing a FIO2 = 1.0 yet the failure to observe significant 
left-sided contrast reflects the failure for saline contrast to survive long enough, to reach 
the left heart. Previous work by our group has demonstrated this theory to not be 
experimentally valid and therefore, saline contrast created from room air is appropriate to 
use in subjects breathing a FIO2 = 1.0 to detect blood flow through IPAVA (54). The 
bubble scoring system used in the current study, although not without precedence (11), 
and previously published (54, 55, 133, 134, 144), is a qualitative approach intended to 
characterize the degree of left sided contrast. This bubble scoring system does not 
represent a means to quantify blood flow through IPAVA. Yet, considering O2 breathing 
does not affect the in vivo dynamics of saline contrast created from room air it is likely 
that the reductions in bubble score during exercise breathing a FIO2 = 1.0 truly reflect a 
reduction in blood flow through IPAVA. Of note, to validate the reproducibility of our 
bubble scoring system, previous work from our lab has demonstrated very good 
agreement with bubble scores assigned by one of two expert sonographers (combined 
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>40 years experience) and cardiologist blinded to the conditions. In one of these studies, 
a cardiologist reviewed 57 saline contrast recordings and reported 100% agreement on 
whether there was or was not left heart contrast, and 53 (93%) were assigned the same 
score (55). 
Conclusions 
 As expected, at baseline without pharmacologic intervention the transpulmonary 
passage of saline contrast occurred during exercise breathing room air and was prevented 
or reduced during exercise breathing a FIO2 = 1.0. These findings were not significantly 
altered following the administration of sildenafil (100 mg, p.o), nifedipine (20 mg, p.o), 
and after acetazolamide (250 mg, p.o., t.i.d for 3 days). Of particular interest is that none 
of these pharmacologic interventions resulted in blood flow through IPAVA during 
exercise breathing a FIO2 = 1.0, despite these drugs being well-known modulators of 
pulmonary vascular tone (9). However, rather than IPAVA being regulated similar to the 
ductus arteriosus or fetal cardiopulmonary circulation, there regulation may be more 
similar to the systemic circulation which is also known to dilate in response to low O2 
tensions and constrict in response to high O2 tensions. Accordingly, and also like the 
systemic circulation, it remains possible that IPAVA are not mediated by these 
mechanisms and/or there are redundant mechanisms facilitating O2 induced IPAVA 
constriction, similar to those redundant mechanisms regulating peripheral blood flow 
(35).  
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 Up until this point, Chapter IV and V included subjects without a PFO, as the 
purpose was to either demonstrate that blood flow through IPAVA, 1) contributed to 
pulmonary gas exchange efficiency, 2) was reduced during exercise breathing 100% O2, 
and was potentially regulated by various pharmacologic interventions. However, I shift 
now to including both subjects with and without a PFO to investigate the effect of human 
acclimatization to hypobaric hypoxia. All prior studies investigating human 
acclimatization to hypobaric hypoxia have presumably been done in subjects with and 
without a PFO and therefore it is unknown to what extent PFO influences acclimatization 
to hypobaric hypoxia.  
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CHAPTER VI 
ALTITUDEOMICS: IMPAIRED PULMONARY GAS EXCHANGE EFFICIENCY 
AND VENTILATORY ACCLIMATIZATION AFTER 16 DAYS AT 5260M IN 
HUMANS WITH PATENT FORAMEN OVALE 
 This chapter is in review with the Journal of Applied Physiology and Steven S. 
Laurie, Julia P. Kern, Kara M. Beasley, Randall D. Goodman, Bengt Kayser, Andrew W. 
Subudhi, Robert C. Roach, and Andrew T. Lovering are co-authors. The data presented in 
this chapter come from a very large, multinational, field based project entitled 
“AltitudeOmics”. However, I performed the experimental work, led this aspect of 
AltitudeOmics, and the writing is entirely mine; Steven S. Laurie, Julia P. Kern, and Kara 
M. Beasley provided technical and editorial assistance; Randall D. Goodman provided 
technical assistance with performing echocardiography during exercise; and Bengt 
Kayser, Andrew W. Subudhi, Robert C. Roach, and Andrew T. Lovering helped develop 
the protocol, and provided guidance and editorial assistance.  
 
INTRODUCTION 
 It is well established that pulmonary gas exchange progressively worsens in a 
workload dependent manner during exercise at sea level (48). This impairment in 
pulmonary gas exchange efficiency during exercise is exacerbated in acute hypoxia, such 
that for any given V̇O2, the alveolar-to-arterial PO2 difference (A-aDO2) is greater 
compared to exercise in normoxia (235). Following acclimatization to hypobaric hypoxia, 
pulmonary gas exchange efficiency is thought to improve compared to acute hypoxia (88, 
203). Seminal work from Dempsey et al. (47) reported a trend for an increased A-aDO2 
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during treadmill walking after 4 days at 3100 m compared to sea level, and a partial 
normalization during the same exercise protocol following 21 days at 3100 m compared 
to that obtained after 4 days. Bebout et al. (13) then demonstrated that, compared to acute 
normobaric hypoxia, acclimatization to 3800 m for 2 weeks resulted in an ~3 mm Hg 
reduction in the A-aDO2 during submaximal cycle ergometer exercise. Calbet et al. (28) 
subsequently reported that, compared to acute normobaric hypoxia, acclimatization to 
5260m for 9-10 weeks resulted in an ~9 mm Hg reduction in the A-aDO2 during 
submaximal cycle ergometer exercise. Collectively, these data suggest that pulmonary 
gas exchange efficiency in non-acclimatized individuals improves with acclimatization to 
high-altitude compared to acute hypoxia. 
 Recently, our group has explored the consequences of an intracardiac right-to-left 
shunt via a patent foramen ovale (PFO) in healthy humans during exercise breathing 
room air and in acute hypoxia. In the course of these investigations it became apparent 
that the presence of a PFO could be critical to the interpretation of work where 
pulmonary gas exchange efficiency is a key element and, to our knowledge, prior work 
investigating human acclimatization to high-altitude have not considered the effect of a 
PFO. The classic study by Hagen et al. (82) reported a PFO prevalence of 25-35% 
identified using a probe during autopsy (n = 965). Recent work from several research 
groups using saline contrast echocardiography (n = 104-1162) report that ~40% of adult 
humans have a PFO (55, 156, 266). Therefore, according to the multiplication rule for 
conditional probability and using a 35% prevalence of PFO, there is a <5% chance that 
the aforementioned studies on pulmonary gas exchange efficiency after acclimatization 
would randomly select all subjects without PFO. Right-to-left blood flow through a PFO 
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occurs when right atrial pressure exceeds left atrial pressure, which can occur transiently 
during normal respiration (64). Thus, right-to-left blood flow through a PFO is likely 
intermittent and variable in volume, however it does result in a measureable impact on 
pulmonary gas exchange efficiency. Lovering et al. (145) found that subjects with a PFO 
have an increased A-aDO2 at rest, breathing either room air at sea level or a normobaric 
hypoxic gas mixture (12% O2). 
 The primary purpose of this study was to investigate pulmonary gas exchange 
efficiency at rest and during exercise in subjects with and without a PFO after 
acclimatization to hypobaric hypoxia. We hypothesized that subjects with a PFO would 
have worse pulmonary gas exchange efficiency after acclimatization to high-altitude 
compared to subjects without a PFO. To test this hypothesis, healthy male and female 
lowlanders, with and without a PFO, were studied at rest and during exercise at sea level, 
after being acutely transported to 5260m, and after living at 5260m on Mt. Chacaltaya, 
Bolivia, for 16 days. This study was conducted as part of the AltitudeOmics project, 
described previously in greater detail (218). 
 
METHODS 
 This study received approval from the University of Oregon, the University of 
Colorado Denver, and the U.S. Department of Defense. All subjects provided verbal and 
written informed consent prior to participation and all studies were conducted in 
accordance with the Declaration of Helsinki. 
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Subject Recruitment and Screening 
 A complete description of the inclusion/exclusion criteria were published in the 
project overview paper of this series (218). Briefly, 21 healthy subjects (9 female) 
recruited from sea level (Eugene, Oregon, 130m, PB = 749 mm Hg) participated in all 
aspects of this study and constitute the AltitudeOmics group of subjects in this report. 
Pertinent to the current report and not described in previous AltitudeOmics publications 
are the methodologies for determining adequate (≥90% predicted) pulmonary function 
and diffusion capacity for carbon monoxide parameters and the echocardiographic 
screening process each subject underwent. 
Spirometry, Diffusion Capacity, and Lung Volumes 
 Baseline pulmonary function was determined using computerized spirometry 
(MedGraphics, Ultima CardiO2, St. Paul, MN, USA) according to American Thoracic 
Society/European Respiratory Society (ATS/ERS) standards (166). Lung diffusion 
capacity for carbon monoxide (DLCO) was determined by the single-breath, breath hold 
method according to ATS/ERS standards (119, 152) using the Jones and Meade method 
for timing (111). Lung volumes and capacities were determined using whole body 
plethysmography (MedGraphics Elite Plethysmograph, St. Paul, MN, USA) according to 
ATS/ERS standards (247). 
Echocardiographic Screening 
 All subjects underwent a comprehensive echocardiographic screening process 
(Philips Sonos 5500, Eindhoven, The Netherlands) by a registered diagnostic cardiac 
sonographer with >25 yrs of experience (R.D.G.) to ensure subjects were free of cardiac 
abnormalities or signs of heart disease, as previously conducted by our group (54, 55, 
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133, 134). Transthoracic saline contrast echocardiography (TTSCE) was used to identify 
the presence of a PFO or the transpulmonary passage of saline contrast via 
intrapulmonary arteriovenous anastomoses (IPAVA) as described previously (139). The 
appearance of ≥1 microbubble(s) in the left heart in any frame during the 20 cardiac 
cycles following right heart opacification identified subjects as either having a PFO or the 
transpulmonary passage of saline contrast (68, 159, 163, 198). Delineation between these 
two sources of left heart contrast results from the timing of contrast appearing in the left 
heart following right heart opacification, in which a microbubble appearing within ≤3 
cardiac cycles is consistent with PFO, while a microbubble appearing after >3 cardiac 
cycles is consistent with transpulmonary passage (27, 49, 96, 132, 159, 163, 198). Saline 
contrast injections were performed during normal breathing as well as after provocative 
maneuvers designed to transiently elevate right atrial pressure and create conditions 
optimal for detection of PFO (e.g., release of a Valsalva maneuver and after coughing). 
Multiple injections were performed as necessary when results were equivocal. Each 
agitated saline contrast injection was scored using a previously published 0-5 bubble 
scoring system (54, 55, 133, 134, 143, 144). Briefly, bubble scores reflect the quantity 
and spatial distribution of contrast in the left ventricle in any single frame throughout the 
20 cardiac cycles post-right heart opacification; 0 = no bubbles, 1 = 1-3 bubbles, 2 = 4-12 
bubbles, 3 = >12 bubbles appearing as a bolus, 4 = >12 bubbles heterogeneously filling 
the left ventricle, and 5 = >12 bubbles homogeneously filling the left ventricle. 
 Of the 21 subjects that participated in this study, there were 11 (7 female) subjects 
with a PFO (PFO+) and 10 (2 female) subjects without a PFO (PFO−). Of note, we 
originally planned on having an equal number of PFO+ and PFO− subjects, although for 
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reasons previously described 3 subjects were excluded (218). At baseline, within the 
PFO+ group, 6 subjects had a bubble score ≥3 upon release of a Valsalva maneuver and 5 
subjects had a bubble score of ≤2 upon release of a Valsalva maneuver. It has recently 
been demonstrated that the degree of left-sided contrast visualized upon release of a 
Valsalva maneuver in PFO+ subjects correlates to the size of the PFO (64). Accordingly, 
those with more contrast (i.e., bubble score ≥3) likely have a larger PFO compared to 
those with less contrast (i.e., bubble score ≤2), and as such there was a range of PFO 
sizes within our PFO+ group. Within the PFO− group, 6 subjects presented with a trivial 
degree of transpulmonary passage of contrast (bubble score = 1) at rest breathing room 
air at SL, and 4 subjects were entirely clear of left-sided contrast during screening. Prior 
work from our lab has excluded subjects demonstrating transpulmonary passage of 
contrast at rest due to the unknown significance of this finding. However, considering the 
circumstances and confines of the current field study based work, we chose to include 
these subjects. No statistical differences were observed within the PFO− group 
comparing those with and without the minimal transpulmonary passage of contrast at rest 
breathing room air at SL. 
Acute Normobaric Hypoxia 
 As part of the preliminary testing at sea level, transthoracic saline contrast 
echocardiography was performed in the PFO− and PFO+ groups at rest breathing room 
air and after 20 min of breathing mild hypoxic gas (14 % O2). Identical to the initial 
screening procedure, agitated saline contrast injections were performed in subjects 
reclined at 45° in the left lateral decubitus position. The primary purpose of these 
measurements in normobaric hypoxia was for an aspect of the project not currently being 
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reported on; however the secondary purpose pertinent to the current work, was to 
determine if subjects would have an increase in left-sided contrast at rest breathing mild 
hypoxic gas compared to room air, as previously demonstrated (134). These studies 
confirmed that both the PFO− and PFO+ groups in this study had an increase in left-sided 
contrast breathing normobaric hypoxia. 
Timeline 
 This report presents data collected over 3 experimental study visits: 1) sea level 
(SL: Eugene, Oregon, 130m, PB = 749 mm Hg); 2) day 1 at high-altitude (ALT1: Mt. 
Chacaltaya, Bolivia, 5260m, PB = 406 mm Hg); and 3) after living at high-altitude for 16 
days (ALT16: Mt. Chacaltaya, Bolivia, 5260m, PB = 406 mm Hg). To provide an acute 
exposure to 5260m on ALT1, the subjects breathed supplemental oxygen (2 L/min, nasal 
cannula or mask) during the drive up the mountain. On arrival at 5260m, the first subject 
immediately began the experimental protocol while the second subject rested while 
continuing to breathe supplemental oxygen for ~two hours until the first subject had 
completed the protocol. A complete description of the study timeline was previously 
published (218). 
Subject Instrumentation and Exercise Protocol 
 A core temperature pill (CorTemp HQInc., Palmetto, FL, USA) was ingested ~5 
hrs prior to the start of exercise. Subjects were instrumented with a 20 G radial artery 
catheter (Arrow International Inc., Reading, PA, USA) under local anesthesia (2% 
lidocaine) and an 18-22 G intravenous catheter was placed in the antecubital fossa. 
Subjects rested on an upright stationary cycle ergometer (Velotron Elite, Seattle, WA, 
USA) for 10 min prior to performing standardized workloads of 70, 100, 130, and 160 
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Watts for 3 min each. Exercise data are presented as the highest iso-workload achieved 
within an individual subject across SL, ALT1 and ALT16. For example, subjects may 
have completed all workloads at SL and ALT16, but only completed 130 W at ALT; in 
this case the iso-workload reported would be data at 130 W, from each SL, ALT1 and 
ALT16. TTSCE was performed at rest and during the last min of each 3 min workload 
with subjects positioned on the cycle ergometer in the forward leaning aerobar position to 
facilitate obtaining a clear apical, four-chamber view. 
Pulmonary Artery Systolic Pressure and Cardiac Output 
 Following each saline contrast injection, pulmonary artery systolic pressure 
(PASP) was assessed from the peak velocity of the tricuspid regurgitation using Doppler 
ultrasound (Sonosite Micromaxx, Bothell, WA, USA) and applied to the modified 
Bernoulli equation (4v2 + PRA), where v is velocity of the tricuspid regurgitation velocity 
envelope and PRA is right atrial pressure, according to the guidelines of the American 
Society for Echocardiography (117, 202, 275). A small volume (<0.5 ml) of air agitated 
with 3 ml of sterile saline was injected and used to help delineate the tricuspid 
regurgitation velocity envelope. Cardiac output was calculated with heart rate obtained 
from the ECG and stroke volume estimates derived from intra-arterial blood pressure 
tracings obtained via a saline filled transducer (Utah Medical, Salt Lake City, UT, USA) 
positioned at heart level and attached to the radial artery catheter (19, 219). 
Arterial Blood Gases, Body Temperature and Blood Lactate 
 At rest and at the end of each 3 min submaximal workload, a 3 ml radial artery 
blood sample was drawn anaerobically over 10-15 sec into a heparinized syringe and 
rapidly analyzed in duplicate (or triplicate if time permitted) for arterial PO2 (PaO2), 
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arterial PCO2 (PaCO2), and pH with a blood-gas analyzer calibrated daily with 
tonometered whole blood (Siemens RAPIDLab 248, Erlangen, Germany). Arterial blood 
gases were corrected for body temperature (48, 113, 205) based on readings from the 
ingested core temperature pill. Arterial O2 saturation (SaO2) and hemoglobin (Hb) were 
measured with CO-oximetry (Radiometer OSM3, Copenhagen, Denmark). Hematocrit 
was analyzed in triplicate at rest and in single measurements for each workload using the 
microcapillary tube centrifugation method (M24 Centrifuge, LW Scientific, 
Lawrenceville, GA, USA). Blood lactate was analyzed in duplicate using the Lactate Plus 
hand held meter and lactate test strips (Nova Biomedical, Waltham, MA, USA).  
Calculations 
 Alveolar PO2 (PAO2) was calculated using the ideal gas equation, using 
temperature corrected PaCO2, and a respiratory quotient (RER) from a 15 sec average of 
metabolic data corresponding to the time and duration of the arterial blood draw: 
P!O! = ! P! !− !e!.!"#$%#!$!×!!!! !!.!"#$"# !×!FIO! !− !PaCO!!× ! FIO! + ! 1!− !FIO!RER  
Equation 2.3. Alveolar Gas Equation 
where TB is core body temperature for temperature correction of water vapor pressure, 
RER is the respiratory exchange ratio (V̇CO2/V̇O2), and PB is barometric pressure that 
was measured daily (Greisinger electronic, GPB 3300). Pulmonary gas exchange 
efficiency (A-aDO2) was determined at rest and during exercise as the difference between 
the temperature corrected PaO2 and corresponding PAO2. 
 Measures of O2 content were calculated from the standard content equation: 
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O!!Content! = ! 1.39!×!Hb!× ! SO!100 + ! 0.003!×!PO!  
Equation 2.7. Oxygen Content Equation 
using an O2 carrying capacity of 1.39 ml O2/g Hb and directly measured Hb (g Hb/dL). 
For arterial O2 content (CaO2) SO2 represents CO-oximetry measured arterial O2 
saturation (SaO2) and temperature corrected PaO2. For end-capillary O2 content (CcʹO2) 
SO2 represents the end-capillary O2 saturation (ScʹO2) calculated from the Kelman 
equation (114) assuming complete alveolar-capillary O2 equilibration such that end-
capillary PO2 (PcʹO2) was equal to PAO2. Mixed venous O2 content (Cv̅O2) was 
calculated using the Fick principle of mass balance (V̇O2 = Q̇T × (CaO2 − Cv̅O2)) using 
measured CaO2, V̇O2, and an estimate of total Q̇T as described above. 
 The fraction of venous admixture (Q̇VA/Q̇T) accounting for the entirety of the A-
aDO2 was calculated from the shunt equation using the previously calculated O2 content 
values: Q!"Q! = !CcʹO! − CaO!CcʹO! − CvO! 
Equation 2.13. Berggren Shunt Equation 
 Alveolar ventilation (V̇A) was calculated using the measured V̇CO2 and 
temperature corrected PaCO2: 
V̇! = V̇CO!!×!863PaCO!  
Equation 2.1. Alveolar Ventilation 
Statistical Analyses 
 All statistical calculations were made using GraphPad Prism statistical software 
(v. 5.0d) and significance was set to p < 0.05. In both the PFO− and PFO+ groups, 
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measured and calculated physiologic variables were compared across time points (e.g., 
SL, ALT1 and ALT16) using a one-way ANOVA. A Newman-Keuls multiple 
comparison post-hoc test was used to determine specific pairwise differences between 
groups and time points. Non-parametric analyses (bubble scores) were done using a 
Kruskal-Wallis one-way ANOVA with a Dunn’s multiple comparison post-hoc test. 
Comparisons were determined a priori and performed two times (at rest and during 
exercise) in the PFO− and PFO+ groups. Differences in measured and calculated 
variables, between the PFO− and PFO+ groups at rest and during exercise were assessed 
using an unpaired t-test with Welch’s correction. Differences in bubble scores between 
the PFO− and PFO+ groups at rest and during exercise were assessed using a Mann-
Whitney t-test. 
 
RESULTS 
Overview 
 Baseline values for anthropometric, exercise, hematologic and pulmonary 
function data at SL for the PFO− (n = 10) and PFO+ (n = 11) groups are presented in 
Table 6.1. Cardiopulmonary data at rest and during exercise for SL, ALT1 and ALT16 
for the PFO− and PFO+ groups are presented in Table 6.2 and Table 6.3. The mean iso-
workload in the PFO− and PFO+ groups was 150 ± 24 W and 136 ± 28 W, respectively, 
which was not different between groups. The presentation of results will sequentially 
describe data collected at rest and during exercise at SL, ALT1 and ALT16 in the PFO− 
and PFO+ groups.  
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Table 6.1. Anthropometric, Exercise, Hematologic and Pulmonary Function Data 
 
PFO−, n=10 PFO+, n=11 
Age, yr 21.1 ± 1.4 20.6 ± 1.6 
Sex, (female) 2 7 
Height, cm 178.4 ± 6.1 173.4 ± 8.8 
Weight, kg 71.5 ± 8.4 68.1 ± 9.7 
V̇O2peak, mL?kg-1・min-1 46.8 ± 7.1 44.0 ± 6.2 
Peak power output, W 311 ± 67 268 ± 64 
Ferritin, ng・ml-1 61.3 ± 30.6 44.0 ± 32.7 
Iron, µg・dL-1 129.5 ± 47.9 134.1 ± 64.1 
FVC, L 5.48 ± 0.92 4.73 ± 1.04‡ 
FVC, %p 100.0 ± 11.0 100.4 ± 11.3 
SVC, L 5.61 ± 1.08 5.01 ± 1.18 
SVC, %p 102.4 ± 13.5 105.6 ± 11.7 
FEV1, L 4.62 ± 0.60 4.07 ± 0.77‡ 
FEV1, %p 101.3 ± 9.0 101.9 ± 7.9 
FEV1/FVC 85.4 ± 9.8 86.4 ± 5.3 
FEV1/FVC, %p 100.9 ± 11.6 100.8 ± 6.1 
FEF25-75, L・sec-1 4.79 ± 1.37 4.51 ± 0.84 
FEF25-75, %p 100.1 ± 28.5 105.1 ± 15.3 
TLC, Lpleth 7.16 ± 1.07 6.28 ± 1.33 
TLC, %p 104.9 ± 8.2 103.3 ± 11.4 
DLCO, mL・min-1・mm Hg-1 43.06 ± 8.74 33.25 ± 10.33‡ 
DLCO, %p 130.6 ± 21.1 110.1 ± 19.4‡ 
DLCO/VA 6.00 ± 0.71 5.61 ± 1.03 
DLCO/VA, %p 124.1 ± 17.5 113.2 ± 21.4 
Values are mean ± standard deviation. FVC, forced vital capacity; SVC, slow 
vital capacity; FEV1, forced expiratory volume in 1 s; FEF25-75, forced expiratory 
flow from 25 to 75% of FVC; TLC, total lung capacity; DLCO, diffusion capacity 
of carbon monoxide; DLCO/VA, DLCO/alveolar volume; %p, % predicted; ‡ p < 
0.05 compared to PFO−. 
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Table 6.2. Cardiopulmonary and Arterial Blood Gas Data at Rest in the PFO− and PFO+ Groups at Sea level (SL), Acute Hypoxia 
(ALT1) and After Acclimatization to High-Altitude (ALT16) 
 
SL 
 
ALT1 
 
ALT16 
 
PFO− PFO+ 
 
PFO− PFO+ 
 
PFO− PFO+ 
V̇E, L?min-1 14.5 ± 4.7 11.7 ± 3 
 
19.4 ± 4.4 16.7 ± 4.9* 
 
26.2 ± 8.9* 18.7 ± 6.5*‡ 
V̇A, L・min-1 8.2 ± 3.8 5.9 ± 2.6 
 
12.3 ± 2.7 10.6 ± 4.8* 
 
19.4 ± 7.8*† 12.4 ± 5.1*‡ 
VD/VT  0.42 ± 0.06 0.46 ± 0.06 
 
0.37 ± 0.11 0.42 ± 0.06 
 
0.38 ± 0.16 0.41 ± 0.05 
V̇O2, L?min-1 0.34 ± 0.1 0.28 ± 0.14 
 
0.43 ± 0.14 0.34 ± 0.12 
 
0.43 ± 0.06 0.35 ± 0.08‡ 
V̇CO2, L?min-1 0.32 ± 0.12 0.25 ± 0.11 
 
0.39 ± 0.1 0.32 ± 0.11 
 
0.4 ± 0.11 0.29 ± 0.09‡ 
RER 0.92 ± 0.08 0.87 ± 0.12 
 
0.93 ± 0.09 0.97 ± 0.09* 
 
0.9 ± 0.07 0.83 ± 0.09†‡ 
V̇E/V̇O2  43 ± 5.7 44.5 ± 9.3 
 
47 ± 7.1 51.4 ± 8.4 
 
61.4 ± 15.2*† 53.2 ± 9.6 
HR, bpm 76.8 ± 15.1 71.5 ± 12.3 
 
87.3 ± 16.5 89 ± 16.2* 
 
93 ± 16 92 ± 14* 
SV, mL 86 ± 18.3 88.2 ± 18.3 
 
90.5 ± 23.1 83.3 ± 13.3 
 
73 ± 16 75 ± 16 
Q̇T, L?min-1 6.5 ± 1.6 6.2 ± 1.3 
 
7.7 ± 1.5 7.3 ± 1.4 
 
6.6 ± 1.2 6.9 ± 1.2 
PASP, mm Hg 30.4 ± 6.4 24.9 ± 7.3‡ 
 
36.6 ± 6.6 31.8 ± 5.1* 
 
34.1 ± 4 31.9 ± 5.6* 
CaO2, ml O2?dL-1 19.7 ± 1.4 18 ± 1.9‡ 
 
14.4 ± 1.2* 13.8 ± 1.7* 
 
20.38 ± 1.91† 17.37 ± 3.2†‡ 
pH 7.43 ± 0.03 7.42 ± 0.02 
 
7.51 ± 0.02* 7.51 ± 0.03* 
 
7.51 ± 0.03* 7.5 ± 0.03* 
HCO3−, mmol?L-1 21.98 ± 1.92 22.67 ± 1.2 
 
20.7 ± 1.31 20.82 ± 2.05* 
 
14.4 ± 1.8*† 15.8 ± 1.1*†‡ 
BE, mmol?L-1 -1.87 ± 1.73 -1.4 ± 0.93 
 
-1.97 ± 1.14 -1.87 ± 1.56 
 
-7.83 ± 1.7*† -6.71 ± 0.81*†‡ 
Hct, % 44.5 ± 3 41.1 ± 3.7‡ 
 
44.3 ± 3.3 42.4 ± 3.5 
 
51.67 ± 3.21*† 47.23 ± 6.14*‡ 
Hb, g?dL-1 14.8 ± 1.1 13.6 ± 1.5‡ 
 
15 ± 1 13.9 ± 1.5 
 
17.16 ± 1.39*† 15.46 ± 2.37‡ 
Core Temp, °C 37.1 ± 0.4 37.2 ± 0.4 
 
36.9 ± 0.5 37.1 ± 0.4 
 
37 ± 0.9 37 ± 0.4 
Lactate, mmol?L-1 0.98 ± 0.42 0.88 ± 0.37 
 
1.16 ± 0.29 1.26 ± 0.59 
 
1 ± 0.3 1 ± 0.3 
n, max 10 11 
 
6 10 
 
9 11 
Values are mean ± standard deviation. V̇E, minute ventilation; V̇A, minute ventilation; VD/VT, dead space to tidal volume ratio; V̇O2, oxygen 
consumption; V̇CO2, carbon dioxide production; RER, respiratory exchange ratio; HR, heart rate; SV, stroke volume; Q̇T, cardiac output; PASP, 
pulmonary artery systolic pressure; CaO2, arterial oxygen content; pH, arterial pH; HCO3−, arterial bicarbonate; BE, arterial base excess; Hct, arterial 
hematocrit; Hb, arterial hemoglobin; Core Temp, core body temperature. * p < 0.05 compared to SL; † p < 0.05 compared to ALT1; ‡ p < 0.05 
compared to PFO−. 
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Table 6.3. Cardiopulmonary and Arterial Blood Gas Data During Exercise in the PFO− and PFO+ Groups at Sea level (SL), Acute 
Hypoxia (ALT1) and After Acclimatization to High-Altitude (ALT16) 
 
SL 
 
ALT1 
 
ALT16 
 
PFO− PFO+ 
 
PFO− PFO+ 
 
PFO− PFO+ 
V̇E, L?min-1 60.7 ± 9.3 56.2 ± 13.7 
 
101.9 ± 23.5* 106.5 ± 19.6* 
 
122.9 ± 27.2* 118.9 ± 38.3* 
V̇A, L?min-1 50 ± 8.3 45.8 ± 11.3 
 
85.9 ± 18.7* 82.5 ± 20.4* 
 
99.6 ± 27.1* 101.8 ± 37.6* 
VD/VT  0.45 ± 0.05 0.48 ± 0.05 
 
0.42 ± 0.08 0.43 ± 0.11 
 
0.44 ± 0.03 0.44 ± 0.05 
V̇O2, L?min-1 2.22 ± 0.37 2 ± 0.47 
 
2.19 ± 0.46 1.94 ± 0.44 
 
2.31 ± 0.48 2.1 ± 0.52 
V̇CO2, L?min-1 2.27 ± 0.42 1.97 ± 0.44 
 
2.29 ± 0.52 2.08 ± 0.46 
 
2.25 ± 0.47 2.03 ± 0.45 
RER 1.02 ± 0.04 0.99 ± 0.05 
 
1.04 ± 0.05 1.07 ± 0.04* 
 
0.95 ± 0.07*† 0.95 ± 0.06† 
V̇E/V̇O2  27.5 ± 1.7 28.3 ± 3.3 
 
46.5 ± 3.8* 54.1 ± 11.3*‡ 
 
53.4 ± 3.7*† 56.2 ± 8* 
HR, bpm 139.2 ± 19.8 143.6 ± 13.3 
 
166 ± 12* 163 ± 12* 
 
154 ± 11 156 ± 18 
SV, mL 132.3 ± 17.1 113.6 ± 12.8 
 
125 ± 18 116 ± 13 
 
113 ± 19 98 ± 36 
Q̇T, L?min-1 18.4 ± 3.5 16.3 ± 2.1 
 
20.8 ± 2.8 19 ± 3* 
 
17.3 ± 2.7 17 ± 1.8 
PASP, mm Hg 50.3 ± 5.7 44.1 ± 10.5 
 
53.6 ± 10.9 52.9 ± 10.5 
 
54.5 ± 10.2 57.7 ± 10.2* 
CaO2, ml O2?dL-1 20.2 ± 1.6 18.4 ± 1.8‡ 
 
14.4 ± 1.18* 13.34 ± 1.81* 
 
17.88 ± 0.85*† 15.47 ± 2.61*†‡ 
pH 7.36 ± 0.04 7.37 ± 0.02 
 
7.44 ± 0.05 7.42 ± 0.04* 
 
7.42 ± 0.04 7.42 ± 0.04* 
HCO3−, mmol?L-1 20.69 ± 1.74 21.1 ± 2.13 
 
15.1 ± 1.2* 14 ± 2.7* 
 
11.4 ± 1.3*† 10.8 ± 2.9*† 
BE, mmol?L-1 -3.98 ± 2.07 -3.44 ± 2.08 
 
-8.1 ± 1.69* -9.35 ± 2.92* 
 
-11.89 ± 1.53*† -12.45 ± 3.17*† 
Hct, % 45.4 ± 3 41.5 ± 3.5‡ 
 
46.17 ± 4.39 43.51 ± 4.4 
 
52.68 ± 3.47*† 48.03 ± 5.29*†‡ 
Hb, g?dL-1 15.2 ± 1.2 13.9 ± 1.4‡ 
 
15.6 ± 1.19 14.63 ± 1.45 
 
17.38 ± 1.12*† 15.84 ± 2.15*‡ 
Core Temp, °C 37.2 ± 0.2 37.4 ± 0.4 
 
37 ± 0.3 37.2 ± 0.4 
 
36.8 ± 0.8 37.2 ± 0.5 
Lactate, mmol?L-1 2.95 ± 1.52 2.88 ± 1.43 
 
7.2 ± 2.8* 8.8 ± 2.1* 
 
5.6 ± 1.5* 6.9 ± 2.1*† 
n, max 6 10 
 
6 10 
 
6 10 
Values are mean ± standard deviation. See Table 6.2 for definitions of acronyms and statistical symbols. 
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Anthropometric, Exercise, Hematologic, and Pulmonary Function Data 
 No differences were observed between PFO− and PFO+ groups in baseline 
anthropometric, exercise, or hematologic variables at SL (Table 6.1). The greater number 
of females in the PFO+ group (n=7) explains the observed differences in absolute 
pulmonary function values and results from the known differences in absolute lung 
volumes between males and females (87).  However, when the pulmonary function data 
were expressed as per cent predicted, there were no differences. Of note, preliminary 
analyses between male and female subjects revealed no differences other than a larger 
CaO2 in males as a result of increased Hb across SL, ALT1 and ALT16 (218) 
Sea Level (SL) 
Pulmonary Gas Exchange Efficiency. Pulmonary gas exchange efficiency (A-aDO2) in 
the PFO− and PFO+ groups at rest (Figure 6.1A) and during exercise (Figure 6.1B) was 
similar. However, within the PFO+ group, 6 subjects had a resting bubble score ≥3 and 5 
subjects had a resting bubble score ≤2 upon release of a Valsalva maneuver. As described 
in the methods, this has been demonstrated to correlate to the size of the PFO. 
Accordingly, subjects with a resting bubble score ≥3 (i.e., a larger PFO) had a greater A-
aDO2 (Figure 6.2A) and thus a greater calculated venous admixture (Q̇VA/Q̇T ) (Figure 
6.2B) compared to those with a resting bubble score ≤2 (i.e., a smaller PFO) during 
submaximal exercise at 100, 130 and 160 W.  
________________________ 
Figure 6.1. (next page) Pulmonary Gas Exchange and Arterial Blood Gases 
Pulmonary gas exchange efficiency (A and B), alveolar PO2 (C and D), arterial PO2 (E 
and F), arterial PCO2 (G and H), and arterial O2 saturation (I and J) for the PFO− and 
PFO+ groups at rest and during iso-workload exercise at SL, ALT1, and ALT16. Data 
presented are mean ± standard error (see Table 6.2 for respective n’s), * p < 0.05 
compared to SL, † p < 0.05 compared to ALT1, ‡ p < 0.05 compared to the PFO− group. 
  
 164 
 
  
SL ALT1 ALT16
0
5
10
15
20
25
Pre-exercise
PFO−
PFO+
*
*
†
A
A-
aD
O
2 (
m
m
 H
g)
SL ALT1 ALT16
0
5
10
15
20
25
Iso-workload
PFO−
PFO+
†
*‡
*
*
B
SL ALT1 ALT16
0
40
50
60
90
100
110
*
*
*†
*‡
C
PA
O
2 (
m
m
 H
g)
SL ALT1 ALT16
0
20
30
40
50
60
90
100
110
‡
*
*
*†
*†‡
E
Pa
O
2 (
m
m
 H
g)
SL ALT1 ALT16
0
15
20
25
30
35
40
*
*
*†
*†‡
G
Pa
C
O
2 (
m
m
 H
g)
SL ALT1 ALT16
0
40
50
60
90
100
110
*
*
*† PFO−
* PFO+
D
SL ALT1 ALT16
0
20
30
40
50
60
90
100
110
*
*
*†
*†‡
F
SL ALT1 ALT16
0
15
20
25
30
35
40
*
*
*† PFO−
* PFO+
H
SL ALT1 ALT16
0
60
70
80
90
100
*
*
*†
*†‡
J
SL ALT1 ALT16
0
60
70
80
90
100
*
*
*†
*‡
I
Sa
O
2 (
%
)
 165 
 
 
Figure 6.2. Effect of PFO Size on Pulmonary Gas Exchange Efficiency 
Pulmonary gas exchange efficiency (A) and calculated venous admixture (B) at SL at rest 
and during exercise at 70, 100, 130 and 160 W in the PFO+ group, separated into PFO+ 
subjects with a resting bubble score of ≤2 upon release of valsalva (shaded circles), and 
those with a resting bubble score of ≥3 upon release of valsalva (open circles). Filled 
circles with dashed line represent PFO− subjects and these data are included for 
comparison only. * p < 0.05 compared to PFO+ subjects with a resting bubble score of 
≤2. 
Transthoracic Saline Contrast Echocardiography. In both the PFO− and PFO+ 
groups, bubble scores in the semi-recumbent position at rest increased when breathing 
14% O2 at SL compared to room air, and they were greater in the PFO+ group compared 
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to the PFO− group when breathing 14% O2 (Figure 6.3). Bubble scores at rest were 
qualitatively lower in both the PFO− and PFO+ groups when subjects were upright on the 
cycle ergometer with a slight forward lean compared to semi-recumbent positioning 
(Figure 6.4A). This is in agreement with prior work (55, 216) as well as in work 
reporting bubble scores in subjects at rest breathing 14% O2 in the semi-recumbent 
position (134) versus positioned in the upright position with a slight forward lean (54). 
 
Figure 6.3. Bubble Scores at Rest Breathing Room Air and 14% O2 
Left-sided contrast (i.e., bubble score) in the PFO− and PFO+ groups in the left lateral 
decubitus position at rest breathing room air and at rest breathing 14% O2. Filled circles 
are PFO− subjects and open circles are PFO+ subjects. * p < 0.05 compared to room 
air, ‡ p < 0.05 compared to the PFO− group. 
Acute Ascent to 5260m (ALT1) 
 Upon arrival to 5260m the cardiopulmonary and respiratory responses between 
the PFO− and PFO+ groups at rest and during exercise were similar. The A-aDO2 
increased ~2-fold compared to SL in both the PFO− and PFO+ groups at rest (Figure 
6.1A) and during exercise (Figure 6.1B). Within the PFO+ group the A-aDO2 increased 
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to the same extent between those with a resting bubble score ≥3 (i.e., a larger PFO) 
compared to those with a resting bubble score ≤2 (i.e., a smaller PFO). Similarly, PAO2, 
PaO2, PaCO2, and SaO2 between the PFO− and PFO+ groups at rest (Figure 6.1C, E, G, 
I) and during exercise (Figure 6.1D, F, H, J) were not different. V̇E and V̇A were both 
increased compared to SL in the PFO− and PFO+ groups, and there was no difference in 
V̇E or V̇A between groups (Table 6.2 and 6.3). Additionally, the change in resting V̇E 
from SL to ALT1 relative to the change in SaO2 (Figure 6.5) was not different between 
the PFO− and PFO+ groups. Surprisingly, in both the PFO− and PFO+ groups, bubble 
scores neither increased at rest nor during exercise at ALT1 compared to SL (Figure 
6.4A and B). 
 
 
Figure 6.4. Bubble Scores at Rest and During Exercise 
Left-sided contrast (i.e. bubble score) in the PFO− and PFO+ groups when upright and 
slightly forward leaning at rest (A) and during iso-workload exercise (B) at SL, ALT1, 
and ALT16. * p < 0.05 compared to SL, † p < 0.05 compared to ALT1, ‡ p < 0.05 
compared to the PFO− group. 
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Figure 6.5. Ventilatory Acclimatization 
Change in minute ventilation relative to the change in arterial O2 saturation from SL to 
ALT1, and from SL to ALT16 in the PFO− and PFO+ groups at rest. Data presented are 
mean ± standard error. † p < 0.05 compared to ALT1, ‡ p < 0.05 compared to the PFO− 
group. 
 
Acclimatization to 5260m (ALT16) 
Pulmonary Gas Exchange Efficiency. Unlike the PFO− group, the A-aDO2 at rest 
(Figure 6.1A) and during exercise (Figure 6.1B) in the PFO+ group did not improve 
(i.e., decrease) compared to ALT1. Furthermore, although there was only a trend for the 
A-aDO2 to be greater in the PFO+ group compared to the PFO− group (p = 0.063) at rest 
(Figure 6.1A), the A-aDO2 was significantly greater in the PFO+ group compared to the 
PFO− group during exercise (Figure 6.1B). Similar to ALT1, within the PFO+ group 
there was no difference in the A-aDO2 between those with a resting bubble score ≥3 (i.e., 
a larger PFO) compared to those with a resting bubble score ≤2 (i.e., a smaller PFO). This 
difference in pulmonary gas exchange efficiency between the PFO− and PFO+ groups at 
ALT16 can also be illustrated by calculating the difference in the total Q̇VA/Q̇T required 
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to account for the entire A-aDO2 for each group between ALT1 and ALT16 (Figure 6.6). 
From ALT1 to ALT16 at rest, the PFO− group showed a ~21% reduction in calculated 
Q̇VA/Q̇T, which was greater than the ~13% reduction in the PFO+ group (Figure 6.6). 
Similarly, from ALT1 to ALT16 during exercise, calculated Q̇VA/Q̇T in the PFO− group 
decreased by ~18%, which was also greater than the ~11% decrease in the PFO+ group 
(Figure 6.6). 
 
Figure 6.6. Calculated Change in Venous Admixture 
Change in minute ventilation relative to the change in arterial O2 saturation from SL to 
ALT1, and from SL to ALT16 in the PFO− and PFO+ groups at rest. Data presented are 
mean ± standard error.  † p < 0.05 compared to ALT1, ‡  p < 0.05 compared to the 
PFO− group. 
 
Ventilatory Acclimatization and Arterial Blood Gases. Importantly, both the PFO− 
and PFO+ groups demonstrated a reduction in PaCO2 and an increase in PaO2 compared 
to ALT1, consistent with acclimatization to high-altitude (Figure 6.1E and G). That said, 
the PFO+ group had no improvement in A-aDO2 from ALT1 to ALT16, and they 
demonstrated a less pronounced degree of ventilatory acclimatization compared to the 
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PFO− group. Only the PFO− group increased V̇A at rest at ALT16 compared to ALT1, 
and V̇A was less in the PFO+ group compared to the PFO− group at rest at ALT16 (Table 
6.2). Consequently, the PFO+ group had reduced resting PAO2, PaO2, SaO2 and 
increased PaCO2 compared to the PFO− group (Figure 6.1C, E, G, I) at rest at ALT16, 
and both PAO2 and SaO2 had not improved after acclimatization compared to ALT1 
(Figure 6.1C and I). This reduced degree of ventilatory acclimatization is also illustrated 
by the change in resting V̇E from SL to ALT16 relative to the change in SaO2 not 
increasing at ALT16 compared to ALT1 in the PFO+ group (Figure 6.5). This contrasts 
with the PFO− group who showed an increase in the change in resting V̇E from SL to 
ALT16 relative to the change in SaO2 at ALT16 compared to ALT1 (Figure 6.5). 
 The difference in V̇A between the PFO− and PFO+ groups at ALT16 was present 
only at rest and not during exercise at ALT16. Nevertheless, only the PFO− group 
increased PAO2 (Figure 6.1D) and decreased PaCO2 (Figure 6.1H) during exercise at 
ALT16 compared to ALT1. Both of the PFO− and PFO+ groups increased PaO2 and 
SaO2 during exercise at ALT16 compared to exercise at ATL1; however, during exercise 
at ALT16, PaO2 and SaO2 in the PFO+ group were lower compared to the PFO− group 
(Figure 6.1F and J). 
Transthoracic Saline Contrast Echocardiography. At rest, bubble scores in the PFO− 
and PFO+ groups were not different at ALT16 compared to ALT1; however, bubble 
scores in the PFO+ group were greater than the PFO− group at ALT16 (Figure 6.4A). 
During exercise, bubble scores in both the PFO− and PFO+ groups remained lower than 
SL values, and were not reduced compared to ALT1 values. 
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Hemoglobin and Hematocrit. Hb and Hct were less in the PFO+ group compared to the 
PFO− group and only the PFO− group increased Hb and Hct compared to ALT1. 
However, according to unpublished observations (Ryan et al., In Preparation) by our 
group, Hb mass increased compared to SL in 19/21 subjects and the 2 subjects who 
lacked an increase in Hb mass were PFO+ females. Statistical analysis of the PFO+ group 
without these two subjects shows no differences between the PFO− and PFO+ groups in 
Hb (p = 0.20) or Hct (p = 0.21) at ALT16; therefore, in both the PFO− and PFO+ groups 
Hb and Hct increased compared to ALT1. 
 
DISCUSSION 
 The primary purpose of this study was to investigate the effect of a PFO on 
pulmonary gas exchange efficiency at rest and during exercise at sea level (SL), after 
rapid transport to 5260m (ALT1) and after living at 5260m for 16 days (ALT16) in 
healthy, PFO− (n = 10) and PFO+ (n = 11) sea level natives. The novel findings in this 
study are: 1) pulmonary gas exchange efficiency did not improve at rest or during 
exercise after acclimatization to 5260m in the PFO+ group; 2) there was a reduced degree 
of ventilatory acclimatization to 5260m in the PFO+ group; and 3) in contrast to acute 
normobaric hypoxia, left-sided contrast did not increase during acute hypobaric hypoxia 
in either of the groups. 
Pulmonary Gas Exchange Efficiency in PFO− and PFO+ Subjects at SL 
 Three distinct factors can impair pulmonary gas exchange efficiency: 1) alveolar 
ventilation-to-perfusion (V̇A/Q̇) inequality; 2) incomplete end-capillary O2 diffusion 
equilibration; and 3) any source of right-to-left shunt [extrapulmonary shunt (e.g. venous 
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blood from the bronchial and Thebesian circulations), intracardiac shunt (e.g. blood flow 
through a PFO), and intrapulmonary shunt]. Although this study did not directly assess 
contributions from V̇A/Q̇ inequality or diffusion limitation, previous work suggests that 
diffusion limitation represents a minimal contribution to the A-aDO2 during submaximal 
exercise (V̇O2 <2.0 L/min) in healthy humans at SL (85, 102, 195, 229, 239) such that the 
majority of the A-aDO2 is explained by V̇A/Q̇ inequality and right-to-left shunt. 
Accordingly, during iso-workload exercise (V̇O2 ~2.0 L/min) in our healthy subject 
population, at SL V̇A/Q̇ inequality and right-to-left shunt were likely the predominant 
contributors to the measured A-aDO2. In both PFO− and PFO+ subjects this would 
include extrapulmonary shunt, and intrapulmonary shunt, if any. However, subjects in the 
PFO+ group also have an additional source of shunt, which is intracardiac shunt via the 
PFO. 
 Right-to-left blood flow through the PFO is dependent upon right atrial pressure 
exceeding left atrial pressure, which can occur transiently during the normal respiratory 
cycle, likely at end inspiration when systemic venous return is augmented by reduced 
intrathoracic pressure (64, 267). Therefore, during normal respiration, right-to-left blood 
flow through the PFO would be expected to be intermittent and variable in volume. 
Although in the current study the A-aDO2 was not different between the PFO− and PFO+ 
groups at rest or during exercise at SL, closer inspection of the data and subject 
characteristics revealed that the size and/or amount of blood flow through the PFO is 
important. Using TTSCE in PFO+ subjects Fenster et al. demonstrated that the degree of 
left heart contrast (i.e., bubble score) observed upon release of a Valsalva maneuver 
predicts the size of PFO determined using intracardiac echocardiography (64). According 
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to these criteria, within the PFO+ group in the current study there were 6 subjects with a 
bubble score ≥3 at rest upon release of a Valsalva maneuver (i.e., a larger PFO), and 5 
subjects with a bubble score ≤2 at rest upon release of a Valsalva maneuver (i.e., a 
smaller PFO). Although the qualitative assessment of left-heart contrast does not 
represent a quantitative measure of blood flow, it is intuitive that a larger PFO should 
permit the passage of a greater volume of blood and thus a greater right-to-left shunt. In 
support of this idea, the subjects with a larger PFO had an approximately two-fold wider 
A-aDO2 at rest and throughout all submaximal workloads at SL compared to those with a 
smaller PFO (Figure 6.2A). PFO+ subjects with a smaller PFO appear indistinguishable 
from the PFO− group, which also supports prior work suggesting that bubble scores <2 
represent a trivial degree of potential right-to-left shunt (133). Taken together, these data 
provide rationale for identifying subjects with a PFO when quantifying pulmonary gas 
exchange efficiency, as the presence of PFO influences the average, and variance of the 
A-aDO2 within a given data set. 
Pulmonary Gas Exchange Efficiency in PFO− and PFO+ Subjects at ALT1 
 At 5260m (PB ~406 mm Hg) inspired PO2 is lowered to ~75 mm Hg, significantly 
reducing PAO2, and reducing the contribution from V̇A/Q̇ inequality on the A-aDO2 
while the contribution of diffusion limitation on the A-aDO2 increases (183, 184, 255). 
The effect that a given volume of right-to-left shunt has on the A-aDO2 is also lessened in 
hypoxia due to the difference between mixed venous PO2 (Pv̅O2) and PaO2 becoming 
less. For this reason, if the shunt fraction via the PFO was constant from SL to ALT1, this 
additional 0.5-2.0% shunt (as it was calculated to be at SL) would account for between 1-
3 mm Hg of the measured A-aDO2 at ALT1. Therefore, it should not be surprising that at 
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ALT1 the PFO− and PFO+ groups had similar degrees of pulmonary gas exchange 
impairment both at rest and during exercise (Figure 6.2B). Additionally, it should not be 
surprising that within the PFO+ group, there was no difference in the A-aDO2 between 
subjects with larger and smaller PFOs corresponding to varying degrees of blood flow 
through the PFO. 
Pulmonary Gas Exchange Efficiency and Ventilatory Acclimatization in PFO− and 
PFO+ Subjects at ALT16 
 Acclimatization to hypobaric hypoxia is characterized by a multitude of 
physiologic adaptations, notably a time-dependent increase in ventilation (250). 
Compared to acute hypoxia, ventilatory acclimatization helps to increase CaO2 by 
increasing PAO2 and the driving gradient for O2 diffusion at the alveolar-capillary 
interface, increasing PaO2 and therefore, SaO2. Consequently, compared to acute hypoxia 
the further increase in V̇A, and therefore PAO2 with acclimatization would theoretically 
reduce the relative contributions from V̇A/Q̇ inequality and diffusion limitation while 
increasing the relative contribution of right-to-left shunt on the A-aDO2. Indeed, an 
increase in V̇A should equate to improved V̇A/Q̇ matching by way of lessening potential 
disparities in the PO2 between alveoli (63, 193, 204). Diffusion limitation would 
theoretically also be reduced compared to ALT1 by way of an increased driving gradient 
for O2 diffusion (243), increased Pv̅O2, and a potential improvement in diffusing capacity 
for O2 (3). Lastly, a given volume of right-to-left shunt would have a greater effect on the 
A-aDO2 due to the difference between Pv̅O2 and PaO2 increasing at ALT16 compared to 
ALT1. 
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Rest. Accordingly, absence of an increased V̇A at rest at ALT16 in the PFO+ group may 
partially explain the absence of a reduction in A-aDO2 compared to ALT1. The less 
pronounced degree of ventilatory acclimatization in the PFO+ group corresponded to a 
lower PAO2, which, compared to the PFO− group, may increase the relative contribution 
and potential for V̇A/Q̇ inequality and, particularly diffusion limitation to contribute to the 
A-aDO2. Additionally, continued right-to-left shunt via the PFO could have also 
contributed to the lack of improvement in A-aDO2 at rest at ALT16. However, the effect 
of this right-to-left shunt via the PFO, although increased compared to ALT1, would still 
likely be minimal considering the magnitude of the increase in PaO2 from ALT1 to 
ALT16 (40 ± 5 mm Hg at ALT1 vs. 46 ± 3 mm Hg at ALT16). Nevertheless, bubble 
scores were increased in the PFO+ group at rest at ALT16 and although this neither 
quantifies blood flow nor strictly reflects blood flow through the PFO, it supports the 
occurrence of right-to-left shunt via the PFO in the PFO+ group. Conversely, in the 
PFO− group PaO2 increased from 40 ± 4 mm Hg at ALT1 to 53 ± 4 mm Hg at ALT16, 
approximately twice as much as of the PFO+ group (p = 0.0003). Importantly, small 
changes in PaO2 in this range on the oxygen-hemoglobin dissociation curve correspond to 
large changes in SaO2, and thus CaO2. Indeed, had PaO2 increased in the PFO+ group to 
the same degree as it did in the PFO− group, SaO2 in the PFO+ group would have 
increased from ~83% to ~88%, corresponding to CaO2 increasing from ~18 mL O2/dL 
blood to ~19 mL O2/dL blood.  
 Why the PFO+ group had a lesser degree of ventilatory acclimatization compared 
to the PFO− group remains unknown, although we speculate that this may actually 
represent a beneficial response to hypoxia in subjects with an intracardiac right-to-left 
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shunt (i.e., the PFO+ group). Increasing ventilation and therefore raising PAO2 would 
increase PaO2 in PFO− subjects to a greater extent than PFO+ subjects, due to the 
continued presence of right-to-left shunt via the PFO. Indeed, perfusion without 
ventilation defines a right-to-left shunt. Therefore, the metabolic demand associated with 
increasing ventilation would potentially benefit PFO+ subjects to a lesser degree in terms 
of raising PaO2, compared to PFO− subjects. Furthermore, considering pH and 
temperature were not different between the PFO− and PFO+ groups, the lower VA in the 
PFO+ group resulted in a higher PaCO2 and thus, a right-shifted oxygen-hemoglobin 
dissociation curve. Estimating this shift based off of the calculated P50 values using the 
Hill equation (Hill coefficient = 2.7), the PFO+ group had a higher P50 (29.1 ± 0.7 
mmHg) compared to the PFO− group (28 ± 1 mmHg), p = 0.036 (90). This would 
facilitate the unloading of O2 at the tissue, which would be beneficial for PFO+ subjects 
considering their impaired ability to raise PaO2 and thus SaO2, due to right-to-left shunt 
via the PFO. Interestingly, in animals with an intracardiac right-to-left shunt and in 
children with cyanotic congenital heart disease, the presence of a right-shifted oxygen-
hemoglobin dissociation curve has also been hypothesized to be a possible compensatory 
mechanism for facilitating O2 unloading and therefore reducing tissue hypoxia (169, 
265). 
Exercise. During exercise the A-aDO2 is greater in acute hypoxia compared to SL and 
decreases following acclimatization to high-altitude compared to acute hypoxia (13, 28, 
47, 150), yet the cause of this subsequent improvement in A-aDO2 remains speculative. 
Considering the sample sizes of these prior studies (n = 6-10), statistically we would 
expect each study to have 2-4 PFO+ subjects, and it is unknown to what extent such 
 177 
subjects could potentially have influenced the findings in these previous studies. In the 
current study when the A-aDO2 data from the PFO− and PFO+ groups is pooled, as 
previously shown, pulmonary gas exchange efficiency improves following 
acclimatization to hypobaric hypoxia (Figure 6.7). However, by prospectively 
identifying PFO− and PFO+ subjects, the current work suggests that this reduction in the 
A-aDO2 after acclimatization was not present in the PFO+ subjects in our study. Within 
the PFO+ group there was no difference in the A-aDO2 between those with a resting 
bubble score ≥3 (i.e., a larger PFO) compared to those with a resting bubble score ≤2 
(i.e., a smaller PFO). Although, as previously discussed, right-to-left blood flow through 
the PFO would be expected to intermittent and variable in volume and dependent on a 
sufficient pressure gradient between the right and left atria. Using pulmonary artery 
systolic pressure (PASP) as an estimate for this potential pressure gradient, PASP was 
~10 mm Hg higher at rest and during exercise at ALT16 in PFO+ subjects with a resting 
bubble score ≤2 (i.e., a smaller PFO), compared to PFO+ subjects with a resting bubble 
score ≥3 (i.e., a larger PFO). Thus, despite the “smaller” PFO, these subjects may have 
had more blood flow through it, such that compared to subjects with a “larger” PFO, 
differences in the A-aDO2 were obscured. 
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Figure 6.7. Pulmonary Gas Exchange Efficiency, Group 
Pulmonary gas exchange efficiency for the combined group data (i.e., both PFO− and 
PFO+ groups) at rest and during iso-workload exercise at SL, ALT1, and ALT16. Data 
presented are mean ± standard error. * p < 0.05 compared to SL, † p < 0.05 compared 
to ALT1. 
 
 In contrast to rest, V̇A and PAO2 were not different between the PFO− and PFO+ 
groups during exercise at ALT16. This suggests that contributions from V̇A/Q̇ inequality 
and diffusion limitation to the A-aDO2 during exercise may be relatively equal between 
the PFO− and PFO+ groups. However, while not directly measured, we cannot rule out 
the possibility that differences between the PFO− and PFO+ groups in terms of V̇A/Q̇ 
inequality and diffusion limitation existed. Nevertheless, the intracardiac right-to-left 
shunt via the PFO in the PFO+ group could have also contributed to the lower PaO2 in 
the PFO+ group (Figure 6.1E), and therefore, contributed to the lack of improvement in 
A-aDO2 compared to ALT1 and significantly greater A-aDO2 compared to the PFO− 
group at ALT16 (Figure 6.1B). The calculated volume of venous admixture required to 
account for the difference in A-aDO2 during exercise at ALT16 between the PFO− and 
PFO+ groups was ~7%. This ~7% difference between the PFO− and PFO+ groups 
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includes all sources of venous admixture, yet this does not preclude the possibility that 
the intracardiac right-to-left shunt in the PFO+ group was contributing to the lack of 
improvement in pulmonary gas exchange efficiency expected to occur with 
acclimatization to high-altitude. 
 Although our exercise data at ALT16 indicate worse pulmonary gas exchange 
efficiency in the PFO+ group, this did not translate into differences in functional exercise 
capacity, that have been described previously (218). However, neither group had an A-
aDO2 >25 mm Hg at this submaximal workload, and therefore it is unlikely that exercise 
capacity would be limited due to pulmonary gas exchange inefficiency. Alternatively, the 
lack of functional difference between groups may also be the result of the right-shifted 
oxygen-hemoglobin dissociation curve that facilitated the unloading of oxygen despite 
the fact that pulmonary gas exchange efficiency did not improve with acclimatization and 
ventilatory acclimatization was less than PFO− subjects. 
Acclimatization and Left-Sided Contrast in PFO− and PFO+ Subjects 
 During exercise in healthy humans agitated saline contrast traverses the 
pulmonary circulation, suggesting an increase in blood flow through large diameter 
intrapulmonary arteriovenous anastomoses (IPAVA) compared to rest (53, 54, 115, 143, 
144, 216). In addition to exercise, acute normobaric hypoxia at rest increases blood flow 
through IPAVA (134) and combining hypoxia with exercise results in augmented left-
sided contrast due increased to blood flow through IPAVA (54, 143). Consistent with 
previous work (134), normobaric hypoxia (14% O2) at SL increased left-sided contrast in 
both the PFO− and PFO+ groups in the supine position (Figure 6.3). However, at ALT1 
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bubble scores were not different compared to SL, and interestingly, bubble scores at 
ALT16 were reduced compared to SL (Figure 6.4). 
 These data are supported by work from Foster et al. (67) demonstrating that after 
3 weeks of acclimatization to 5050 m only 1/8 PFO− subjects had transpulmonary 
passage of saline contrast at rest. Yet all 8 PFO− subjects had transpulmonary passage of 
saline contrast in conditions of acute normobaric hypoxia (10% O2) in a non-acclimatized 
state. The current work supports these findings by also demonstrating a reduction in 
bubble scores in both PFO− and PFO+ subjects, at rest and during exercise, and in both 
acute hypobaric hypoxia as well as after acclimatization to hypobaric hypoxia (Figure 
6.4). The unexpectedly low bubble scores at ALT1 and further reduction in bubble scores 
at ALT16 are intriguing, and for which there are several possible explanations. Foster et 
al. hypothesized that the reduction in blood flow through IPAVA could be a result of the 
increase in SpO2 and decrease in Q̇T that occurs following acclimatization to high-
altitude. It is known that increases in Q̇T and decreases in SaO2 are potential mechanisms 
explaining the increase in blood flow through IPAVA at SL (24, 133, 134). Foster et al. 
also hypothesized that some degree of pulmonary vascular remodeling occurred over the 
21 day time span that may contribute to the reduction in blood flow through IPAVA.  
 Both of these hypotheses imply a time-dependent reduction in blood flow through 
IPAVA during acclimatization to hypobaric hypoxia, and our data at ALT16 and data 
from Foster et al. at 21 days support this possibility. However, our data at ALT1 suggest 
that part of this decrease may be due to hypobaria per se. All agitated saline contrast 
injections (i.e., at SL, ALT1 and ALT16) consisted of 3 ml of saline combined with 1 ml 
of room air. Thus, the ~50% reduction in barometric pressure at 5260m would result in 
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an ~50% reduction in the absolute moles of gas within the 1 ml volume, although it is 
unknown to what extent, if any, this would effect microbubble size or time to dissolution. 
Importantly however, the degree of right-sided contrast was qualitatively not different at 
ALT1 or ALT16 compared to SL. Nevertheless, this qualitative assessment of right-sided 
contrast does not preclude the possibility that in vivo microbubble dynamics are altered in 
hypobaric hypoxia. Ultimately, although hypobaria might play a role in the reduction in 
bubble scores at ALT1, it likely does not explain the further reduction coincident with 
acclimatization to high-altitude as noted above. 
Summary 
 The current study aimed to assess the impact of a PFO on pulmonary gas 
exchange efficiency at rest and during exercise at SL, with acute transport to 5260m, and 
after living at 5260m for 16 days. We identified an improvement in pulmonary gas 
exchange efficiency with acclimatization to high-altitude similar to previous 
investigations; however, this finding was not present in PFO+ subjects. The additional 
source of intracardiac right-to-left shunt in PFO+ subjects may be sufficient to explain 
their impaired pulmonary gas exchange efficiency at rest and during submaximal exercise 
compared to PFO− subjects at SL. However, the contribution of this right-to-left shunt to 
pulmonary gas exchange efficiency is reduced at altitude and may only partially explain 
the lack of improvement in pulmonary gas exchange efficiency at ALT16. PFO+ subjects 
demonstrated a less pronounced degree of ventilatory acclimatization to 5260m, 
concomitant with a greater A-aDO2 and lower PaO2 and SaO2. Although future work is 
needed to corroborate these findings, we speculate that this reduction in ventilatory 
acclimatization may be beneficial in PFO+ subjects by limiting the metabolic cost of 
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hyperventilation, which would not effectively increase PaO2. Ultimately, a more effective 
strategy may be to ventilate less, resulting in a right-shifted oxygen-hemoglobin 
dissociation curve that facilitates O2 unloading at the tissue when O2 loading is hindered 
by the presence of an intracardiac right-to-left shunt.  
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CHAPTER VII 
CONCLUSIONS 
MAIN FINDINGS 
 One of the primary critiques pertaining to the undefined physiologic relevance of 
blood flow through IPAVA is whether or not this blood flow contributes to pulmonary 
gas exchange efficiency. Several studies have demonstrated a correlation between 
increases in blood flow through IPAVA and increases in the A-aDO2, however no study 
has demonstrated an increase in blood flow through IPAVA when potential contributions 
from V̇A/Q̇ inequality and diffusion limitation to the A-aDO2 are minimized. 
Accordingly, an experimental paradigm preventing contributions from V̇A/Q̇ inequality 
and diffusion limitation was employed in Chapter IV, and blood flow through IPAVA 
was demonstrated to occur at a time when pulmonary gas exchange efficiency became 
worse. Another primary critique pertaining to the undefined physiologic relevance of 
blood flow through IPAVA is the undefined mechanistic regulation of these vessels. The 
experimental paradigm used in Chapter IV also provided a means to pharmacologically 
increase Q̇T with and without changes in PASP, and blood flow through IPAVA appears 
to be increased by increases in Q̇T independent of changes in PASP. 
 Similarly, the hyperoxia-mediated reduction in blood flow through IPAVA is 
another controversial area as this finding suggests, 1) these vessels are regulated opposite 
to the conventional circulation, and 2) the shunt fraction measured using the 100% O2 
technique when blood flow through IPAVA is not present, may not be equal to the shunt 
fraction occurring when breathing a FIO2 <1.0, when blood flow through IPAVA is 
present. Chapter V pharmacologically targeted the pulmonary vasculature during exercise 
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breathing a FIO2 = 1.0 and demonstrates that sildenafil, nifedipine, and acetazolamide 
have no discernable effect using TTSCE on blood flow through IPAVA during exercise 
breathing a FIO2 = 1.0. 
 In contrast to the hyperoxia-mediated reduction in blood flow through IPAVA, 
acute normobaric hypoxia increases blood flow through IPAVA, yet the effect of long-
term hypoxia on blood flow through IPAVA remains unknown. This area was 
investigated by studying human acclimatization to hypobaric hypoxia (5260m) for 16 
days, and the data are presented in Chapter VI. It was observed that blood flow through 
IPAVA is reduced in acute hypobaric hypoxia, and is further reduced following 
acclimatization to hypobaric hypoxia. Accordingly, these data suggest an effect of 
hypobaria per se on blood flow through IPAVA, yet this does not entirely explain the 
subsequent reduction in blood flow through IPAVA following acclimatization. 
Secondarily, in Chapter VI we present data demonstrating the physiologic significance of 
a PFO, in both the context of pulmonary gas exchange efficiency at rest and during 
exercise at sea level, and in the context of acclimatization to hypobaric hypoxia. 
 
SUMMARY AND FUTURE DIRECTIONS 
 Intrapulmonary arteriovenous anastomoses have been unequivocally 
demonstrated to exist in animal models and in isolated and perfused human lungs using 
solid microspheres, and convincingly so in healthy humans using 99mTc-MAA and 
TTSCE. However, critics remain skeptical of the physiologic relevance of blood flow 
through IPAVA, primarily because of the undefined contribution of blood flow through 
IPAVA to pulmonary gas exchange efficiency, and the undefined mechanistic regulation 
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of blood flow through IPAVA. Furthermore, the classical understanding of pulmonary 
gas exchange efficiency in healthy humans emphasizes the relative contributions of V̇A/Q̇ 
inequality and diffusion limitation, while downplaying the relative contribution of right-
to-left shunt; because functional gas exchange dependent methods do not detect 
significant right-to-left shunt. 
 Accordingly the discrepancy between these two distinctly different approaches to 
studying the pulmonary circulation and pulmonary gas exchange efficiency may be 
reconciled in several ways. First, it remains possible that blood flow through IPAVA, 
although detected using anatomic based methods, participates in some degree of gas 
exchange and therefore is not a source of true shunt and instead is a source of ‘venous 
admixture’. If so, inert gas methods may interpret this blood flow as an area of low V̇A/Q̇, 
but not below the 0.005 threshold for intrapulmonary right-to-left shunt, or potentially 
even below the 0.1 threshold for ‘low V̇A/Q̇’. Alternatively, non-capillary gas exchange 
may result in inert gases diffusing out of the blood, prior to reaching IPAVA, and 
therefore not being retained as evidence of right-to-left shunt. Non-capillary gas 
exchange has been demonstrated to occur in humans (108, 109, 209) and cats (40) and 
therefore provides a basis for this concern. Furthermore there exists considerable data 
demonstrating the exchange of inert gases within the conducting airways and even 
trachea (220). These data predominantly affect inert gases of high-solubility and high 
molecular weights (not necessarily sulfur hexafluoride), although these data do suggest 
the mathematical constraints and theory of the MIGET may be incompletely defined. 
However, to what extent these potential inaccuracies impact the overall V̇A/Q̇ distribution 
is unknown. Lastly, the relatively inconsistent data reported from both within a given lab 
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group, and across different labs, using the MIGET raises the concern that despite the 
theoretical ‘exquisite’ sensitivity of the MIGET, in practice it may not be able to detect 
small but significant shunts such as the PFO which is present in 35-40% of the 
population. Indeed, all humans have a certain degree of postpulmonary right-to-left shunt 
via the bronchial and Thebesian circulations of the lungs and heart, respectively, and the 
MIGET cannot differentiate this postpulmonary shunt from diffusion limitation. 
Therefore, even at rest the measured A-aDO2 should always exceed the predicted A-
aDO2, yet the reverse is often reported (85, 101, 175, 195, 239), or the two are 
superimposable (185, 229, 235), leaving no room for postpulmonary shunt. This is a very 
important distinction, because this suggests the baseline measure does not reflect what 
one would expect based on the known, and unquestioned presence of postpulmonary 
right-to-left shunt in all humans. Therefore, the MIGET does not seem to have the 
sensitivity to detect postpulmonary right-to-left shunt in humans, and thus, raises the 
question; can the MIGET detect the same volume of intrapulmonary right-to-left shunt in 
humans during exercise? 
 Potential support for the MIGET to be capable of detecting small volumes of 
right-to-left shunt comes from work using the MIGET in healthy subject at rest breathing 
room air and 100% O2 (236). In this study 4 healthy young subjects and 5 healthy older 
subjects were studied. It was shown in young subjects breathing room air that the shunt 
measured using the MIGET was 0%, which increased in 3 of the 4 young subjects to 
~0.5% when breathing 100% O2. In the older subjects the shunt measured when breathing 
room air was also 0%, which increased in all 5 subjects to ~3.5% (range = 0.8% – 10.7%) 
when breathing 100% O2. These measured values of right-to-left shunt, using the 
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MIGET, include only intrapulmonary and intracardiac shunt. Intracardiac shunt would 
also have been present when breathing room air, and thus, the increased shunt detected 
when breathing 100% O2 is from an increase in intrapulmonary shunt, which the authors 
speculated was secondary to atelectasis. In this study the shunt fraction was also 
measured using the 100% O2 technique simultaneously with the MIGET. In young 
subjects the shunt fraction using the MIGET was ~0.5% when breathing 100% O2, which 
contrasts with the 100% O2 technique value of ~4.25%. Similarly, in older subjects the 
shunt fraction using the MIGET was ~3.5% when breathing 100% O2, which contrasts 
with the 100% O2 technique value of ~8.66%. The measured values of right-to-left shunt 
using the 100% O2 technique include intrapulmonary, intracardiac, and postpulmonary 
shunt. The authors speculated that the reason for the consistently larger shunt fractions 
measured using the 100% O2 technique was due to the inclusion of postpulmonary shunt, 
as well as known errors associated with accurately measuring PaO2 when breathing 100% 
O2. The A-aDO2 in young and older subjects breathing 100% O2 was ~76 mm Hg and 
~133 mm Hg, respectively. Which are markedly higher than previous reports, of ~15 mm 
Hg at rest breathing 100% O2 (39) and ~30 mm Hg during exercise breathing 100% O2 
(233). Therefore, it is possible that there were errors in the blood gas measurements, 
however even if this accounted for half of the difference in shunt fraction, as the authors 
speculated, the remaining value of ~1.9% in young subjects and ~2.5% in older subjects 
is then due to postpulmonary shunt. To summarize, these data do provide evidence that 
the MIGET can detect a small volume of right-to-left shunt in subjects at rest breathing 
100% O2, but does not detect these same volumes of right-to-left shunt in these same 
subjects at rest breathing room air. 
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 When breathing 100% O2, the reduction in blood flow through IPAVA that has 
consistently been demonstrated using anatomic methods, precludes this technique from 
assuming the measured shunt fraction is the same regardless of the FIO2. This is of course 
only if the possibility is entertained that blood flow through IPAVA provides a source of 
shunt or venous admixture when breathing a FIO2 <1.0. 
 Anatomic based methods have the unique strength of quantifying the volume of 
blood flow through IPAVA in an approach independent of pulmonary gas exchange. 
While functional gas exchange dependent methods have the unique strength of 
quantifying gas exchange dependent processes, i.e., V̇A/Q̇ inequality and diffusion 
limitation. Taken together, it seems appropriate to merge both approaches and investigate 
pulmonary gas exchange efficiency from a more inclusive view. Nevertheless, before this 
multi-view approach is reasonable; the aforementioned limitations of the MIGET will 
need to be addressed. One possibility for addressing, at least in part, this concern would 
be to measure the A-aDO2 in subjects with and without a PFO while simultaneously 
quantifying right-to-left shunt using the MIGET and 99mTc-MAA. The premise for this is 
that differences in the A-aDO2 can be detected in subjects with and without a PFO at rest 
via arterial blood gas analysis; when diffusion limitation can be excluded from 
contributing to the A-aDO2, and potential impairments in V̇A/Q̇ inequality, if present, 
would likely be similar in subjects with and without a PFO. Right-to-left shunt via the 
PFO is interpreted by the MIGET as a V̇A/Q̇ ratio of ≤0.005, meaning it is 
indistinguishable from intrapulmonary right-to-left shunt. Thus, the sensitivity of the 
MIGET in practice can be assessed through determining whether or not it detects the 
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additional source of right-to-left shunt via the PFO. This additional source of right-to-left 
shunt via the PFO should also be quantifiable using 99mTc-MAA, and through back 
calculating the required volume of venous admixture to account for the entire A-aDO2 
from the arterial blood gases. There is understandably a certain inherent degree of error 
associated with each of these measures; nevertheless, this may be an enlightening 
direction to pursue. 
 Perhaps the most important next step will be do quantify blood flow through 
IPAVA during the conditions presented in Chapter IV, and demonstrate an increase in 
blood flow through IPAVA that can be distinguished from postpulmonary shunt. 
Currently, we cannot definitively refute the possibility that the increase in A-aDO2 is 
entirely due to an increase in postpulmonary shunt, potentially predominantly from 
Thebesian blood flow. Although our experimental conditions strongly suggest blood flow 
through IPAVA contributes to pulmonary gas exchange efficiency, quantifying the 
volume of blood flow through IPAVA using a technique independent of pulmonary gas 
exchange would lend further support to this conclusion. 
 Another critical step will be to directly visualize IPAVA, both in healthy humans 
and in such a way that provides a means to isolate and perfuse these vessels. Visualizing 
IPAVA in healthy humans may be possible using high-resolution computed tomography, 
however the challenge will be to balance the effective resolution with the necessary dose 
of radiation. In the 1950’s Tobin and Zariquiey visualized via vascular casting the 
presence of arteriovenous anastomoses between the pulmonary arterial and venous 
circulation. However, vinyl vascular casting does not permit the ability after the fact, to 
isolate and perfuse the vasculature. Isolating IPAVA would permit the ability to perfuse 
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the vessel and demonstrate it being regulated opposite to the conventional pulmonary 
circulation. Furthermore, potential molecular mechanisms regulating the vascular tone of 
IPAVA could be investigated in this preparation. 
 To come full circle and return to the concluding statement of the Historical 
Perspective in Chapter I (p. 12), the methodological limitations in Haldane’s 
measurement of arterial PO2 led him to the incorrect conclusion, that the lungs secreted 
oxygen. Similarly, the methodological limitations of the MIGET, and assumptions 
regarding the effect of breathing hyperoxia on the pulmonary vasculature, may lead to the 
incorrect conclusion that right-to-left shunt is not significantly contributing to pulmonary 
gas exchange efficiency during exercise.  
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